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ABSTRACT 
Immunotherapy with allodepleted donor T-cells improves immune reconstitution after 
haploidentical SCT, but infection and leukaemic relapse remain problematic. To develop a 
rational approach to refining allodepletion, we characterized the expression of surface markers 
and cytokines on proliferating alloreactive T-cells flow cytometrically. CD25 was expressed 
on 83 % of CFSE-dim alloreactive T-cells, confirming this as an excellent target for 
allodepletion. 70 % of the alloreactive CD25-ve population expressed CD71, identifying this as 
a novel marker to target alloreactive T-cells that persist after CD25 depletion. We compared 
residual alloreactivity to host or 3rd party after CD25 vs combined CD25/71 immunomagnetic 
depletion in 8 HLA-mismatched donor-recipient pairs. In 1o MLRs, residual responses to host 
were undetectable after CD25/71 depletion. In 2o MLRs, CD25/71 depletion resulted in 
significantly lower residual proliferative response to host than CD25 depletion (median 4.8% 
of the response of unmanipulated PBMC vs 9.9%, p < 0.01). Likewise, the median residual 
reactivity to host in IFN-γ ELISPOT assays was significantly lower after combined CD25/71 
than CD25 allodepletion (14.1 % vs 54.6%, p < 0.05). Third party responses after CD25/71 
allodepletion were equivalent to unmanipulated PBMCs in both assays. In pentamer and IFN-γ 
ELISPOT assays, anti-viral responses to CMV, EBV and adenovirus were preserved after 
combined CD25/71 allodepletion. Finally, we showed that CD25/71 allodepleted T-cells can 
be redirected to recognize and secrete IFN-γ and granzyme B in response to CD19 cell lines 
and primary ALL blasts through lentiviral transfer of a chimeric αCD19ζ TCR. This strategy 
may facilitate immunotherapy with larger doses of allodepleted T-cells after haplo-SCT, 
enhancing graft versus leukaemia and anti-viral effects. 
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INTRODUCTION 
Haematopoietic stem cell transplantation (HSCT) involves the intravenous infusion of 
autologous or allogeneic stem cells collected from bone marrow, peripheral blood, or umbilical 
cord blood to re-establish haematopoietic function in patients with damaged or defective bone 
marrow or immune systems. HSCT is a potential curative therapy for haematological 
malignancies by enabling both dose escalation in chemoradiotherapy and through an 
immunologically graft versus leukaemia (GVL) effect, mediated by donor T-cells. However, 
alloreactive donor T-cells can also cause a graft versus host disease (GVHD), which is a major 
complication post allogeneic transplantation.  
 
Haploidentical Transplantation 
 
The lack of fully HLA- matched donors is a major limitation to the applicability of HSCT. The 
ideal donor, a HLA-matched sibling donor is only available for 30 % of patients. For patients 
lacking a matched sibling donor, HSCT can be performed from an unrelated adult donor or 
cord blood. In contrast, the probability of finding a matched unrelated donor ranges from 10 % 
in poorly represented ethnic groups to 60 % in Caucasians.1 However, almost all patients have 
a HLA-mismatched family haploidentical donor, generally a parent or sibling. Haploidentical 
donors are matched with the recipient for 1 HLA haplotype and mismatched for the other. One 
potential advantage of using haploidentical donors 2 is that the donor could be chosen 
depending upon HLA type, CMV status, or other features such as NK cell alloreactivity. 
Another advantage is equal availability of donors for all ethnic and racial groups in contrast to 
matched unrelated donors. Haploidentical transplantation is now performed for patients with a 
variety of haematological malignancies, non haematological malignancies, 
immunodeficiencies and inborn errors of metabolism. 
 
Although encouraging data have been obtained, this approach is only being explored at centres 
with expertise in this area. Due to the high precursor frequency of alloreactive T cells in the 
haploidentical setting, rigorous T cell depletion is needed to prevent GVHD. The Perugia 
group pioneered progress in this field by developing the strategy of infusing  mega dose, 
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CD34- selected stem cells ( >10 x 106/kg) which were T cell depleted by  virtue of positive 
CD34 immunomagnetic selection using a Clinimacs device (Miltenyi Biotec).3 This approach 
resulted in over 4 log T cell depletion. Typically a dose of 104/kg residual T cells is infused 
with the graft. While this vigorous T-cell depletion is necessary to avoid GVHD, this leads to 
delayed immune reconstitution, predisposing to a high risk of viral infections and leukaemic 
relapse. 
 
One of the largest series of haploidentical transplants in the paediatric area has been done at 
The University of Tuebingen.4 Using CD34 positively selected grafts, they demonstrated in 63 
patients, engraftment in 98 % and grade 2 GVHD in 7 %. Overall survival after 4 years was 40 
%, with the major causes of death being relapse (30 %) and viral infections (14 %). 
Haploidentical transplantation has now become a well-established method and should be 
considered in all patients who need stem cell transplantation but lack a matched or single 
allelic mismatched donor. This method makes motivated donors available for almost all 
paediatric patients, since parents can donate stem cells for their children. Stable survival rates 
have been obtained and the problems of engraftment and GVHD have largely been resolved. 
However, the profound delay in T-cell reconstitution predisposes to high morbidity/mortality 
from relapse and viral infections. 
 
Poor immune reconstitution post haploidentical transplantation is the key factor contributing to 
the high transplant-related mortality associated with this form of HSCT and preventing broader 
use of this approach. In one series of 20 children who were prospectively followed up after 
receiving CD34 + selected haploidentical transplants,  NK cells were the first lymphoid cells 
to emerge during the first 4 weeks post transplantation.5  Reconstitution of the T- and B-cell 
occurred much later. For the first 6 months after haploidentical transplantation, patients are 
profoundly T-lymphopoenic, with a few circulating memory T-cells with a limited diversity, 
derived from graft-contaminating T-cells that have expanded in the antigenic milieu of the 
host. T-cell counts reached > 100/µl after a median of 72 days, with CD8 cells recovering 
faster than CD4 cells. A second wave of T-cell regeneration derived from donor stem cells, 
was found to start after 6 months resulting in T-cells that expressed a naive phenotype 
(CD45RA+). This increase in the number of naive T cells encompassed both CD8+ and CD4+ 
fractions and had a more diverse TCR repertoire. The mean time to normal T-cell numbers was 
450 days. Immune reconstitution in adult recipients of haploidentical grafts is even slower 
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where CD4+ counts remained below 100 and 200/µl for 10 and 16 months respectively, 
reflecting reduced thymic function compared to children.6  
 
This profound delay in T-cell reconstitution predisposes to an increased risk of morbidity and 
mortality from viral infections. An updated analysis of viral morbidity and mortality in 
paediatric haploidentical recipients showed that until day 180 post stem cell transplant (SCT) 
the cumulative incidence of all lethal viral infections (adenovirus n = 5, cytomegalovirus n = 
3, herpes simplex virus n = 1) was 16 % for the whole cohort of patients.7 Adenovirus is a 
particularly important pathogen with a cumulative incidence of adenovirus-associated 
mortality was 8.5 %. Similarly, an update from the Perugia group showed that the transplant 
related mortality (TRM) for haploidentical transplants was 47 % in a 100 high risk leukaemic 
patients who were in complete remission, and 63 % in those who were transplanted in relapse.8  
70 % of deaths were due to infection. The probability of relapse depended on the status of 
remission at the time of transplant, with most relapses occurring in patients not in remission at 
the time of transplant. The probability of relapse for AML patients in complete remission 
(CR1) was 18 % and for ALL it was 22 %. For patients not in remission, the figures for AML 
were 34 %, and ALL 90 %. Thus, improving immune reconstitution in haploidentical 
transplantation is vitally important to resolve the issue of virus and relapse associated 
mortality. 
 
In order to overcome the slow immune reconstitution after haplo-SCT, and transfer NK and 
other accessory cells with the graft, a number of groups have investigated negatively selecting 
haploidentical grafts with CD3 immunomagnetic beads (typically in combination with a B cell 
depletion), rather than positively selecting for CD34, using a reduced intensity conditioning 
(RIC) regime. The resulting grafts typically contain rather more T-cells than a CD34 selected 
graft (median 14 x 104/kg) and several logs more NK cells (35 x 106/kg after CD3/19 depletion 
compared to 0.003 x 106/kg after CD34 selected grafts) .9,10 Engraftment occurred in 91 % of 
patients, with more rapid T-cell reconstitution (median CD3 count 350/µl at 3 months) 
compared to previously reported with CD34 selected grafts. However, 36 % of patients 
developed significant acute GVHD (grade 2 or greater), thus suggesting that the enhanced T- 
cell reconstitution was in fact due to the higher T-cell dose that was infused with the graft. 
Furthermore, it was not clear if the improved T-cell reconstitution is simply due to expansion 
of alloreactive T-cells in patients who have developed GVHD. In an adult cohort using this 
regime, T-cell reconstitution remained slow (median CD3 count was 227 cells/µl on day 
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+100), there was a high incidence of severe acute GVHD ( 48 %), with relapse and infection 
accounting for a majority of deaths (overall survival 31 % after 241 days ).9 An update of this 
group’s experience with CD3/19 depleted RICs in 29 children/adolescents demonstrated that 
significant acute GVHD remained problematic (17 %) as did relapse (34 %), and deaths from 
adenoviraemia (7 %).11  There has been no formal assessment of anti-viral immune responses 
and T-cell repertoire using this approach. Thus immune reconstitution after CD3/19 depleted 
haploidentical HSCTs needs further study.  
 
In summary, strategies using mega doses of CD34-selected stem cells have shown that haplo-
SCT is feasible, but is compromised but the profound delay in T-cell reconstitution. Newer 
regimes using RIC, with combined CD3/19 depletion have emerged, leading to somewhat 
quicker T-cell reconstitution, but they have been complicated with significant rates of GVHD. 
What is needed is a means of selectively enhancing desirable anti-viral and anti-leukaemic T-
cell responses after haploidentical-SCT without causing GVHD. In order to do this, we need to 
understand the pathogenesis of GVHD. 
 
Immunobiology of GVHD 
 
Acute and chronic GVHD are a major cause of non relapse morbidity and mortality after stem 
cell transplantation. Acute GVHD often presents initially with a skin rash. Anorexia, nausea, 
and watery/or bloody diarrhoea are typical manifestations of gastrointestinal GVHD. Liver 
GVHD may present with jaundice and derangement of liver function tests. Chronic GVHD has 
more diverse manifestations and can resemble autoimmune syndromes, such as scleroderma, 
with salivary and lachrymal gland involvement, and pulmonary involvement. For the purposes 
of epidemiological studies, acute GVHD occurs within 100 days after transplantation and 
chronic GVHD after this. 
 
 GVHD is primarily a T cell mediated disease. The principal task of the immune system is to 
distinguish self from non-self. Major Histocompatibility Complex (MHC) molecules provide 
the crucial surface upon which the antigen receptors on T lymphocytes (T cell receptors or 
TCR) recognize foreign (non-self) antigens The MHC is highly polymorphic from individual 
to individual, and segregates in families in a Mendelian co dominant fashion. The genes of the 
HLA locus encode two distinct classes of cell surface molecules, classes I and II. Class I 
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molecules are expressed on the surfaces of virtually all nucleated cells at varying densities, 
while class II molecules are more restricted to cells of the immune system, primarily B 
lymphocytes, dendritic cells  and monocytes. There are three different class I (HLA-A, -B, -C) 
and class II (HLA-DQ, -DR, -DP) antigens. HLA-A, -B and -DR antigens appear to be the 
most important loci determining whether transplanted cells initiate a graft versus host reaction. 
The normal function of these molecules on antigen presenting cells is to  present antigenic 
fragments (in the form of linear peptides) to the CD4 positive helper T-cells (class II), or CD8 
positive cytotoxic effector T-cells (class I). This process of antigen presentation consists of the 
binding of a single T-cell receptor to a complex on the surface of an antigen- presenting cell, 
consisting of the MHC molecule and a peptide fragment derived from the foreign antigen. 
Intracellular-derived antigens are predominantly presented via MHC-class I, whereas 
exogenous antigens are mainly presented via class II. 
 
The major prerequisites for GVHD to occur are that the transplanted graft must contain 
immunologically competent cells and the recipient expresses tissue antigens that are 
recognized as foreign by the donor.12 The first prerequisite is fulfilled by mature T 
lymphocytes. After allogeneic transplant, the severity of GVHD corresponds with the number 
of donor T cells infused13  and T cell depletion reduces the incidence and severity of acute 
GVHD. Differences between host and donor MHC and minor histocompatibility antigens are 
the most important risk factor for initiation of GVHD. There are two forms of T-cell 
allorecognition, which are summarised in Fig. 1. 
 
a) Direct presentation of alloantigen- The response to intact allogeneic major 
histocompatibility (MHC) molecules plus foreign peptide is known as direct recognition. i.e. 
the host antigen presenting cell (APC) presents foreign MHC/ peptide to the donor T cells. 
This pathway is thought to be the dominant pathway involved in the early alloimmune 
response as the relative number of T cells that proliferate on contact with allogeneic or donor 
cells is extraordinarily high compared with the number of clones that target antigen presented 
by self-APC 
 
b) Indirect presentation of alloantigen- The indirect alloresponse is recognition of peptides 
from allogeneic MHC proteins presented by self MHC molecules. This occurs when donor 
APC process and present recipient alloantigens (e.g. from apoptotic cells) to donor T-cells a 
phenomenon called cross-presentation. 
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Minor histocompatibility antigens are polymorphisms of peptides that are presented in the 
context of the MHC 14  
 
Figure 1 Pathway of T cell Recognition. Reproduced from 14 There are 2 forms of allorecognition. Host 
APCs presenting foreign MHC to donor T cells (a) is called direct allorecognition. Indirect allorecognition occurs 
when donor APCs present host MHC molecules to donor T cells (b). Minor histocompatibility antigens are 
polymorphisms of peptides presented in the context of MHC and explain how GVHD occurs in the matched 
sibling setting. 
 
 As seen in Fig 2 the pathophysiology of GVHD can be thought of as a three step process 12,15  
(1)- tissue damage to the recipient by the chemo radiotherapy conditioning regimen (2) donor 
T-cell activation and clonal expansion (3) Effector phase with further damage to recipient 
tissues caused by donor T-cells. 
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Figure 2: Three phases of GVHD. In the first phase, chemoradiotherapy damages host tissues, leading to 
release of proinflammatory cytokines and absorption of lipopolysaccharide across bowel mucosa. This leads to 
upregulation of MHC molecules and in phase 2 host APCs interact with donor T cells. The latter secrete cytokines 
leading to the generation of the effector phase (phase 3). In phase 3 effector CTLs damage host tissue by the 
FAS/FAS ligand pathway and release of granzyme B. There is further release of proinflammatory cytokies 
leading to a vicious cycle (' the cytokine storm') 
 
Phase 1- Damage to host by Chemo radiotherapy 
 
High dose chemo radiotherapy regimens damage host tissue, particularly the gut, and allows 
lipopolysaccharide (LPS) from bacteria in the bowel to leak into adjacent tissues and the 
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bloodstream. Distinct classes of conserved microbial molecules and necrotic cell elements 
activate Toll like receptors on various cells such as dendritic cells, NK cells, macrophages, and 
eosinophils,  leading to the release of inflammatory cytokines such as tumour necrosis factor α 
﴾TNFα﴿, IL-1, IL-6, IL-1216 and interferon gamma (IFNγ), the latter promoting up regulation 
of  MHC antigens on antigen presenting cells (APCs) and maturation of dendritic cells (DCs)  
As part of the innate response, neutrophils, macrophages and eosinophils migrate to damaged 
tissue and cause further injury. Damaged host tissues responds with further secretion of 
proinflammatory cytokines, such as TNF-α and IL-1, resulting in the so called “cytokine 
storm’.  
Phase 2- Donor T cell activation 
(a) Target Antigens  
 
The precursor frequency of T cells that can recognize a mismatched MHC is very high (up to 
5-10 % of the T cell repertoire)17,18.  Mismatched MHC molecules on recipient APC are 
foreign to the donor T cells. In contrast, on self APCs, most of the self MHC molecules are 
displaying self peptides, and any foreign peptide probably occupies 1 % or less of the total 
MHC molecules expressed. As a result, the density of allogeneic determinants on allogeneic 
APCs, is much higher than the density of foreign peptide-self MHC complexes on self APCs, 
highlighting the importance of direct allorecognition. The abundance of recognizable 
allogeneic MHC molecules may allow activation of T-cells with low affinities for the foreign 
MHC, thereby increasing the number of T cells that can respond.  
 
The highly polymorphic nature of the MHC implies that an allogeneic MHC molecule will 
differ from self MHC molecules at multiple amino acid sites. One theory of promiscuous 
recognition, entails that the peptide is ignored by the T cell receptor (TCR), allowing the TCR 
to recognize the MHC molecules themselves. Thus, each allogeneic MHC molecule can be 
recognized by a multiple T cell clones. However, there is evidence that TCRs recognize 
primarily intact peptides on MHC molecules, interacting with high specificity with each 
peptide MHC complex.17 Thus, any cell may express multiple distinct peptide MHC 
complexes composed of different peptides bound to one or a few alleles of the foreign MHC 
molecules. As only a few hundred peptide MHC complexes are needed to activate a particular 
T cell clone, many different clones may be activated by the same allogeneic cell. This may 
explain the high precursor frequency of alloreactive donor T cells.     
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In haematopoietic cell transplantation, the principal antigenic targets of the T- cells of the 
graft, are the host MHC molecules if the patient and donor MHC molecules differ. However, 
for grafts matched at the MHC, mismatching of minor histocompatibility antigens (MHags) 
appears to underlie the development of GVHD. Because the manner in which a particular 
protein is processed is dependent upon genes outside of the MHC, two siblings, despite having 
identical MHC molecules, will have many different peptides in the MHC groove.19 The 
identification of the particular peptides responsible for GVHD has been an area of intense 
research. It remains unclear how many such peptides behave as MHags antigens. Although up 
to 50 such antigens are estimated to exist in mice, the precise number in humans is unclear. 
Many potential MHags antigens exist in humans, but the actual number that may cause GVHD 
is probably limited. One such example is HA-1.Mismatching of HA-1 between donor/recipient 
pairs has been significantly associated with GVHD.20, 21 
(b) Role of APCs 
In the first stage of GVHD, the host conditioning leads to a loss of epithelial integrity, 
systemic exposure to microbial products and activation of the innate immune system. Toll like 
receptors on APCs, are sensitive to these microbial products, leading to a cascade of events 
that promotes maturation of dendritic cells (DCs). Very small numbers of host DCs and other 
APCs, surviving for the first few days after conditioning are able to prime donor T-cell 
activation and differentiation.22 Naïve donor T-cells interact with host APCs, and are initially 
trapped within secondary lymphoid organs. There, they undergo rapid proliferation, and 
subsequently enter the circulation and travel to tissues such as gut and skin where they mediate 
GVHD.  
Recipient APCs are essential for direct allorecognition, as seen when alloreactive donor NK 
cells kill recipient MHC class I mismatched DCs, protecting mice from GVHD.15  The vital 
role of MHC Class I and II have been highlighted by a series of elegant knockout experiments. 
When donor CD8 T-cells were infused into a MHC mismatched mouse model lacking the β2 
microglobulin (which is required for antigen presentation to occur through MHC class I), there 
was no GVHD. To highlight the role of donor APCs, the converse experiment was done, with 
β2 microglobulin deficient bone marrow infused in a mismatched setting. GVHD occurred but 
was less severe. This indicated that recipient APCs are required for GVHD to occur, but this 
may be enhanced by cross priming through engrafted donor DCs. 15 MHC class II deficient 
APCs were unable to elicit GVHD, in a CD4 dependent GVHD model, but GVHD occurred 
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when wild type APCs were infused. Thus recipient APCs are essential in the early stages post 
BMT to initiate GVHD, but then donor APCs participate later on to maximize the severity of 
GVHD. 
(c) T cell Subsets in GVHD 
 
T-cells are the main inducers of GVHD in humans, as their depletion prevents GVHD, as 
exemplified in haploidentical SCT.15,23 CD4 and CD8 proteins are co-receptors for MHC class 
II and class I molecules, respectively. CD4+ cells appear critically involved in GVHD 
pathogenesis.18,24 Following cognate interaction with activated APC, CD4+ T-cells are driven 
towards T-helper cell type 1 (Th1)-biased cytokine production, promoting T-cell proliferation 
(IL-2) and further differentiation, so that very large amounts of pro-inflammatory cytokines 
are generated [particularly interferon γ (IFN-γ), TNFα], which induce tissue damage in a 
MHC-independent fashion. In contrast, donor CD8+ T-cells differentiate into efficient 
cytotoxic T lymphocytes (CTL), capable of causing host tissue damage in an MHC-I 
dependent fashion via their perforin/granzyme and FasL cytotoxic pathways.23 Grafting of TH2 
polarized T-cells reduces GVHD severity and mortality.25 However, both TH1 and TH2 
pathways can contribute to GVHD pathogenesis, with TH2 being particularly important in 
chronic GVHD. T-cells from mice deficient in signal transducer and activator of transcription 
4 (STAT 4, a Th1 associated molecule) and from mice deficient in STAT-6 ( a Th2 associated 
molecule) each induced distinct syndromes that were less severe, than those resulting from 
GVHD induced by wild type donor T-cells.15 
 
(d) Role of Memory/Naïve T cells in GVHD 
 
Peripheral T-cells can be divided broadly into 2 groups: T-cells that have never been activated 
by antigen (naïve T-cells), and antigen experienced T-cells (memory T-cells). Naive T-cells 
preferentially recirculate between blood and secondary lymphoid tissues, entering lymph 
nodes from the blood by crossing high endothelial venules. Naïve T-cells are characterized by 
the expression of CD45RA, CCR7, and CD62L+. These molecules allow naïve cells to home 
to lymphoid organs. 26 Upon antigen exposure naïve T-cells proliferate extensively, but lack 
immediate effector functions. 
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In contrast, memory and effector T-cells, unlike naive T-cells, can migrate efficiently into non 
lymphoid tissues and into sites of inflammation/ infection, subsequently entering afferent 
lymphatic vessels and travelling to local lymph nodes in the afferent lymph.26 Central memory 
(CM) T-cells have lost the expression of CD45RA but retain CCR7 expression. They retain 
homing ability to lymphoid organs and display intermediate proliferative and effector 
capacities. Effector memory (EM) T-cells ( CD45 RA-CCR7-) travel to inflamed tissues, 
where they proliferate poorly but have potent effector functions.27 
 
Initially, naïve T-cells interact with APCs, and then proliferate and differentiate into effector 
T- cells, including memory T-cells. Several independent groups have intriguingly found that 
the naïve (CD62L+) T-cells, but not memory T-cells (CD62L-) caused acute GVHD across 
different donor/recipient strain combinations in mouse models. 28 This may partly be explained 
by the ability of T-cells which are CD62 L+ to home to peripheral tissue.  In HLA-matched 
donor pairs, only naïve CD45 RA + CD8 cells, and not memory CD45 RO+ cells 
demonstrated cytotoxicity to the allogeneic stimulators.Thus, the authors concluded that the 
minor histocompatibility alloreactive CD8 cells are found predominantly in the naïve 
compartment. 29 However, cytotoxicity is only one aspect of an alloresponse and other 
measures of alloreactivity were not tested.  CCR7 deficient lymphocytes show impaired 
homing to lymphoid tissue and CCR7 antagonists have been shown to reduce murine chronic 
GVHD,30 and in human BMT recipients, those who have received a high percentage of donor 
derived CD4+CCR7+ T cells (>73.5 % of CD4+ cells) in their grafts, showed earlier onset and 
more severe acute GVHD.31  Thus, there is considerable evidence, particularly in mouse 
models that the majority of alloreactive T-cells reside in the naïve compartment.  
 
The majority of the above data has been generated using mouse T-cells. The situation in 
humans may be more complex. Human memory T-cells (CD45RA-) cells proliferate and 
secrete IL-2 in response to alloantigen as well as naïve CD45RA+ cells, 31,32  though they had 
reduced cytotoxicity to alloantigen.33 Additionally, transfer of memory T-cells and memory 
stem cells has been shown to promote GVHD30,34,27 and GVHD is also more severe in male 
recipients of multiparous female donors, suggesting the transfer of donor memory cells.35 
Thus, in humans, the relative role of naïve and memory T-cells in the pathogenesis of GVHD 
is yet to be determined.  
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(e) T cell Cytokines 
 
The presentation of alloantigen induces a response involving proliferation of donor T-cells and 
secretion of interleukin-2 (IL-2) and interferon γ (IFNγ) leading to the generation of T 
cytotoxic clones, as seen in Fig 2 .  
 
IL-2 is a critical cytokine for T-cell survival, differentiation and proliferation and plays a 
major role in generation of T-regulatory responses. It is mainly produced by CD4+ T-cells and 
acts as a growth factor in an autocrine or paracrine manner promoting T-cell clonal expansion, 
differentiation into memory and effector T-cells, NK cell proliferation, and increased cytotoxic 
activity. Serum IL-2 receptor levels are elevated in acute GVHD.36  The central importance of 
IL-2 signalling in GVHD is illustrated by the drugs that are used to combat it. Ciclosporin and 
FK506, the drugs most commonly used for GVHD prophylaxis, inhibit IL-2 production by 
inhibiting signalling through the T-cell receptor. Likewise, rapamycin and dacluzimab both of 
which inhibit signalling through the IL-2 receptor, show some efficacy in treating steroid 
refactory GVHD.37 
 
Interferon gamma (IFNγ) activates macrophages to kill phagocytosed microbes, promotes the 
differentiation of naïve CD4+ T-cells to the Th1 subset and inhibits the differentiation of Th2 
cells. IFNγ enhances the expression of MHC class I and II molecules and up regulates co- 
stimulators on APCs. Grafting of IFNγ deficient donor cells has been shown to lead to both 
accelerated and diminished GVHD depending on the conditioning regimen.38 Thus, IFNγ 
appears to have both protective and pathogenic effects in GVHD. 39 One possible explanation 
could be due to differential effects of IFNγ on different organ systems. In a mouse GVHD 
model, donor derived IFNγ promoted acute GVHD by accelerating Th1 differentiation and by 
augmenting inflammatory cytokine generation in the gut. However, donor derived IFNγ 
inhibited the development of idiopathic pulmonary syndrome by inhibiting donor cell 
migration and expansion within the lung and inhibited cutaneous GVHD.  
 
One cytokine frequently implicated in the evolution of GVHD is TNF-alpha (TNFα). The 
secretion of TNFα in GVHD is related to endotoxin release from gut flora. Endotoxin is a 
well-known stimulus for TNFα production and release. Gnotobiotic mice, defined as animals 
free of pathogens, are protected from GVHD following BMT. Recolonization by gram-
negative bacteria subsequently led to GVHD in these animals. It appears that damage to the 
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gastrointestinal tract from radiation and/or chemotherapy allows flora and endotoxins to enter 
the circulation leading to TNFα secretion from monocytes. Variations in donor or recipient 
genes that encode the pattern recognition receptor (NOD2/CARD15) affect the response of 
macrophages to bacterial toxins and can affect the incidence of gut GVHD.40 The major 
cellular source of TNFα is activated mononuclear phagocytes, although antigen stimulated T-
cell and NK cells can also produce it. TNF-α can (1) cause cachexia, which is a characteristic 
feature of GVHD; (2) induce maturation of DCs, thus enhancing alloantigen presentation; (3) 
recruit effector T-cells, neutrophils, and monocytes into target organs through the induction of 
inflammatory chemokines; and (4) cause direct tissue damage by inducing apoptosis and 
necrosis.34 Donor T-cell derived TNFα has been shown to promote GVHD18, especially in the 
liver and gut and is also required for GVL activity. 41 The presumed contribution of tumor 
necrosis factor-alpha (TNFα) to acute GVHD and the association of higher serum levels with 
severe GVHD42 provide the rationale for the use of anti-TNFα antibodies (e.g. infiximab) in 
the treatment of GVHD43. 
 
IL-15 is produced predominantly by cells of the monocyte/macrophage, dendritic and stromal 
cell lineages and is critical for the survival of CD8 memory T-cells that are involved in 
GVHD. Administration of exogenous IL-15 worsens the severity of GVHD in mouse models 
and was associated with a dramatic expansion and activation of effector-memory CD8+ T-
cells.44 Recently a new subset of CD4+ T-cells, which produce IL-17 (Th17 cells) has been 
characterised. These cells have been implicated in autoimmune diseases such as multiple 
sclerosis, and rheumatoid arthritis. Preliminary data suggests that they may have a role in acute 
and chronic GVHD (CD4+ T-cells from IL-17 knockout mice caused less GVHD than wild 
type) though further work is required to confirm this data.45,46  
 
Genetic variants in cytokine secretion can also affect GVHD severity. IL-10 promotes 
tolerance by suppressing the release of inflammatory cytokines and inhibiting the activation of 
donor T-cells. Homozygosity for a common polymorphism of the IL-10 promoter increases 
IL-10 production and reduces the incidence of GVHD. 16  
(f) Leukocyte Migration 
 
Donor T-cells migrate to lymphoid tissues, recognize alloantigens on either host or donor 
APCs, and become activated. They then exit the lymphoid tissues and traffic to the target 
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organs and cause tissue damage. The molecular interactions necessary for T-cell migration and 
the role of lymphoid organs during acute GVHD have recently become the focus of a growing 
body of research. However, interfering with T-cell trafficking may hinder T-cell immunity to 
leukaemia and viral antigens. Thus the challenge for developing leukocyte migration 
antagonists to prevent GVHD is selectivity.  
 
Phase 3- Effector Phase 
Effector mechanisms of acute GVHD can be grouped into cellular effectors [e.g. cytotoxic T 
cells (CTLs)] and inflammatory effectors such as cytokines. Perforin-dependent cytolysis and 
Fas-mediated apoptosis are the two important mechanisms for T-cell mediated cytotoxicity in 
GVHD. The principal mechanism of CD8+ CTL- mediated target cell killing is the delivery of 
cytotoxic proteins stored within cytoplasmic granules to the target cell, thereby triggering 
apoptosis of the target cells. These granules contain granzymes A, B, and C, perforin, and 
serglycin. The latter assembles complexes of perforin and granzyme. Perforin’s main function 
is to deliver the granzymes into the target cell. Once inside the cell, the granzymes cleave 
substrates and trigger apoptosis. Mice which received perforin deficient T-cells develop all the 
signs of GVHD, but only after a significant delay in onset,47 suggesting  that perforin plays a 
role in the pathogenesis of GVHD. CTLs also kill targets by expressing FAS ligand (FasL) that 
binds to the death receptor Fas. This interaction activates caspases and leads to apoptosis of 
targets.   Mice which received FasL defective T-cells develop severe cachexia, but only 
minimal GVHD-associated changes in liver or skin, suggesting that, FasL plays a particular 
role in GVHD affecting these target tissues. In a MHC class I-mismatched lethally irradiated 
murine model, wild type and either perforin deficient or FasL deficient CD8+ T-cells 
expanded early after transplantation, followed by a contraction phase in which the majority of 
expanded CD8+ T-cells were eliminated. In contrast, doubly deficient CD8+ T cells exhibited 
prolonged expansion, causing lethal GVHD.48 Results in the doubly deficient animals suggest 
that both perforin and FasL play an important role in the regulation (i.e., contraction) of 
expanded alloreactive CD8+ T cells. Thus these molecules appear to have a dual role in 
GVHD. 
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Co stimulatory Interactions 
(a) Co stimulatory Receptors 
T-cells require two separate signals to enter the cell cycle: 
• Signal 1 is antigen-specific and is provided by the engagement of the T-cell receptor 
with peptide complexed with MHC on the antigen presenting cell  
• Signal 2 is provided by the interaction of one or more T-cell surface receptors with 
their specific ligands on the APC cell surface (co-stimulatory pathways).  
Inadequate stimulation of these co-stimulatory molecules can lead to T-cell anergy and 
apoptosis.  There are two major groups of co stimulatory receptors: the immunoglobulin super 
family including CD28 and inducible T-cell co-stimulator (ICOS) and the tumour necrosis 
factor super family including OX40, CD27, 4-1BB, CD30 and HVEM (herpes virus entry 
mediator). 25 
 
CD28 is constitutively expressed on 90 % of human CD4 cells and 50% of human CD8 cells. 
CD28 binds to CD80 and CD86 which are expressed on dendritic cells (see Fig 3 and Table 1). 
This interaction strongly amplifies weak T-cell receptor (TCR) signals, activates transcription 
factors, and accelerates intracellular vesicular trafficking. CD28 signalling stabilizes IL-2 
mRNA and activates transcription factors NF-κβ and AP-1. These two effects increase IL-2 
production by 100 fold. CD28 can promote enhanced activation and survival both of antigen 
presenting cells and T-cells.  
 
In addition to these ligands that transduce a co-stimulatory or activating signal, cytotoxic T 
lymphocyte-associated antigen 4, or CTLA4, which also binds B7-1 and B7-2, provides an 
inhibitory signal. Although CD28 is expressed on resting T-cells, CTLA4 is expressed on the 
cell surface only after initial T-cell activation. CTLA-4 acts as a negative regulator of the 
CD28- CD80/86 signalling. It has a higher affinity for CD80/86 than CD28. CD28 signalling 
leads to increased expression of CTLA-4, which in turn negatively feeds back to inhibit the T- 
cell responses. The importance of CTLA4 is illustrated by the following observations: 
• CTLA4 knockout mice develop massive lymphoproliferative disease, culminating in early 
death 49 
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• The administration of blocking anti-CTLA4 monoclonal antibodies exacerbates autoimmune 
disease and prevents induction of T-cell anergy 50  
• Blockade of the CD28/CD80:86 interaction by administration of CTLA4-Ig greatly reduced 
lethal GVHD after haploidentical SCT in humans, and did not inhibit donor T cell 
engraftment.30 However, CD28 is constitutively expressed on T-cells, so that targeting CD28 
would be predicted to lead to extensive loss of desirable T-cells responses as well as 
alloreactive T-cells. 
 
ICOS is present on resting T-cells but is up regulated on both CD4 and CD8 cells following T- 
cell activation and interacts with ICOS ligand which is present on dendritic cells, B cells and 
macrophages. 51 In mouse GVHD models, administration of ICOS deficient CD4 cells led to 
reduced GVHD morbidity and delayed mortality. These CD4 cells showed impaired effector 
functions, as characterized by reduced CD95 ligand expression, and lower levels of IFNγ and 
TNFα . However, the administration of allogeneic ICOS deficient CD8 cells led to increased 
expansion of these cells and increased cytokine release, due to impaired apoptosis of these T-
cells.52 Thus ICOS has paradoxical effects on the regulation of CD4 and CD8 alloreactive T- 
cells in GVHD. 
 
OX40 (CD134) is a member of the TNF receptor super family, and interacts with OX40 
Ligand, which is present on activated dendritic cells. OX40 ligation results in expression of 
CXC chemokine receptor 5 by activated T-cells, directing CD4+ T-cells to B cell follicles. In 
concert with that of 4-1BB and possibly CD30, OX40 ligation results in an increase in anti-
apoptotic proteins, regulating effector persistence.51 In mixed lymphocyte reactions OX40 has 
been shown to be strongly up regulated on human CD4+ lymphocytes.53 Transfer of OX40 
deficient T-cells into a lethal mouse GVHD model ameliorated GVHD compared to infusion 
of wild type T-cells.54  However, in patients with acute GVHD, there was no increase in OX40 
expression on T lymphocytes but there was increased OX40 expression during chronic GVHD, 
which declined with successful treatment.55  More recently, OX40 has been shown to act as an 
inhibitory receptor on T-regulatory cells.56  Co-transfer of T-regulatory cells to mice prevented 
lethal GVHD but pre-treatment of these T-regulatory cells with an agonistic OX40 antibody, 
worsened GVHD. However, in view of OX40 and ICOS both being unregulated on activated 
T-cells, both would be reasonable targets to explore for allodepletion. 
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 Figure 3: T cell/APC Co stimulatory Interactions. CD40 and CD28 amplify a cascade of 
secondary co-stimulatory pathways. Following initial TCR stimulation and CD28 ligation the expression of 
multiple other co-stimulatory receptors belonging to the immunoglobulin and TNF superfamilies is rapidly 
induced. In this way, CD28 can promote enhanced activation and survival both of antigen presenting cells and T 
cells, as well as B cell-mediated humoral responses. CD40 ligation results in increased ligand density of both 
CD80/86 and OX40L. OX40 ligation results in expression of CXC chemokine receptor 5 by activated T cells, 
directing CD4 T cells to B cell follicles, where the upregulation of ICOS by CD28 enables interactions favouring 
germinal centre development and antibody class-switching. OX40 ligation, in concert with that of 4·1BB and 
possibly CD30, results in an increase in anti-apoptotic proteins, regulating effector persistence. Expression of 
CTLA-4 is also enhanced by CD28 signalling, and favours downregulation of T cell responses and Th1 
polarisation. Interactions of T cells with antigen presenting cells (APC) at sites of peripheral tissue inflammation 
via the PD-1:PD-L1/L2 system results in inhibitory signalling with reduced cytokine secretion and cell cycle 
arrest. The existence of a further co-stimulatory receptor exerting positive signalling in this system remains 
possible Reproduced from51 
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CD40 Ligand (CD154) is expressed primarily on activated T-cells and interacts with CD40 on 
antigen presenting cells. This interaction is important for antibody class switching and up 
regulation of CD80 and CD86 on APCs. Administration of anti-CD154 led to reduced acute 
and chronic GVHD in murine models, but significantly reduced GVL30,57   Anti CD40 Ligand 
antibody has been shown in vitro to potently inhibit primary and secondary MLRs, by causing 
anergy.58   
 
4-1BB (CD137) is up regulated on activated T-cells and NK cells and interacts with 4-1BB 
ligand which is expressed on APCs. CD137 is important in co-stimulation of CD8+ effector 
memory cells, and anti CD137 antibodies, inhibit CD4 and CD8 T-cell mediated GVHD.30.  
Hartwig et al demonstrated that CD8 CTL cultures, stimulated weekly with HLA-mismatched 
AML blasts 59 showed maximal expression of CD137 on day 1 after stimulation, with 
subsequent rapid downregulation. However, our method of identifying alloreactive T-cells 
(carboxyfluorescein succimidyl ester dye (CFSE) dilution), only detects these cells at later 
points in co-culture. Thus, we would be unable to characterize CD137 expression in the 
proliferating alloreactive T-cell population, and we therefore decided not to examine this 
marker. 
 
Co-stimulatory 
pathway 
Methods used to evaluate the role of the pathway Results 
CD28 CD28-deficient T cells, CTLA4–immunoglobulin fusion proteins, 
CD80- and CD86-specific antibodies, and CD80- and CD86-
deficient mice 
Model-dependent reduction in 
GVHD (more apparent for CD4+ 
T cells) 
HVEM Soluble receptors and HVEM-specific antibody Diminishes GVHD in Parent F1 
model with sub lethal irradiation 
ICOS ICOS blockade and ICOS-deficient T cells Promotes GVHD, effector 
maturation and TH1-cell 
polarization 
OX40 OX40L blockade and OX40-deficient T cells OX40 promotes GVHD; CD4+ T 
cell more than CD8+ T cell 
CD30 CD30 blockade, CD30-deficient T cells and CD30L-deficient 
recipients 
Promotes CD4+ T-cell-mediated 
but not CD8+ T-cell-mediated 
GVHD 
CD153 (CD30L) Agonist antibody Promotes CD4+ T-cell-mediated 
and CD8+ T-cell-mediated 
GVHD 
PD1 PD1 blockade, PD1-deficient T cells Inhibits GVHD 
CD30L, CD30 ligand; CTLA4, cytotoxic T-lymphocyte antigen 4; GVHD, graft-versus-host disease; HVEM, herpes-virus-
entry mediator; ICOS, inducible T-cell co-stimulator; OX40L, OX40 ligand; PD1, programmed cell death 1; TH, T helper. 
Table 1:Co stimulatory Antigens and their actions Reproduced from15 
(b) Activation Markers 
Characterizing the phenotype of alloreactive T-cells is critical to enable rational approaches to 
allodepletion. Activated T-cells characteristically up regulate markers such as CD25, CD69, 
CD95, and HLA-DR. 
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CD25 is strongly expressed on proliferating alloreactive T-cells.24,60 CD25 (IL-2 receptor) has 
three chains:α,β, and γ. Resting cells express CD25 composed of β and γ chains which bind to 
IL-2 with moderate affinity, allowing resting T-cells to respond to very high concentrations of 
IL-2.  Upon activation of the T-cell, the α chain is also synthesized and this creates a receptor 
with a much higher affinity for IL-2. CD25 shows higher expression on T-regulatory cells than 
activated cells. Thus, any CD25 based allodepletion strategy will delete target T-regulatory 
cells. Binding of IL-2 by CD25 triggers cell proliferation and differentiation into effector cells. 
 
CD69 is a type II integral membrane protein belonging to the family of C- type lectin 
receptors. It has been shown to form a complex and negatively regulates with sphingosine 1 
phosphate recpetor-1 (S1P1). It acts downstream of IFNα/β to inhibit the egress of 
lymphocytes from lymphoid organs.61 It is one of the earliest detectable cell surface markers 
detectable when resting lymphocytes are stimulated by mitogen. In  MLRs, it has been 
detected at 24 hours, rising to a peak at 96 hours and then plateauing.62 
 
CD95 (Fas antigen) is a 45 kDa cell surface type 1 membrane protein member of the tumour 
necrosis factor (TNF)/nerve growth factor receptor family. Once triggered by its cognate 
antigen, Fas ligand, Fas initiates a series of events that lead to apoptosis of the cell. This 
process involves the formation of the death inducing signalling complex, consisting mainly of 
Fas –associated death domain and caspases 8 and 10 proteins. Mutations in the Fas gene have 
been shown to be responsible for autoimmune lymphoproliferative syndrome (ALPS), a 
disorder characterized by autoimmunity, and lymphoproliferation.63  Fas has been shown to be 
up regulated in mouse models of GVHD64, and on CD8+ cells in patients with acute GVHD.65 
In MLRs Fas expression is  low on Days 1-3 but then is up regulated rapidly peaking on day 
5.66 Susceptibility of lymphocytes to apoptosis in MLR cultures using anti Fas antibodies 
increases above baseline on Day 5 and peaks on day7.66 Transfection of antigen presenting 
cells using Fas ligand has been shown in a mouse model to induce clonal deletion of antigen 
specific T-cells.67 
 
CD71 is a type II transmembrane glycoprotein largely expressed on proliferating cells 
including proliferating T-cells where it is involved in iron homeostasis.68 Iron is involved in 
essential cellular functions such as energy transport and DNA synthesis. Transferrin is the 
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main protein involved in serum iron transport and iron uptake is essentially dependent on 
receptor-mediated endocytosis, involving the transferrin receptor. CD71 is homodimeric 
receptor (180 kDa) which allows internalization of iron-bound transferrin in clathrin-coated 
pits. In endosomal vesicles, iron is then released by compartment acidification (pH 5–5.5), 
while apo-transferrin and CD71 are recycled into the blood or to the cell surface, respectively. 
CD71 expression is strictly regulated by intracellular iron level: CD71 mRNA is stabilized and 
abundant in iron-deficient cells to increase extracellular iron uptake. This post-transcriptional 
regulation is allowed by the presence of iron responsive elements (IRE) in the 3'-untranslated 
region of the CD71 transcript that are recognized by two iron regulatory proteins.  
CD71 has been shown to be important in the pathogenesis of GVHD. Nguyen et al. 
demonstrated in a MLR69 that there was strong up regulation of CD71 on alloreactive T-cells, 
peaking on days 7-9 with CD71 showing best correlation with T-cell proliferation. Transferrin 
is a critical growth factor for lymphocytes in vitro. 70 Proliferating thymocytes and 
lymphocytes express high levels of the transferrin receptor, and anti CD71 antibodies inhibit 
thymocyte and lymphocyte proliferation and differentiation in vitro. Administration of anti- 
CD71 antibodies have been shown in mismatched mouse model to significantly prolong 
pancreatic islet graft survival71. This was associated with a reduction in IL-2, IFNγ levels and a 
rise in IL-10. Drobyski et al demonstrated that administration of gallium (a metal that binds to 
transferrin, depriving proliferating cells of iron) potently inhibited MLRs and prolonged 
survival in a mouse model of GVHD.72 The low level of CD71 expression on resting 
lymphocytes and its significant up regulation in a MLR make it an important marker to 
examine in allodepletion. 
 
HLA-DR is a class II molecule and is up regulated on activated T lymphocytes in mixed 
lymphocyte cultures peaking between days 7-9.69   
(c) Signal Transduction by the TCR Complex 
Following T-cell activation, four major biochemical events occur within the cytoplasm. These 
include the following: 
• Hydrolysis of membrane bound inositol phospholipid  
• Increases in cytoplasmic calcium  
• Tyrosine phosphorylation of a variety of proteins  
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• Increases in protein kinase C activity.  
T-cell signalling pathways co-ordinately activate the transcription of genes that are silent in 
naïve T-cells. When T-cell activation occurs, lck, a src tyrosine kinase phosphorylates ITAM 
(immunoreceptor tyrosine based activation motifs) residues found on the CD3ζ  and CD3 
complex. This in turn leads to activation of another tyrosine kinase called Zap 70. This leads to 
activation of important downstream pathways such as Ras-Map kinase pathway, the protein 
kinase C pathway and the calcium-calcineurin pathway. These in turn lead to up regulation of 
transcription factors such NFAT (nuclear factor of activated T-cells), NF-κβ, and AP-1. These 
stimulate the expression of various genes involved in T-cell responses such- as IL-2. 
Calcineurin dephosphorylates cytoplasmic NFAT, permitting its translocation to the nucleus 
where it binds to the IL-2 promoter sequence and then stimulates transcription of IL-2 mRNA. 
NF-κβ is another important nuclear transcription factor that is activated by several different 
signals that include TNF, IL-1, and LPS. In the resting cell, this molecule is found in a 
heterodimeric form in the cytoplasm bound to inhibitors of κβ (Iκβs). Signal induced 
degradation of the Iκβs frees the NFκβ, permitting it to enter the nucleus where it binds to its 
specific binding site. Transcription of a number of different genes including MHC class I, and 
IL-2 then ensues.  
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Phenotypic Characterization of Proliferating Alloreactive T cells 
 
As outlined above alloreactive T-cells have been identified by a variety of phenotypic 
endpoints, including expression of activation markers/co-stimulatory molecules, cytokine 
secretion in response to alloantigen and proliferation. While alloreactive T-cells have multiple 
phenotypes, proliferation in response to alloantigens is their most basic hallmark. To monitor 
T-cell proliferation, T-cells can be labelled with carboxyfluorescein succimidyl ester (CFSE) 
dye. CFSE is a membrane permeable dye that binds to intracellular proteins, and upon cell 
division, the cell fluorescence decreases by half. Therefore by following the CFSE dim cells, 
one can analyse the dividing cells Using this technique, Godfrey et al24 identified alloreactive 
T-cells flow cytometrically by co-culturing CFSE stained CD4+ cells with alloreactive 
PBMCs or dendritic cells. Two distinct populations, the CFSE Dim or dividing alloreactive T- 
cells, and the CFSE bright or non-dividing, non alloreactive T-cells were discernible. Dendritic 
cells were superior stimulators of alloreactive T cell proliferation than PBMCs as they were 
able to recruit a larger frequency of T-cells to divide in response to alloantigen. (Fig 4a, b)  
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Figure 4: Clear separation of CFSE Dim and CFSE Bright in allogeneic MLRs. CFSE labelled 
CD4+ cells were co cultured with HLA mismatched PBMCs or dendritic cells. The no of CFSE Dim cells after 7 
days in the DC co cultures was almost double that of the PBMCs co cultures. Thus, dendritic cells are superior in 
stimulating alloreactive T cell proliferation compared to PBMCs. The majority of CFSE Dim cells are CD25 + 
(C,D) There remain CD25- CFSE dim cells (Figure C). There are also CFSE Bright CD25+ cells. The nature of 
the latter are unknown. Reproduced from24 
 
Thus, by labelling T-cells with CFSE, it is possible to identify alloreactive T-cells in a MLR, 
allowing us to investigate their phenotype. Furthermore, flow cytometric depletion of CFSE-
dim T-cells almost completely abrogated in vitro alloreactivity in secondary MLRs and 
markedly reduced GVHD in an MHC Class II disparate murine model. FACS analysis of the 
CFSE dim population showed that this strongly expressed CD25 whilst the CFSE bright 
population had weak staining of CD25 (5 % of cells) (Fig 4c,d). It was unclear whether this 
latter population were anergic T-cells, regulatory T-cells or T-cells which were about to 
    CFSE Bright CD25 +     CFSE Bright CD25- 
CFSE Intensity 
No 
of 
Cells 
CD25 
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divide. CFSE-based precursor frequency analysis indicates that approximately 5% (range, 
3.1%-6.5%) of the CD4+ T-cells are recruited into cell division by the mature DCs which is 
significantly higher than that obtained by limiting dilutional assays.18  
 
Infusion of CFSE bright T-cells into an animal model of GVHD led to prolonged survival 
compared to infusing CFSE dim or unmanipulated PBMCs24. However infusing CFSE Bright 
(non alloreactive T cells), into a mouse leukaemia model, did not support donor engraftment or 
enhance tumour control compared to a bone marrow, though it did reduce GVHD. 73 This 
suggests that depletion of alloreactive T-cells may compromise GVL responses, and that novel 
methods of preserving this are required. 
 
Graft versus Leukaemia 
The rationale for using immunotherapy to prevent and/or treat the re-emergence of malignancy 
is based in part upon the following observations 
1. There is an increased relapse rate after syngeneic transplants (where there is no 
alloreactivity) or after T-cell depleted BMT 74 
2. Association between GVHD and a lower risk of relapse. Relapse is related to the HLA 
disparity between donor and host and the number of T-cells infused.75 
3. The infusion of donor leukocytes into patients who have relapsed following an 
allogeneic HCT has directly resulted in a GVL effect, especially in chronic myeloid 
leukaemia (CML)  
 
Donor lymphocyte infusions (DLI) can restore durable remissions in patients with 
haematological malignancies (particularly myeloid) who have relapsed post BMT. This effect 
is most impressive in chronic phase CML (cytogenetic response of between 70-80 % in 
chronic phase), EBV lymphoproliferative disease (LPD) and paediatric juvenile 
myelomonocytic leukaemia. DLI shows lesser degrees of activity in acute myeloid leukaemia 
(AML), myelodysplasia, myeloma, Hodgkin’s lymphoma, chronic lymphocytic leukaemia, 
and Philadelphia positive acute lymphoblastic leukaemia.76 The efficacy of DLI also reflects a 
complex equation between the nature of the leukaemia, the tumour burden, the kinetics of 
leukaemic cell growth, the potential for alloreactivity and the T-cell dose. Up to 50 % of 
patients experience significant GVHD with DLI, but a proportion do experience GVL without 
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GVHD, suggesting that GVL can be separable from GVHD, particularly when DLI are 
administered in a dose escalating fashion.77-79 
 
The cell populations capable of recognizing and lysing malignant targets can be divided into 
two broad categories based upon the mechanism of cellular recognition: cytotoxic T-cells 
(CTLs) and natural killer (NK).  T-cells do so in a HLA-restricted manner, and NK cells kill 
via the presence or absence of receptors such as KIRs. It is thought that T-cells mediate their 
GVL effect in three ways;80  
 
A) Direct killing of leukaemia cells by perforin and granzyme attack from cytotoxic 
lymphocytes (CD4+, CD8+ and NK cells); 
B) Apoptotic death through the Fas/Fas ligand pathway (CD4+ and CD8+ T cells),  
C) Cytokine-mediated leukaemia cell death (e.g. IFNγ , TNFα) or control of proliferation 
(mainly CD4+ cells) 
It now appears that as well as initiating the alloresponse, CD4+ T-cells are also critical in the 
effector phase of GVL. CD4+ cells produce cytokines with a wide spectrum of biological 
activities: production of IL-2 and IL-12 recruits NK cells and CD8+ T cells into the immune 
responses and augments their antitumor cytotoxicity. IFNγ and TNFα inhibit leukaemia cells 
directly and both cytokines up regulate MHC and Fas antigen expression rendering targets 
susceptible to cytotoxicity by T-cells. CD4+ cells therefore have a role both as effectors and as 
orchestrators of the GVL response.  
Targets for the GVL Effect 
Cytotoxic T-cells (CTLs), recognize malignant cells as foreign when unique antigens are 
expressed by the tumor. CTL responses in GVL are directed against 3 broad classes of antigen: 
• Minor histocompatibility antigens  
• Tumour associated antigens 
• Viral Antigens 
(a) Minor Histocompatibility Antigens  
 
One of the most important T-cell targets in GVL reactions are minor histocompatibility 
antigens. Minor histocompatibility antigens (mHAgs) are highly immunogenic peptides which 
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are presented in a HLA restricted manner. Polymorphisms in these mHAgs between donor and 
host can result in GVHD and GVL. GVHD can be seen in male recipients of HLA identical 
grafts from female donors, due to recognition of minor antigen (HY) encoded by the Y 
chromosome. Conversely, these mHAgs are responsible for graft rejection in female recipients 
of HLA identical grafts from male donors. Some mHAgs are present ubiquitously (e.g. HY), 
and thus CTLs directed against these antigens will result in GVL and GVHD. Others, such as 
HA-1 and HA-2 are only present on haematopoietic tissues, and thus should only elicit GVL 
responses, though in fact HA-1 mismatching has been shown to be associated with GVHD.20  
 
HA-1 and HA-2 are both encoded by biallelic gene systems with one being immunogenic, and 
the other nonimmunogenic.81 The immunogenic peptides encoded by HA-1H and HA-2V are 
presented on HLA-A2 molecules and then recognized by HLA-A2 restricted CTLs, whilst the 
non immunogenic peptides, are functionally silent due to poor presentation. Thus, while HA-1 
and HA-2 are potential targets of immunotherapy, the applicability of this approach would be 
limited to patients who are HLA-A2 positive and who carry at least one immunogenic variant 
that have a donor who is homozygous for the nonimmunogenic allele. It is estimated that only 
10-15 % of sibling transplants expose a GVL effect of HA-1 mismatching.75  In one study 
where there was a HA-1/HA-2 mismatch between donor and recipient, 33 % of CTL clones 
generated after DLI were specific for HA-1 and HA-2. The other 67 % of leukaemia reactive 
CTLs were of unknown specificity.75 This shows that the immune system reacts against a 
variety of antigens to eradicate leukaemic clones. A clinical vaccine trial with HA- 1 or HA-2 
peptides after HSCT in HLA-A2+ve patients is currently in progress. 
(b) Tumour Associated Antigens 
 
Tumour associated antigens are those antigens that are expressed in cancer cells, but at low 
levels or not at all, in normal tissue. Whilst considerable effort has been made to identify 
tumour specific neoepitopes e.g. created by leukaemic fusion genes such as BCR-ABL, there 
is little evidence that such epitopes are processed and presented in vivo or that they are 
significant targets for a GVL response. However, an increasing body of evidence suggests that 
over expressed tumour associated antigens may be used as targets to augment GVL responses. 
Proteinase 3 is a tumour associated antigen and is over expressed in CML and AML. PR1 is a 
HLA-A2 restricted peptide derived from proteinase 3. PR1-specific CTLs have been shown to 
kill myeloid leukaemic colonies that over express proteinase 3, but not normal marrow cells. 82 
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Increased numbers of high avidity PR1 CTLs have been seen in CML patients who develop 
cytogeneic remission in response to IFNα.75  Low frequencies of PR1 CTLs are also found in 
healthy donors.83  
 
Other tumour associated antigens include Wilm’s Tumour Protein (WT1), which is over 
expressed in myeloid malignancies. WT1, a zinc-finger transcription factor, was initially 
described as a tumor-suppressor gene in childhood Wilms' tumor. WT1 is abundantly over 
expressed in most human leukaemia cells, including AML, CML and acute lymphocytic 
leukaemia, with higher levels associated with a worse prognosis. Leukaemia stem cells express 
between 10- to >100-fold more WT1 protein than normal CD34+ cells. T-cells can distinguish 
this difference in protein expression, as CD8+ CTLs generated against WT1 lyse leukaemic 
CD34+ but not normal CD34+ cells, and inhibit growth of leukaemic but not normal myeloid 
colonies.84 Thus, like PR3, WT1 might serve as a useful target for adoptive T-cell therapy.  
Phase 1/II clinical trials using peptide vaccines with PR1 and WT1 in HLA-A2  patients with 
AML and CML are currently underway.85 Of note, allodepletion strategies using LCLs, (which 
do not express myeloid antigens) as APCs, have been shown to preserve potential anti-myeloid 
tumor T-cell responses.86 
(c) Viral Antigens 
 
Latent EBV infection is associated with non-Hodgkin’s lymphoma, Burkitt’s lymphoma, NK 
cell lymphoma, lymphoproliferative disease, Hodgkin’s lymphoma, and nasopharyngeal 
carcinoma, making adoptive T cell strategies targeting EBV a potential option. DLI and 
adoptive transfer of EBV-specific CTLs have led to remissions in post transplant 
lymphoproliferative disease and Hodgkin’s disease.76,87,88 
 
Improving Anti-leukaemic and Anti-viral Responses post 
Haploidentical BMT 
As highlighted above, the requirement for rigorous T-cell depletion in haplo-SCT to avoid 
GVHD leads to a delay in immune reconstitution leading to a high mortality from viral 
infections/relapse. There have been numerous approaches to improving immune reconstitution 
after haplo-SCT.  As the frequency of allo-reactive T-cells is logs higher than anti-viral/anti-
leukemic T-cells, unmanipulated DLI cannot be used, without the risk of severe GVHD.89 
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Thus, there is a need to addback T-cells responsible for the GVL and anti-viral responses, but 
without allo-reactive T-cells that cause GVHD.  There are several approaches to this problem: 
(a) Adoptive Transfer of T cell precursors 
(b) Alloanergisation  
(c) Antigen Specific CTLs 
(d) DLI transduced with suicide gene  
(e) Allodepletion 
 
(a) Adoptive Transfer of T cell Precursors 
 
One way to minimize GVHD after adoptive immunotherapy is to transfer T-cell precursors 
rather than mature T-cells. These T-cell precursors will progress through the thymus, and the 
alloreactive T-cells will be deleted, allowing T-cell reconstitution but without GVHD. 90 Using 
this approach, mouse T-cell precursors generated in vitro from stem cells ( isolated on the 
basis of culturing mouse stem cells on mouse stroma expressing Notch-1 ligand), were 
transferred to HLA mismatched mice after lethal irradiation and T-cell reconstitution was 
assessesed.90  Compared to mice receiving stem cells alone, mice receiving T-cell precursors, 
showed enhanced thymic reconstitution and a rapid recovery of host-tolerant CD4 and CD8 
populations with normal T-cell repertoires, cytokine secretion and proliferative responses to 3rd 
party antigen. These mice did not develop GVHD, reflecting depletion of alloreactive T-cells 
in the thymus, leading to tolerance. Significant GVL effects were seen in mouse lymphoma 
models that received these precursors and such mice had superior survival compared to control 
mice.  This approach is attractive as it uses the host’s thymic system to deplete alloreactive T- 
cells, but thymic activity in adults is limited and further studies on whether it is similarly 
possible to isolate and transfer human T-lymphoid progenitors under GMP conditions are 
required. 
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(b) Alloanergisation 
 
Interest in the manipulation of the CD28:B7 pathway in transplantation has focused on the 
administration of CTLA4-Ig, which is a recombinant fusion protein that contains the 
extracellular domain of soluble CTLA4 combined with an IgG1 heavy chain. CTLA4-Ig has a 
higher affinity for the B7 molecules than CD28, resulting in blockade of the CD28-B7 
interaction and hence T-cell anergy in vitro. Guinan et al. used this approach by co-culturing 
T-replete donor marrow cells with recipient mononuclear cells ex vivo in the presence of  
CTLA4-Ig.91. 12 patients with predominantly high risk malignancies underwent haploidentical 
transplants using alloanergised grafts. All patients received at least 107 CD3+ cells/kg with the 
bone marrow i.e. 3 logs more than routinely transferred with a haploidentical graft. The 
precursor helper T-cell frequency against recipient stimulators was reduced by between 1-3 
logs, but third party responses were not significantly reduced. All patients engrafted. The 
incidence of GVHD was impressively low given the number of T-cells infused, as only three 
of the eleven evaluable patients developed acute GVHD (≥ grade 2), and only one went onto 
develop chronic GVHD. There were four deaths due to infection (2 from aspergillus, 1 
bacterial, 1 from toxoplasmosis). 5 of the 12 were alive at the time of analysis. The low 
survival rate was partly due to the high risk cohort, many of whom had been heavily pre-
treated. However, effect of alloanergisation on desirable anti-viral/ anti-leukaemic responses 
was not formally assessed and it is possible that the high rate of infectious deaths reflects a 
negative effect of CTLA-4 Ig on bystander T-cells responsible for such responses. Further, 
anergy can be reversed e.g. by addition of exogenous IL-2 so that it is possible in the 
appropriate cytokine milieu, anergised alloreactive T-cells could cause GVHD.  Unfortunately, 
further clinical studies were not possible since a GMP CTLA4-Ig is not available. However, 
clinical studies using newly developed similar agents are shortly to begin in The US. 
(c) Antigen Specific CTLs 
The feasibility of adoptive immunotherapy to improve immunity post –HSCT has been 
demonstrated by studies where ex vivo generated CTL, directed against viral antigens have 
been infused post HLA- matched SCT.   
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1. Adoptive Immunotherapy for EBV 
 
By repetitively stimulating PBMCs with lethally γ-irradiated EBV-transformed autologous B 
lymphoblastoid cell line (LCL), EBV-specific CTL lines can be generated in vitro which 
recognize the immunogenic type 3 antigens, chiefly EBNA-3. Using such an approach, 
Rooney et al infused retrovirally marked donor-derived EBV CTLs. After infusion of these 
CTLs, there was a 4 log rise in the precursor frequency of EBV CTLS in the patients' blood, 
and the EBV viral load decreased by 2-4 logs. None of these patients developed EBV post 
transplant lymphoproliferative disease (PTLD), compared to 11 % in historical control group. 
No GVHD occurred following the infusion of these CTLs, and the neomycin gene could be 
detected up to 7 years after the infusion, indicating long term persistence of these CTLs.92 A 
number of other groups have replicated this data and over 100 patients have been treated with 
EBV CTLs post HSCT to date. The results show clearly that prophylactic infusion of donor-
derived EBV CTLs is safe and effectively prevents PTLD in HSCT patients at high risk of this 
complication. Smaller numbers of patients with established PTLD have also been treated and 
this too appears effective, although sometimes associated with significant local inflammatory 
reactions at the site of disease. The major limitation of this approach is the time taken to 
generate CTLs (10 weeks) and the resources needed to do this under GMP conditions. 
Together with the apparent efficacy and simplicity of pre-emptive therapy with rituximab to 
prevent PTLD, this has limited the broader use of this approach. 
 
2. Adoptive Immunotherapy for CMV 
 
A number of studies have investigated whether adoptive immunotherapy with CMV CTLs 93 
can be used to prevent opportunistic CMV infection after allogeneic HSCT. 94 95,96 Initial 
studies with CD8+ CTL clones,93 demonstrated that this approach could be used to safely 
augment CMV-specific immunity post-SCT but this approach was extremely laborious and 
responses were poorly maintained in the absence of CD4 T-helper cells. Subsequently, shorter 
culture protocols utilizing CMV-lysate pulsed dendritic cells or monocytes as stimulators have 
been used to generate polyclonal CTL lines, comprising both CD4 and CD8 populations.  
 
Infusion of  CMV CTLs into 16 patients  (matched related/unrelated BMTs who were CMV 
PCR positive), 94 after the first detection of CMV viraemia, led to a massive in vivo expansion 
of CMV CTLs, (3-5 logs), within days of adoptive transfer with low rates of GVHD and 
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secondary reactivation. Similar results were obtained by Einsele et al 95. These studies 
demonstrate adoptive immunotherapy with CMV-specific CTLs to be feasible, safe and 
provide evidence that this approach augments in vivo cell-mediated immunity to this virus. 
However, demonstration of clinical efficacy in preventing CMV associated complications or 
secondary reactivations will require much larger randomised studies. 
 
Whilst the 4 week period of co-culture required for the generation of CMV-specific CTLs by 
in vitro repetitive stimulation, enables CTLs to be generated pre-emptively in response to viral 
reactivation, the existing culture protocols are too complex and laborious for use outside 
highly specialised centres. For adoptive immunotherapy to be more broadly applicable, 
simpler, robust and more rapid protocols for isolation of viral-specific T-cells are needed. One 
novel approach to isolating CMV-specific T-cells exploits the secretion of IFNγ by both CD4+ 
and CD8+ T-cells following stimulation with purified pp65, the immunodominant antigen of 
CMV. Virus-specific T-cells can then be selected using the immunomagnetic beads (the so 
called ‘γ-capture system’). Preclinical studies have demonstrated that it is possible to select 
CMV-specific T-cells with reduced alloreactivity using this system97 and clinical studies 
utilising this approach are now underway. 
 
In an alternative approach to simplify the generation of CMV-specific CTLs, Moss et al 
developed a technique of selecting CMV CTLs by staining with HLA- peptide tetramers, 
followed by magnetic bead selection. 98 CMV-specific CD8+ cells were infused directly into 
nine patients within 4 h of selection. CMV-specific CD8+ T cells became detectable in all 
patients within 10 days of infusion, and were persistent in the patients studied. CMV viremia 
was reduced in every case and eight patients cleared the infection, including one patient who 
had a prolonged history of CMV infection that was refractory to anti-viral therapy. Though this 
approach significantly shortened the time to infusing CMV CTLs, it is limited to donors who 
have the appropriate HLA type, and the durability of such responses in the absence of CD4 + 
helper T-cells remains to be determined. 
 
3. Adoptive Immunotherapy for Adenovirus 
 
Adenoviral infections are significant causes of morbidity and mortality after HSCT,     
especially after T-depleted haploidentical transplants. Though adenovirus specific-CTLs have 
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been generated by repetitive stimulation of donor-T cells with APC transduced with an 
adenoviral vectors89, there has only been one clinical trial of adenovirus specific-CTLs infused 
post HSCT, which used the IFNγ capture system to isolate adenovirus (ADV)-specific T-cells. 
Though highly specific antigen responses were demonstrated in vitro when the expanded 
adenovirus- specific T-cells underwent restimulation with ADV-pulsed target cells there was 
still significant anti host reactivity.99  Using this approach in mismatched unrelated donor 
HSCTs, Feutchinger et al, infused adeno-specific T-cells (doses 103/kg) into 9 paediatric 
patients who were adenovirus PCR positive100. In 5 patients, clearance of the virus was 
associated with adenovirus T-cell expansion but one patient developed GVHD. Concurrent use 
of anti-viral agents in this study, and any possible recovery of donor derived adenovirus-
specific CTLs, independent of infused CTLs, makes it hard to determine the efficacy of this 
approach. Further studies are needed to demonstrate the safety and efficacy of this approach, 
particularly in the context of haploidentical HSCT. 
 
4. Adoptive Immunotherapy for Aspergillus 
 
By repetitively stimulating donor APC pulsed with CMV/aspergillus antigens, T-cell clones to 
aspergillus and CMV have been generated.101 T-cell clones which reacted to host antigens 
were discarded but non reactive clones were pooled and infused post haploidentical BMT. In 
46 control transplant recipients who did not receive adoptive therapy, pathogen-specific T-cells 
occurred in a low frequency and displayed a low interferonγ /high interleukin-10 production 
phenotype. In the 35 recipients who received a single infusion of CMV/aspergillus T-cells 
(dose range of 105 to 106 cells/kg) there was a high-frequency of T-cell responses to pathogens, 
which exhibited a protective high interferon-γ/low interleukin-10 production phenotype within 
3 weeks of infusion. Frequencies of pathogen-specific T-cells remained stable over time, and 
were associated with control of Aspergillus and cytomegalovirus antigenemia and infectious 
mortality.101 However, one patient who received 3 x 106 /kg T cells developed GvHD, and 
generation of antigen specific clones is highly labour intensive and required prolonged culture 
thus limiting this approach to prophylactic infusions in high risk patients. 
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5. Trispecific CTLs 
 
Leen et al infused trispecific CTLs (recognising CMV, EBV, adenovirus), to adult and 
paediatric patients undergoing matched unrelated or related donor transplants without any 
significant toxicities or GVHD.102 These CTLs were generated by repeatedly stimulating donor 
PBMCs with EBV LCLs transduced with a chimeric adenovirus CMVpp65 vector. The CMV 
and EBV CTLs expanded post infusion, but the adenovirus CTLs only expanded in those 
patients who had adenoviral infection. Infusion of these CTLs led to a reduction in viral DNA 
to all three viruses in patients with infection, resolution of adenoviral pneumonia in one case, 
and was associated with enhanced viral immunity in IFNγ ELISPOT assays. However, in vitro 
IFNγ release and cytotoxicity responses were far higher for CMV responses that adenovirus. 
This may reflect competition among the various immunogenic components leading to a single 
viral antigen dominating the immune response. This study demonstrated that it is possible to 
generate effector T-cells against multiple pathogens in a single co-culture However, as with 
the above approaches, the generation of trispecific CTLs involves prolonged cell culture (10 
weeks) and it is too labour intensive to enable this approach to be routinely used in large 
numbers of patients. In contrast, allodepletion has been shown to provide anti-viral responses 
to all three viruses and is simpler, and more robust than such approaches. 
 (d) Donor Lymphocyte Infusion and Suicide Gene therapy 
 
A suicide gene codes for a protein able to convert a non toxic prodrug into a toxic product. 
Thus, the transfer of a suicide gene into donor lymphocytes can allow the selective elimination 
of transduced lymphocytes should GVHD occur. The most effective current suicide gene is the 
Herpes simplex thymidine kinase (HSV-TK). The HSV-TK protein converts ganciclovir to a 
phosphorylated compound which is toxic to cells, by inhibiting DNA chain elongation. A 
phase 1/2 clinical study of adoptive transfer of HSV-TK transduced donor T lymphocytes at 
doses of 105/kg-108/kg to patients affected by disease relapse after matched related or 
mismatched related HSCT demonstrated 103,104 that  35 % or patients achieved a complete 
remission, and 29 % a partial response. The anti-tumour effect was strongly correlated with the 
in vivo expansion of TK+ cells. Administration of ganciclovir led to complete elimination of 
the TK+ cells and successfully treated GVHD.  
 
Although these preliminary studies suggest that this approach can safely be used improve 
immune reconstitution after SCT, genetic modification of T lymphocytes with retroviral 
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vectors requires polyclonal activation which may compromise affect third party and antiviral 
responses, particularly to EBV.27,76 Treatment of CMV infection with ganciclovir also led to 
the elimination of HSV-TK T-cells. 3 of 17 patients died of viral infections after day 100, 
suggesting that this approach may affect the anti-viral immunity of the transduced 
lymphocytes.105 Furthermore, this approach was limited by host immune responses to the 
HSV-TK, which occurred in a number of cases, 104,106 resulting in elimination of the 
transduced T-cells.  
 
The above trials have used a retroviral vector system which relies on preactivation of T-cells 
with CD3/28 stimulation to allow efficient entry of the viral vector into the T-cells. However 
this preactivation impairs anti-viral and third party activity of the transduced T-cells. 107,108 
Lentiviral vectors may serve as an alternative because they can transduce non cycling cells. T- 
cells can be induced in G1 phase by stimulation with IL-7, and transduced within 48 hours. A 
shorter culture time with less expansion, preservation of the naïve phenotype and unskewed 
TCR repertoire would favour maintenance of T-cell function. Lentiviral vectors may also 
reduce the risk of insertional mutagenesis because of an alternative insertion profile.109 Qasim 
et al developed a lentiviral HSV-TK construct for transduction of T-cells in a cytokine culture 
without preactivation of the T-cell receptor. In contrast to polyclonally activated T-cells, 
efficient transduction was obtained with preservation of anti-viral 107, and third party responses 
and there was minimal up regulation of T-regulatory numbers.  
 
In view of the immunogenicity of the HSV-TK, alternate suicide genes have been investigated. 
The most promising of these utilises a chimeric protein consisting of caspase 9 fused to human 
FK506 binding protein (FKBP) which appears not to be immunogeneic. Adding the drug 
AP1903, dimerizes the chimeric protein and leads to cell death. 110  Brenner et al transduced 
CD25 immunotoxin allodepleted donor T-cells with a retroviral construct consisting of an 
inducible caspase 9 (iCasp9) suicide gene, and a selectable marker (truncated CD19). The 
residual donor T-cells were efficiently transduced, expanded, and subsequently enriched by 
CD19 immunomagnetic selection to >90% purity. These engineered T-cells retained anti-viral 
specificity and functionality, and contained a subset with regulatory phenotype and function. 
Activating iCasp9 with a small-molecule dimerizer rapidly produced >90% apoptosis. 
However, concerns remain about the basal toxicity of iCasp9 to T-cells in the absence of 
dimerizer and this approach has not yet been tested clinically.  
 
 48
An alternative approach to safely administering DLI in the haploidentical setting involves 
infusing regulatory T-cells (Tregs). T-regs are functionally defined as T-cells that inhibit 
immune responses by influencing the activity of other cell types. High CD4 (+) FOXP3 (+) T-
cell counts in the donor graft have been associated with a reduced risk of GVHD. 111 In a 
mouse leukaemia model, transfer of donor Tregs suppressed the proliferation of alloreactive 
donor T-cells, without affecting GVL effects. 112 This was associated with a reduction in the 
expression of CD25 on alloreactive T-cells, reduced proliferation of donor T cells, and reduced 
serum levels of IFNγ and TNFα. Transfer of Tregs in established GVHD was less effective, 
suggesting that early transfer is required for an optimum effect. This data suggested that 
GVHD is a cytokine dependent process highly sensitive to T regs activity, whilst the anti-
leukaemic activity mediated by the perforin lysis pathway was relatively insensitive to the 
effect of T regs.  
 
However, whilst this data looked very promising it is unlikely that such a clear delineation in 
humans is possible. The major risk of the therapeutic use of T regs is generalised 
immunosuppression compromising desirable anti-viral and anti-leukaemic responses. Whilst 
the induction of T regs occurs after specific activation, they then appear to suppress 
proliferation of all T-cells regardless of their antigenic specificity.113 The high ratio of T regs: 
effector T cells used in mouse BMT studies (1:1) above, would not be feasible clinically for 
adoptive transfer without ex vivo expansion. This is compounded by the fact that the best 
marker of human T regs is an intracellular marker FoxP3, making cell sorting to obtain a pure 
Treg population difficult. The long term survival of in vitro selected and expanded Tregs in 
vivo is not known.113 Nevertheless, the Stanford group under Robert Negrin are planning a 
clinical study looking at adoptive transfer of Tregs + DLI post SCT. 
 
(e) Selective Allodepletion 
 
 Allodepletion strategies aim to selectively deplete alloreactive T-cells after stimulation in an 
ex vivo mixed lymphocyte reaction (MLR) and then infuse the residual donor T-cells with the 
aim of improving anti-viral and anti-leukaemic responses post-SCT. The advantages of this 
approach are that alloreactive T-cells are permanently removed, and that it has the potential to 
improve immunity to multiple pathogens simultaneously. Strategies to deplete alloreactive T- 
cells include negative selection of donor T-cells expressing activation markers (e.g. CD25, 
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CD69, HLA-DR)114-118, killing activated T-cells by photodynamic purging52, inducing Fas 
mediated apoptosis119, or chemotherapy agents.120,121 
 
 
 
1. Allodepletion Targeting Activation Markers 
(a) CD25 Based Allodepletion 
 
CD25 is highly expressed on alloreactive T-cells and there have been a variety of methods 
targeting this antigen, including immunotoxins or immunomagnetic depletion. RFT5-SMPT-
dgA is a CD25 immunotoxin consisting of a mouse IgG1 anti CD25 conjugated via a hetero-
bifunctional crosslinker to a chemically deglycosylated ricin A chain (dgA). Depletion of 
CD25+ alloreactive T-cells by the addition of this immunotoxin led to a greater than 98% 
reduction in residual proliferation to host cells in the HLA mismatched setting whilst retaining 
proliferative responses to CMV, and Candida, and cytotoxic T-lymphocyte precursor (CTLp) 
frequencies against CMV/EBV infected targets.122 Furthermore precursor frequencies of anti-
leukaemic T cells against myeloid leukaemias were not reduced with use of this immunotoxin. 
122,123 Differences in the techniques used, such as the type of stimulator cells used and the 
methods used for assaying residual alloreactivity against host (see Discussion) may account for 
the variability observed in residual anti-host responses  after CD25 based allodepletion. 
 
Vitetta et al. compared the effectiveness of 2 CD25 immunotoxins RFT5-SMPT-dgA and 
Ontak, (a fusion protein of IL-2 and diphtheria toxin), and anti CD25 microbeads, in their 
ability to delete CD25+ alloreactive T cells. 124 They showed  that RFT5-SMPT-dgA, CD25 
beads or a combination of RFT5 and CD25 beads were equally effective in depleting 
alloreactive CD4 + CD25 expressing T-cells without affecting third party responses. Ontak 
however, depleted CD4+CD25+ cells poorly. RFT5-SMPT-dgA was more effective than 
CD25 beads or Ontak at depleting CD8+CD25 expressing alloreactive T cells. Ontak again 
was poor at depleting CD8 + CD25 + alloreactive T-cells.  These data suggest that CD25 
depletion with RFT5 immunotoxin or immunomagnetic beads is superior to Ontak, but it 
should be noted that functional analysis of residual alloreactivity after secondary stimulation of 
allodepleted cells was limited in this study. 
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CD25 is expressed on T regulatory cells, and thus one potential concern is that, by depleting 
the T regulatory cells, this would lead to an increase in GVHD and autoimmunity. This has not 
been seen in clinical studies to date (see below), probably because effective allodepletion, 
leads to a low incidence of alloreactive effector cells, and therefore concomitantly depleting T 
regulatory cells in this situation will not lead to GVHD.  
 
One critical issue for all allodepletion strategies targeting activation markers is the choice of 
host antigen-presenting cells: if antigen presentation is ineffective this will result in less 
activation and hence less effective depletion of host-reactive T-cells. Our group has previously 
demonstrated that using HLA mismatched EBV transformed lymphoblastoid cell lines (LCL) 
as antigen presenting cells rather than PBMCs, gave a more consistent depletion of in vitro 
alloreactivity using the CD25 immunotoxin (CD25IT).86  There was an average 15 fold 
decrease in proliferation in primary MLRs using this approach (see Fig 5B) and a residual 
proliferation to host  was significantly lower (mean 0.8 %) after stimulation with LCL than 
PBMCs (mean 8.5 %) in the same donor-recipient pairs (Fig 5C).  
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Figure 5: Depletion of alloreactive T cells by anti-CD25 immunotoxin. (A) FACS analysis 
showing increased expression of CD25 (y axis) on CD3/4/8+ T cells after activation with HLA-mismatched LCLs 
and effective depletion of CD3+/CD25+, CD4+/CD25+, and CD8+/CD25+ cells following treatment with anti-
CD25 immunotoxin. The figure shows a representative FACS analysis from 6 different donor-recipient pairs. The 
percentage of double-positive cells is indicated. (B) Primary mixed lymphocyte reaction showing a mean 15-fold 
decrease in proliferation in response to HLA-mismatched LCL stimulators after treatment with anti-CD25 
immunotoxin (IT). Results are the mean ± SD of 5 haplo-identical donor-patient pairs each assayed in triplicate. 
(C) Residual proliferation in 7 donor-patient pairs after allodepletion with anti-CD25 immunotoxin following 
stimulation of donor PBMCs with PBMCs (R/S 1:1) or LCLs (R/S 40:1) from the same HLA-mismatched 
recipient. Residual proliferation was calculated using the formula in "Results" and was significantly higher after 
stimulation with PBMCs (P < .05).  Reproduced from 86 
 
As relapse and viral reactivation are the major causes of mortality post haploidentical 
transplantation, determining whether T-cell responses to such antigens following allodepletion 
is of paramount importance. Using CD25 immunotoxin based allodepletion, Amrolia et al 
demonstrated that following allodepletion, anti-viral responses to adenovirus and CMV 
following allodepletion  were preserved on HLA tetramer (see Fig 6) and IFNγ ELISPOT 
 52
assays.86  The use of LCLs as APCs, led to a partial reduction in EBV-specific responses, but 
significant activity was retained through the non shared haplotype.  
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Figure 6 : CMV-specific CD8+ T cells are not deleted by allodepletion. The figure shows FACS 
analysis following staining of either unmanipulated PBMCs (right and centre columns) or allodepleted cells (left 
column) from 4 HLA-A2–positive, CMV-seropositive donors with IgG PE (left column) or an HLA-A2–CMV 
pp65 tetramer (centre and right columns). The percentages of tetramer-positive cells as a proportion of CD8+ cells 
with isotype subtracted are shown. Reproduced from 86 
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As LCLs do not express myeloid or leukaemic antigens, allodepletion using this approach did 
not affect the frequency potential myeloid tumour antigens such as the PR1 epitope of 
proteinase 3. (See Fig 7) Thus, CD25IT based allodepletion preserved anti-viral responses in 
vitro to CMV, adenoviral antigens and potential myeloid tumour antigens. 
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Figure 7: CD8+ T cells specific for the myeloid tumor epitope PR1 are retained after 
allodepletion after stimulation with mismatched LCLs but not CML PBMCs. (A) FACS 
analysis following staining with HLA-A2–PR1 tetramer of unmanipulated PBMCs (top row) or allodepleted 
PBMCs (bottom row) from a patient with CML. In each case isotype controls are shown on the left and tetramer-
stained cells on the right. Allodepletion was performed after stimulation with allogeneic HLA-A2–positive 
PBMCs from a mismatched donor with CML. (B) FACS analysis following staining with HLA-A2–PR1 tetramer 
of unmanipulated PBMCs or allodepleted T cells from 2 HLA-A2–positive patients with CML. Allodepletion was 
performed after stimulation with either HLA-A2–positive or –negative LCLs. The percentages of tetramer-
positive cells as a proportion of CD8+ cells (isotype subtracted) are shown. Reproduced from 86 
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Despite almost complete depletion of CD25+ve T-cells with CD25IT based allodepletion, 
residual alloreactivity against host stimulators was often detectable in the allodepleted T-cells. 
Rested CD25IT generated allodepleted T-cells demonstrated a median 17-fold reduction in 
IFNγ release in an ELISPOT assay, when stimulated with host antigen-presenting cells 
compared to unmanipulated PMBCs,125 but there were still significant residual responses to 
host in 7/12 donor recipient pairs (see Fig 8).  This suggests, that combining CD25-based with 
alternative methods of allodepletion may be necessary to enhance allodepletion and hence 
enable higher T-cell doses to be infused in order to improve anti-viral and anti-leukaemic 
responses.  
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Figure 8: Significant Residual IFNγ Responses to Original Stimulator remain in many 
donor recipient Combinations despite CD25IT Allodepletion. Normal donor PBMCs  were co-
cultured with HLA mismatched LCLs and a day 3 CD25 IT allodepletion. In 12 donor recipient pairs, on day 5 
thawed unmanipulated PBMCs or rested CD25IT allodepleted PBMCs were stimulated with host LCLs in an 
IFNγ ELISPOT assay.  Results are expressed as Spot forming cells SFC/105 PBMCs. Reproduced from 125 
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(b) Non CD25 based Allodepletion 
 
CD69 is one of the earliest markers to be up regulated in a MLR (within 24 hours). A number 
of groups have targeted CD69 to deplete alloreactive T-cells and  have demonstrated  a mean 
residual alloreactivity of between 1.5 % to 25 % with maintenance of third party responses 
after CD69 allodepletion.116,117 Anti CMV and EBV activity and responses against potential 
tumour antigens (e.g. WT-1) were maintained in the allodepleted fractions. Furthermore, 
unlike CD25 based allodepletion, CD69 allodepletion does not affect T regulatory cells.126. 
Koh et al demonstrated that infusion of CD69 allodepleted donor T-cells led to significantly 
enhanced survival compared to unmanipulated donor T-cells in a MHC mismatched mouse 
model.127 
 
This has encouraged investigators to examine combined anti CD25/69 depletion, with the aim 
of enhancing existing CD25 based allodepletion strategies. Depletion of CD25 or CD69 alone 
led to a 60 % reduction in HTLp frequency against host stimulators but targeting CD25 and 
CD69 using immunomagnetic allodepletion, led to a 80 % reduction in residual alloreactivity  
in secondary MLRs, and a 80 % reduction in HTLp frequencies, compared to unmanipulated 
controls, with preservation of anti-3rd party responses.115 Van Dijk et al depleted alloreactive 
T-cells expressing CD25, CD69, CD71 and HLA-DR using an immunomagnetic allodepletion 
and this resulted in a 1 log reduction in alloantigen specific helper T lymphocyte precursor 
(HTLp) frequency without affecting third party responses. 118 
 
Numerous other activation antigens have also been targeted for allodepletion strategies. 4-1BB 
(CD137) is upregulated on activated T-cells early in a MLR and CD137 is important in co- 
stimulation of CD8 effector memory cells. Anti CD137 antibodies, inhibit CD4 and CD8 T- 
cell mediated GVHD. Hartwig et al generated CTL cultures by stimulating CD8+ lymphocytes 
with single HLA mismatched AML blasts or renal carcinoma cells. 59 On Day 21 of the 
culture, the lymphocytes were stimulated with HLA-negative K562 cells transfected with the 
disparate HLA-Class 1 cDNAs. After 24 hours, the CD137 positive alloreactive T-cells were 
depleted using MACS technology. CD137 negative cells and unmanipulated CTL cells were 
then stimulated with the original AML blast/renal carcinoma cells or the K562 cells expressing 
the disparate HLA antigen in a 2º IFNγ ELISPOT. In 15 donor-recipient pairs, the allodepleted 
fraction showed a median residual activity of 9.5 % to the transfected K562 cells, and 58% 
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residual activity to the leukaemic/ carcinoma cell line compared to sensitized non depleted 
PBMCs from the same donor. Chromium release cytotoxicity assays showed that the 
allodepleted fraction lost reactivity to the single HLA mismatched K562 lines but maintained 
cytotoxicity against the leukaemia/carcinoma cell lines. Anti-EBV and CMV activity was 
maintained despite allodepletion as assessed by tetramer and IFNγ ELISPOTS. However, 
unlike CD25 or CD69 a clinical grade CD137 antibody does not exist limiting this approach. 
Furthermore, a significant residual alloreactivity was still evident to the single class MHC 
mismatched K562 cells after CD137 allodepletion. The effectiveness of CD137 allodepletion 
in haploidentical mismatched donors is not known. These studies demonstrate that there are a 
host of different approaches to targeting alloreactive T-cells based on their expression of 
activation markers, but these have not been compared with each other and the optimal method 
and marker is yet to be determined. 
 
2. Activation Induced Cell Death 
 
Activation induced cell death is an important physiological pathway to control the expansion 
of activated T-cells. CTLs kill targets by expressing FAS ligand (FasL) that binds to the death 
receptor Fas. This interaction activates caspases and leads to apoptosis of targets. Alloreactive 
T-cells up regulate the Fas antigen, and upon addition of a Fas Ligand agonistic antibody in an 
ex vivo MLR, there was a  80 % reduction in proliferation in a 2º MLR, compared to 
controls.119,128  This approach maintained third party activity, and in mouse model of GVHD, 
transfer of CD95 allodepleted T-cells prevented lethal GVHD, compared to untreated T-cells. 
Another approach has been to transfect APCs, with a Fas Ligand vector, to therefore lead to 
clonal deletion of alloreactive T-cells expressing the Fas antigen. 67 The transfected APCs, led 
to a large decrease in the T-cell proliferation to the original stimulator in MLR, but responder 
cells were able to maintain third party responses. This decrease was specific to Fas-Fas ligand 
interaction, because when responder T-cells from Fas knockout mice were used, the Fas ligand 
transfected APCs, had no effect on the proliferation. Limitations of this approach include the 
lack of a GMP grade CD95 agonistic antibody, and the possibility of inducing fatal hepatic 
damage with a CD95 antibody,129 due to expression of CD95 expression on hepatocytes. 
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3. Photodynamic Purging 
 
Photodynamic purging (PDP) involves the administration of a photosensitizing agent, followed 
by activation of the agent by light of the appropriate wavelength. One such agent, TH9402 is 
taken up by T-cells and is then actively extruded by the multi drug transporter P-glycoprotein 
170 (P-gp170). However, p-gp170 is inactivated upon T-cell activation, leading to a selective 
retention of the dye in the mitochondria of activated T-cells. Following exposure to visible 
light (512 nm), the dye becomes cytotoxic leading to the generation of free radicals which 
resulting in cell death. The capacity of TH9042 to reduce alloreactivity is primarily due to 
depletion of  CD25 positive alloreactive T cells, but may not affect CD25+FoxP3 + regulatory 
T-cells.130 Some CD25+ve T cells remain after treatment, though whether they are residual 
alloreactive T-cells or regulatory T-cells is not known. PDP treatment also removes B cells, 
and this may also account for account for some of the effect of photodynamic purging. 
 
 Thus this approach could lead to the selective deletion of alloreactive T-cells, which become 
activated in a MLR, leaving resting T-cells intact. 52 Allodepleted donor T-cells generated 
using PDP demonstrated a significant reduction in IFNγ release in ELISPOT assays when 
compared to sensitized non PDP treated PBMCs but had a residual response to host of over 6 
times higher than that of unmanipulated PBMCs.33 Though the IFNγ ELISPOT showed that 
PDP treated donor cells still had significant alloreactivity, when these cells were infused into a 
mouse model, there was no clinical GVHD. Moreover, adoptive immunotherapy with PDP 
treated donor T-cells in a mouse tumour model, demonstrated improved survival, prevented 
relapse, and promoted immune reconstitution.33  More recently, Mielke et al demonstrated a 4 
log reduction in residual alloreactivity to host following PDP purging of allodepleted donor T- 
cells in a clinically applicable system.131 Third party responses were maintained but anti-viral 
responses in the aforementioned studies were not systematically examined. In this regard, 
Perruccio et al observed  large decreases in T-cell responses to viral/fungal antigens, using a 
similar PDP approach.132 
 
Preliminary results of a phase 1 clinical study of adoptive transfer of PDP treated donor T-cells 
after haplo-SCTs in 13 high risk adult patients with haematology malignancies, have been 
reported by Roy et al 133. Patients received escalating DLI with donor PDP treated T-cells at 
doses of 104/kg to 105/kg. Anti host cytotoxic T lymphocyte precursors (CTLp) were reduced 
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by 1.5 log after PDP treatment, whilst activated CD25 + T cells were depleted by over 90 %. 
Of 11 evaluable patients, none developed acute GVHD, whilst 3 developed chronic GVHD. 5 
patients died (4 due to infections including 1 EBV LPD), and the other of relapse.133  Immune 
reconstitution was disappointingly poor, with a relatively high mortality from infectious 
deaths, suggests that PDP may affect the anti-viral function of the residual allodepleted T-
cells. Other clinical studies of photodynamic purging with higher doses of allodepleted T-cells 
are currently ongoing. 
 
4. Chemotherapy Based Methods of Allodepletion 
 
Alloreactive cells are characterized by their ability to proliferate in response to alloantigen. 
With this in mind several groups have looked at adding chemotherapeutic agents to ex vivo 
MLRs, to preferentially kill proliferating cells. Fludarabine, is an adenine nucleoside analogue 
that inhibits DNA synthesis when incorporated into the replicating chain. It also has potent 
immunosuppressive effects including profound depletion of CD4+ cells. In a MHC-
mismatched murine SCT model Waller et al treated mismatched donor lymphocyte infusions 
(DLI) with fludarabine ex vivo for 24 hours, prior to infusion.120  Recipients of fludarabine 
treated DLI did not develop GVHD and had superior engraftment and chimerism analysis 
compared to T-cell depleted bone marrow. In contrast, mice receiving unmanipulated DLI with 
bone marrow showed high rates of GVHD. The mechanism of fludarabine’s actions appeared 
to be a selective depletion of naïve T-cells, whilst preferentially preserving memory T-cells.  
134 While such an approach is conceptually attractive, fludarabine is very potently 
immunosuppressive, and such a strategy would require careful dose titration experiments to 
minimize effects on desirable anti-viral and anti-leukaemic T-cell responses. 
 
Other groups have targeted proliferating T-cells directly in an ex vivo MLR. Addition of 
trimetrexate, an anti folate drug,135 inhibited proliferation in a MLR due to apoptosis in the 
proliferating cells. Combining trimetrexate mediated allodepletion with a CD25 immunotoxin 
(Ontak) was superior to either alone in inhibiting proliferation to host stimulators in a primary 
MLR. This combination did not affect proliferative responses to third party or Candidal 
antigens. This approach is potentially clinically applicable, but again would require careful 
titration to avoid toxicity to desirable T-cell responses. However, the CD25 immunotoxin used 
was Ontak, which has been shown to be inferior to ricin based CD25 immunotoxin.124 
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Bortezomib is a reversible proteosome inhibitor.136 By inhibiting proteosome activity and thus 
preserving Ikβ activity, it inhibits the translocation of NF- kβ into the nucleus. Bortezomib 
inhibits proliferation in vitro MLRs, 55,121 due to selective apoptosis of the proliferating 
alloreactive T-cells. 55,136 Blanco et al used this approach to selectively delete alloreactive T- 
cells.55 This study however, was limited by the assays used to assess residual alloreactivity. 
The percentage of viable CD25+ T-cells in the bortezomib treated MLR was lower than in the 
CD25-ve fraction but 55 % of CD25+ve alloreactive cells still remained viable. CD69 
expression after secondary stimulations was used to assess residual alloreactivity but CD69 is 
only expressed on a minority of alloreactive T-cells. The effect of bortezomib on reducing 
CD69 expression in the 2º MLR was modest (7.1 % in unmanipulated T-cells vs 2.9 % in the 
bortezomib MLR). There was no comment in the paper about the effect on desirable anti-
leukaemic or anti-viral responses, though 3rd party responses were decreased suggesting that 
this approach may target bystander cells. 
 
In mouse GVHD models, administration of bortezomib on days 0-3 post BMT along with 
allogeneic T-cells, led to improved survival due to decreased GVHD compared to addback of 
unmanipulated T-cells.121 However, delayed administration of bortezomib (days 5-7 post 
BMT), led to enhanced gut GVHD, and increased mortality.137  Histopathological examination 
of the mice that received delayed administration of bortezomib, showed significant increases 
in TNFα receptor transcription in gut cells and increased serum TNFα, IL-1, and IL-6. Thus, 
the effects of bortezomib on GVHD, are critically dependent on its timing. PS-1145 is a 
selective inhibitor of NF- kβ, and delayed administration of this agent protected mice from 
lethal GVHD and did not cause gut toxicity.136 This suggests that toxicity of delayed 
administration of bortezomib is due effects from proteosome inhibition other than NF-kβ 
inhibition.  
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Clinical Trials of Allodepleted Donor T cells Generated with 
CD25 Immunotoxin (RFT5) 
 
Andre-Schmutz el al performed a clinical study of add back CD25 immunotoxin (RFT5-
SMPT-dgA) allodepleted donor T-cells after HLA mismatched BMT.138 They treated 15 
paediatric patients in this study, 13 of whom had haploidentical transplants, and 2 received 
matched unrelated donors. Five patients had high risk haematological malignancies, the rest 
were transplanted for metabolic/immunodeficiency disorders.  Donor PBMCs were co-cultured 
with irradiated host PBMCs for 3 days in vitro.  Harvested cells were then treated with an 
overnight incubation with the CD25 immunotoxin. The efficacy of depletion was assessed by 
flow cytometric analysis of CD3+CD25+ expression and by residual proliferation to host in a 
primary MLR.  Allodepleted T-cells were only infused after engraftment, if there was no 
GVHD, and no residual anti thymocyte globulin detected.  Doses infused ranged between 1 -8 
x 105 T cell/kg. GVHD occurred in 4 patients (two patients developed had grade 1 GVHD of 
the skin, two others developed grade 2 of gut and skin). One of the latter went onto develop 
chronic GVHD of the skin. Onset of GVHD did not correlate with the number of T-cells 
infused but rather with residual proliferation to host in 1º MLRs. The 4 patients who developed 
GVHD all had a residual proliferation of greater than 1%, thus suggesting that targeting CD25-
ve alloreactive T-cells may reduce the incidence of this complication.  
 
Preliminary studies on immune reconstitution suggested that this was enhanced following 
transfer of allodepleted donor T-cells compared to historical controls. Infusion of allodepleted 
T-cells led to enhanced CD3, CD4 and CD8 recovery, particularly in those patients who had 
viral reactivations. Responses to PHA were also enhanced. These T-cells had a memory 
phenotype and a diverse T-cell receptor repertoire. Two patients who had active CMV 
infection, showed strong cytolytic activity against CMV infected targets, 4 weeks after 
infusion of allodepleted T-cells, suggesting that T-cells encountering their cognate antigen 
show considerable expansion. Although viral specific immunity was not systematically 
assessed, one case of adenoviraemia, and another of EBV lymphoproliferative disease, who 
were both resistant to conventional treatment, responded following infusion of allodepleted T-
cells.  
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Three of the five leukaemic patients died of relapse. Eight patients were alive and well with a 
median follow up of 24 months.  This study showed that administering allodepleted T-cells 
generated using CD25 immunotoxin was safe and that deleting T regulatory cells did not lead 
to enhanced GVHD. However, in view of the high mortality from relapse enhanced 
allodepletion is needed, thus allowing higher doses of T-cells to be infused to augment anti- 
leukaemic responses. 
 
Solomon et al. used CD25 immunotoxin (RFT5-SMPT-dgA) based allodepletion in an adult 
trial in the HLA-matched setting. Sixteen patients with a median age of 65 and advanced 
haematological malignancies underwent reduced intensity transplants using HLA-identical 
sibling donors. G-CSF mobilised peripheral blood stem cells were T-cell depleted by CD34 
selection. Donor T-cells from the negative fraction were then incubated with irradiated host T- 
cells (OKT3 immunomagnetically selected) in a 1:1 ratio. 139 The immunotoxin was added 
after 24 and 48 hours of co-culture, and cells were harvested at 72 hours. The stem cells and 
the allodepleted product were co-infused on day 0 of the procedure. The median T-cell dose 
infused was 1.0 x 108/kg (range 0.2-1.5 x 108/kg). Successful depletion of alloreactivity was 
observed in 9 out of 11 patients as tested in helper T lymphocyte precursor (HTLp) assays. 
There was a ½ log mean reduction in the HTLp frequency against host stimulators after 
allodepletion, though with a large range (range 2-11 fold). The rates of acute grade II-IV 
GVHD observed were relatively high (46 % ± 13 %) but grades III-IV GVHD was uncommon 
(12 ± 8 %). Seven out of 14 patients developed chronic GVHD. The likelihood of GVHD was 
inversely correlated to the post depletion HTLp frequency. i.e. patients who had retained high 
HTLp precursor frequencies after CD25 allodepletion developed GVHD. There was no 
relationship to the starting HTLp frequency. There were 5 relapse deaths, with a 2 year 
probability of relapse of 56 %. The major flaw in this study was that the host antigen 
presenting cells used (expanded T-cells) may induce suboptimal activation of CD25 
expression in alloreactive T-cells, particularly in the absence of HLA-mismatch, and hence 
inadequate depletion of alloreactivity. Nonetheless, these data suggests that targeting 
alternative CD25-ve markers may be valuable in enhancing existing CD25 based allodepletion. 
Further analysis of this cohort showed effective T regulatory cell reconstitution at 1 month 
post BMT.140 Thus acute GVHD occurring in this cohort was unlikely to be due to removal of 
CD25 positive T-regulatory cells, but rather due either to inadequate up regulation of CD25, or 
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the presence of CD25 negative alloreactive T-cells.140  This emphasizes the need to 
characterize the phenotype of alloreactive T-cells that do not express CD25.  
Follow up on immune reconstitution in these studies was limited and there was no formal 
assessment of anti-viral immunity. Equally it was unclear how many allodepleted cells were 
needed to improve immune reconstitution without causing GVHD in the haploidentical setting. 
To address this, Amrolia et al performed a trial in 16 paediatric haploidentical transplants 
recipients, comparing immune reconstitution after addback of 2 dose levels of allodepleted T-
cells. 8 patients were treated at dose level 1 (104/kg/dose), comparable to the number of 
unmanipulated T-cells given in a standard haploidentical graft, whilst the other half received a 
higher dose of  105/kg/dose.141 Each arm received 3 doses of allodepleted T-cells. 12 of the 
patients had high risk haematological malignancies, and 6 of these were not in remission. Host 
LCL were co cultured with donor PBMCs for 72 hours prior to the addition of CD25 
immunotoxin (RFT5-SMPT-dgA).  Each patient was scheduled to receive 3 doses of 
allodepleted T-cells at either dose level on days +30, +60, and +90 post transplant, providing 
their was no evidence of grade II or greater GVHD, or until total circulating T-cell numbers 
were greater than 1000/µl. The primary aims were to compare toxicity (i.e. GVHD), and 
immune reconstitution between the two dose levels. Secondary outcomes were 
frequency/outcome or viral infections, and day 100 and 1 year overall/disease free survival. 
The efficacy of allodepletion was assessed by FACS (residual % of CD3+CD25) and residual 
proliferation in 1º MLR. The residual percentage of CD3+/CD25+ cells in the infused 
allodepleted cells ranged from 0.01% to 0.27% (median 0.08%), and the residual proliferation 
against host cells in the primary MLR ranged from 0% to 3.1% (median, 0.02%). 
Error! Bookmark not defined. 
Most (13 of 16) patients completed their scheduled infusions: the remainder did not because of 
GVHD (n = 2) or autologous reconstitution (n = 1). Immunosuppression was withdrawn prior 
to infusion of the allodepleted products. Two patients developed GVHD, one at dose level 1 
(after 1 infusion Grade IV skin GVHD), and at dose level 2 (Grade II skin GVHD after 2 
infusions). Both patients went onto develop chronic GVHD, affecting the liver in one, and skin 
and mouth in the other. This incidence of GVHD is equivalent to what one would see in 
standard T-cell depleted haploidentical transplants without T-cell addback. There was no 
relationship between the occurrence of GVHD and residual proliferation to host in this study. 
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Figure 9: Enhanced CD3 Recovery in dose level 2 patients between 3-5 months post SCT. Donor PBMCs 
were cocultured with host LCLs and on day 3 a CD25 allodepletion was done using CD25IT. These allodepleted 
donor T cells were infused at specific time points at either 104/kg in one cohort or 105/kg in the other cohort. 
Those who received dose level 2 ( 105/kg) had superior T-cell recovery compared to dose levels 1 (104/kg) 
Reproduced from 141 
With regards to immune reconstitution, CD3 numbers were significantly higher in dose levels 
2 (105/kg) patients between 3-5 months post BMT, compared to dose level 1(104/kg). (See Fig 
9). This was true in both the CD4 and CD8 compartments. Area under the curve analysis also 
showed that CD3, CD4, and CD8 recovery at 4 and 6 months was significantly improved.  
 
There was no difference in B and NK-cell recovery between the 2 groups. The majority of 
recovering T-cells in the dose levels 1 group were of a naïve phenotype (CD45RA+, CCR7+), 
whilst in dose level 2 the majority of T-cells had an effector memory phenotype ( CD45RA-, 
CCR7-). Effector memory T-cells were significantly higher in dose level 2 between 3-5 
months post BMT. This is important, as effector memory cells responses are likely to be long 
lived.  
 
To determine whether the improved immune reconstitution was due to infusion of the 
allodepleted T cells, or due to naïve precursors passing through the thymus, T-cell receptor 
signal joint excision circles (TRECs) were analyzed by real time polymerase chain reaction 
(PCR). TRECs were detected at low levels in 3 of the 5 patients assessed on dose level 1 at 4 
and 6 months. TRECs were undetectable in 4 out of 4 dose level 2 patients who were analyzed 
at these time points. This suggests that the improved T-cell reconstitution observed in patients 
treated at dose level 2 was due to the infusion of allodepleted T-cells.  
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Tetramer and IFNγ ELISPOT assays were used to analyze viral-specific immunity. At dose 
level 1, none of the 6 evaluated patients had a significant CD8+tetramer population 
recognising EBV epitopes up to 12 months post BMT, despite the fact 2 had viral 
reactivations. In contrast, at dose level 2, tetramers were detected in 3 of the 4 evaluated 
patients, shortly after viral reactivation. Similarly for CMV, none of the 6 evaluable patients at 
dose level 1 had tetramer positive populations before 9 months post BMT, despite 5 of them 
having viral reactivations. At dose level 2, 2 of the 4 patients had tetramer positive populations 
detected as early as 2 months post BMT, again in one of these in response to viral reactivation. 
These data suggests that at doses of 105/kg there is considerable peripheral T-cell expansion in 
response to the T-cells seeing their cognate antigen. Likewise, using IFNγ ELISPOTs to assess 
the function of these viral-specific T-cells, EBV immunity in dose level 2 was of a greater 
magnitude and occurred earlier than in dose level 1. Only 2 of 7 evaluable dose level 1 patients 
had a significant response (defined as >200 spot forming cells/106 PBMCs) to EBV LCL, 
compared to 4 out of 6 treated at dose level 2. Once again, in general these responses were 
correlated with viral reactivation.  Similar data was obtained for CMV.  
 
Nine patients (of the 16 at risk) had CMV reactivation. They were treated with ganciclovir ± 
foscarnet though none developed CMV related disease. Six patients had EBV reactivations, 
but none needed treatment with rituximab, or developed lymphoproliferative disease. There 
were three probable fungal infections which resolved with antifungal therapy. There were 2 
cases of adenoviraemia. In one patient, this led to fatal disease of the liver. The other patient 
did not clear the virus despite anti-viral treatment with cidofovir and ribavarin and 3 doses of 
allodepleted T-cells at dose level 2, and he was subsequently given a single dose of 
allodepleted T-cells at 2.5 x 106/kg on a compassionate basis, with rapid clearance of the virus. 
This suggests that infusing higher doses of allodepleted donor T-cells is required to combat 
pathogens which have a low precursor frequency (e.g. adenovirus). Another patient had 
progressive multifocal leucoencephaolpathy due to JC virus, which showed a significant 
clinical and radiological improvement following infusion of allodepleted T-cells at dose level 
2. This patient showed marked improvements in cognitive function, and motor skills, 
associated with improvement in their T-cell numbers.  
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At a median follow up of 33 months, 7 patients in this study have relapsed and 5 are alive and 
disease free. Thus this study showed that infusions of allodepleted T-cells at dose level 2 post 
haplo-SCT led to; 
• Low incidence of GVHD  
• More rapid recovery of T-cells with memory phenotype 
• Absence of TRECs + diverse TCR repertoire 
• Accelerated recovery of viral-specific immunity and a low incidence of infection 
related deaths 
• Clinical responses 
 
 
However, clearly relapse remains a major problem. Selective allodepletion will deplete T-cell 
responses against the mismatched HLA alleles and ubiquitous minor histocompatibility 
antigens presented by the shared HLA alleles. Nonetheless, anti-leukaemic activity may be 
retained after allodepletion 86,122,142 In particular, T-cell responses to potential myeloid tumour 
antigens are preserved by virtue of their lack of expression on the LCL used as stimulators. 
86Likewise, allorestricted responses against tumour, haematopoietic-specific and minor 
histocompatibility antigens presented through the non-shared haplotype143-146 should also be 
retained. It is unclear how many allodepleted donor T-cells would be required to confer 
clinically relevant anti-leukaemic responses in the haploidentical setting: because of the 
possibility of allorestricted responses, this may in fact be considerably lower than the numbers 
of DLI required to induce GVL after HLA-matched SCT. Because of the limitations of 
experimental models, it may be that this question can only be answered in clinical studies.  
 
Likewise, the fact that the patient who cleared adenovirus only did so after receiving 2.5 x 106 
T cells/kg suggests that the protective response against pathogens with a low T cell precursor 
frequency may require larger doses of allodepleted T-cells to be infused. Our in vitro data 
suggests that a median 17 fold reduction in alloreactivity (as assessed by ELISPOT) after 
CD25 immunotoxin based allodepletion, together with the fact that 2/16 patients did develop 
GVHD, suggests that it may not be safe to give larger doses of allodepleted T-cells using this 
strategy alone. Thus, in subsequent studies we need to enhance depletion of allo-reactive cells 
so that can add back sufficient T-cells for protective anti-leukemic responses without causing 
GVHD.  
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Adoptive Immunotherapy with Genetically Modified Donor T 
cells 
 
As noted above, the major cause of mortality following adoptive transfer of CD25 allodepleted 
donor T-cells after haploidentical transplantation was relapse.141 Potentially, the anti-
leukaemic activity of allodepleted T-cells could be augmented by redirecting the specificity of 
T-cells. One approach to do this is by transducing allodepleted donor T-cells using chimeric T-
cell receptors.  The advantage of redirecting the specificity of allodepleted T-cells using 
chimeric TCRs is that the latter are not MHC restricted. 
Chimeric T cell Receptors 
 
Tumour cells evade recognition and elimination by immune effectors by a variety of ways: 
1) low or absent expression of tumour antigens 
2) expression of antigens that are shared with normal cells, so that the immune system has 
become tolerant 
3) down regulation of MHC molecules 
4) defective pathways of antigen presentation  
5) absence of co-stimulation 
6) secretion of inhibitory molecules e.g. IL-10, transforming growth factor-β 
7) expansion of T regulatory cells 
 
Chimeric T cell receptors (ChTCR) can potentially overcome some of the above difficulties. 
ChTCR are artificial T-cell receptors constituted by an antigen recognizing antibody molecule 
linked to a T-cell triggering domain. The most common form of these molecules are fusions of 
single-chain Variable fragments (scFv) derived from monoclonal antibodies, fused to CD3-
zeta endodomain (see Fig 10). Such molecules result in the transmission of a zeta signal in 
response to recognition by the scFv of its target. An example of such a construct is 14g2a-Zeta, 
which is a fusion of a scFv derived from hybridoma 14g2a (which recognizes 
disialoganglioside GD2). When T-cells express this molecule (usually achieved by 
oncoretroviral vector transduction), they recognize and kill target cells that express GD2 (e.g. 
neuroblastoma cells). To target malignant B cells, investigators have redirected the specificity 
of T-cells using a chimeric immunoreceptor specific for the B-lineage molecule, CD19. The 
main advantages of this approach are: 
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1. It overcomes the lack of immunogeneic tumour antigens on leukaemic blasts by 
redirecting T-cells to surface molecules they express. 
2. It enables targeting of tumour cells in a HLA-independent fashion, so that a 
single vector can be used to treat all patients expressing the surface molecule       
(in contrast to transfer of exogenous TCR) 
3. It overcomes tumour evasion by down regulation of HLA molecules or defects 
in antigen processing 
 
T cell mediated function should be more effective that that of infused monoclonal antibody as 
cytokine release at the site of a tumour can lead to amplification of the anti-tumour response. 
Redirected T-cells can also home to tumour sites, proliferate locally, and penetrate solid 
tumours. Critically, eradication of tumours, by adoptive immunotherapy will depend on the 
transformation of tumour CTLs into memory long lasting CTLs.  
 
Figure 10:  Structure of Chimeric TCR. A chimeric TCR consists of a monoclonal antobody binding domain 
complexed to the signalling regions of the TCR. This enables the recptor to bind independent of the HLA. Upon 
binidng to it cognate antigen, signalling through the TCR leads to T-cell proliferation and differentiation. 
Signal
VH VL
Linker [(gly4)ser]n
Spacer- Hinge-CH2-CH3 of IgG1
CD28 Transmembrane
CD3 ζ Endodomain
Ectodomain
 
The extracellular domain consists of 147 (see Fig 10) 
• Ectodomain (Signal sequence) - to allow entry into the endoplasmic reticulum and 
transport to the cell membrane. This is essential if the receptor is to be glycosylated and 
anchored in the cell membrane. Generally, the signal peptide natively attached to the 
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amino-terminal is the component most commonly used (e.g. in a scFv with orientation 
light-chain - linker - heavy chain, the native signal of the light-chain is used) 
 
• Ectodomain - antigen recognition region 
 
The antigen recognition domain is usually a scFv. This consists of variable domains of 
a monoclonal antibody, linked together as a single chain Fv (scFv). Most scFvs are 
generated from mouse hybridomas. Connecting the VH  and VL is a linker [(gly4)ser]n, 
which is at least 12 amino acids in length, which allows the correct stereotactic 
orientation of the scFv.148 
 
There are however many alternatives. An antigen recognition domain from native TCR 
alpha and beta single chains have been described, as have simple ectodomains (e.g. 
CD4 ectodomain to recognize HIV infected cells) and more exotic recognition 
components such as a linked cytokine (which leads to recognition of cells bearing the 
cytokine receptor). In fact almost anything that binds a given target with high affinity 
can be used as an antigen recognition region.148 Importantly, if the antigen recognition 
domain is derived from a monoclonal antibody, this may potentially be immunogeneic, 
as may junctional regions within the ChTCR. 
 
• Ectodomain (The Spacer region) - A spacer region links the antigen binding domain 
to the transmembrane domain. It should be flexible enough to allow the antigen binding 
domain to orient in different directions to facilitate antigen recognition. A spacer 
region separating the antigen binding region and the signalling domain seems to be 
necessary to enable optimal function of constructs The simplest form is the hinge 
region from IgG1 though alternatives include the CH2CH3 region of immunoglobulin , 
portions of CD3 or from the hinge –CH2- CH3 of the human IgG 1 molecule. 
 
• Transmembrane Domain- This is a hydrophobic alpha helix that spans the 
membrane. Generally, the transmembrane domain from the most membrane proximal 
component of the endodomain is used. Different transmembrane domains result in 
different receptor stability. The CD28 transmembrane domain results in a highly 
expressed, stable receptor. 148 
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• Endodomain- consists of the signalling component of region of the TCR (usually 
CD3ζ). CD3-zeta contains 3 immunoreceptor tyrosine-based activation motifs 
(ITAMs). This transmits an activation signal to the T cell after antigen is bound. CD3-
zeta may not provide a fully-competent activation signal and additional co-stimulatory 
signalling is needed. For example, chimeric CD28 and OX40 can be used with CD3-
Zeta to transmit a proliferative / survival signal, or all three can be used together149 
 
A variety of haematological malignancies could be targeted using an approach involving a 
ChTCR e.g. CD19 and CD20 have been targeted for B cell lymphoid tumours, and CD30 for 
lymphomas.  
 
Targeting CD19 on Malignant B cells 
 
The CD19 molecule is a 95 kDa membrane glycoprotein, found on human B lymphocytes at 
all stages of maturation, but usually disappears upon differentiation to terminally differentiated 
plasma cells.150 It is expressed on most ALL, CLL and B cell lymphomas. CD19 is rarely lost 
during the neoplastic transformation and is not expressed on haematopoietic stem cells, or 
normal tissues outside the B lineage. CD19 is also not shed into the circulation and therefore 
there is no soluble CD19 to compete with binding to a CD19 ChTCR. 
 
Human peripheral blood T-cells transduced with a retroviral vector carrying a CD19-TCRζ 
have been shown to potently kill and to secrete Th1 cytokines in response to CD19+ve 
leukaemic cell lines and B-ALL blasts in vitro. 151 CD19chTCR redirected T-cells, traffic to 
the bone marrow and have led to the eradication of established Burkitts lymphoma and 
prolonged survival in a SCID-beige mouse tumour model.152 Incorporation of a suicide gene 
(HSV-1 TK) construct resulted in their elimination following ganciclovir. 147  
 
Limitations of Chimeric TCRs 
 
Targeting endogenous antigens such as CD19 would lead to a loss of B cells and a reduction in 
humoral immunity necessitating immunoglobulin infusions, thus limiting this approach to high 
risk ALL patients. There also remain concerns over the persistence of these genetically 
modified T-cells in vivo. Adoptive transfer of ex vivo expanded CD4 ζ modified syngeneic 
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CD8+ T cells in HIV infected twin pairs, showed in vitro cytotoxicity, but failed to induce 
objective clinical responses. The observed lack of antiretroviral activity was associated with a 
rapid decline in gene marked cells following transfusion. Although 1st generation chTCRs 
were able to kill in vitro and produce IFNγ, they showed diminished IL-2 production and thus 
poor proliferation and survival. 153  Many tumours lack co-stimulatory molecules so that when 
the chTCR interacts with its receptor, it will get 1 signal, but no co-stimulatory signal 2. This 
will lead to poor proliferation and anergy or cell death. As noted above, the incorporation of a 
co-stimulatory domain in cis may improve the expansion and survival of T-cells transduced 
with chimeric chTCRs. 
 
 
The short life span of chTCRs in vivo may be due to a host immune response to the foreign 
proteins on the receptor. The immunogenicity of recombinant receptors can be reduced by 
using human antibody fragments as recognition domains.153 Transfer of antigen specific CD4+ 
helper cells has been shown to be vitally important in CTL function. Co-administration of 
CD4+ and CD8+ chTCRs in HIV patients showed persistence for at least 1 year, but no 
significant therapeutic effects were seen. Thus transfer of CD4 + antigen specific T-cells may 
help with persistence, but effective anti-tumour activity will require T- cell proliferation, and 
establishment of memory T-cells.  
 
So far transduction of T-cells with chTCRs has been with retroviral transduction. The ability 
of retroviruses to integrate into the host cell chromosome raises the possibility of insertional 
mutagenesis and oncogene activation. Acute leukaemia has developed in 4 of 9 children 
treated with gene therapy for X-linked SCID in France154 and 1 out of 10 in the UK. This 
adverse event was attributed to the integration of the retrovirus into the LMO2 locus, a key 
transcription factor in T-lymphoid progenitors, resulting in aberrant expression of this gene 
and uncontrolled proliferation of T-lymphoid blasts in 2 patients. However, in these studies 
CD34 selected haematopoietic progenitors were transduced. There have been no reported cases 
of insertional mutagenesis in patients followed up over an extended period following treatment 
with retrovirally transduced mature lymphocytes. Likewise, there have also been no reported 
cases of insertional mutagenesis, in patients treated with T cells retrovirally transduced with a 
chimeric TCR to treat HIV or neuroblastoma. 
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Oncoretroviral transduction uses high doses of IL-2, OKT3 and/or CD28 stimulation to 
maximize T-cell proliferation. This however converts naïve T-cells into an effector phenotype, 
and has been associated with a reduction in anti-viral and third party immunity.107 Thus, any 
transduction of allodepleted T-cells with a chTCR may need a gentler stimulation in order to 
preserve the phenotype of the T-cells, and thus not compromise on anti-viral immunity. 
Furthermore, an inverse relationship between the acquisition of effector functions and the 
capacity to mediate tumour reduction in vivo (in mouse models) has been demostrated155. Fully 
differentiated tumour CTLs showed potent in vitro cytotoxicity, but naïve T-cells showed poor 
in vitro cyotoxicity. In vivo, however, tumour shrinkage was greatest when naïve T-cells were 
infused and poorest when fully differentiated T-cells were administered. Possible reasons for 
this discrepancy could lie in the ability to naïve T-cells to home to tumour sites, due to 
expression of CD62L, proliferate and secrete IL-2, express co-stimulatory molecules, and 
express less proapoptotic molecules than fully differentiated CTLs155. Thus, to maximize 
tumour activity as well as maintaining third party activity and minimize insertional 
mutagenesis, we have investigated a lentiviral gene transfer of a chimeric TCR into 
allodepleted T-cells. It has been shown that it is possible to efficiently transduce T-cells with a 
lentiviral vector using less intensive pre-stimulation with low dose IL-2 or IL-7  with 
preservation of the phenotype and anti-viral immunity of transduced T-cells.107 Additionally, 
using SIN (self inactivating) lentiviral vectors, will minimize the risks of insertional 
mutagenesis .147  
 
Enhancing Chimeric TCR Signalling  
 
The CD3ζ signalling domain appears insufficient to fully activate of manipulated T-cells to 
proliferate. Integration of the signal transduction domain of the co-stimulatory molecules (2nd 
generation ChTCR) e.g. CD28, ICOS, CD134, or CD137 enhances the proliferative properties 
of gene modified cells, leading to greater secretion of IL-2, and prolonged survival.149,153 The 
signalling characteristics of ChTCR can be further improved by linking in cis more than one 
co-stimulatory domain or a combination of co-stimulatory and co-receptor domains to the 
TCRζ chain (3rd generation ChTCR) e.g. linking the CD28 with the OX40 domain markedly 
increased proliferation, cytokine release and effector function. Moreover, the combination of 
ζ-chain together with the co-receptor (lck) and co-stimulatory (CD28) signals in a single 
receptor has been demonstrated to enhance ChTCR sensitivity and potency.147 
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An alternative approach is to use dual specific T-cells. Dual specific EBV T-cells recognize 
EBV antigens through their native TCR, and the ChTCR target (e.g. CD19) through the 
ChTCR. Using this approach, the engagement of the native TCR in vivo by recurrent EBV 
infections is capable of constantly, stimulating the ChTCR redirected T cells. EBV CTLs 
transduced with a retrovirus carrying the CD19ζ transgene specifically lysed and secreted 
IFNγ in response to CD19+ cell lines and primary ALL blasts in a MHC unrestricted 
fashion.151 Similarly, bispecific CD19 redirected influenza specific CTLs have been shown to 
safely mediate regression of Daudi lymphoma tumors in NOD/SCID mice and this was 
enhanced by vaccination with T antigens presenting cells modified to present influenza 
antigens.156  
 
Lentiviral Vectors 
 
The lentivirus, when compared to gammaretroviruses has a more complex genome and 
consequently a more complex replication cycle. In addition to gag, pol and env genes, they 
encode two regulatory gene, tat and rev, essential for efficient viral gene expression and four 
accessory proteins termed vpr, vpu, nef, and vif. Lentiviral vectors (LVs) which are based on 
lentiviruses, such as HIV-1, can integrate a copy of their genome into the DNA of host non- 
dividing cells. This ability is particularly advantageous in T-cell gene therapy since cells may 
be transduced without extensive prestimulation, thus avoiding prolonged ex vivo culture that 
may result in loss of proliferative and homing ability, and reduction in anti-viral responses. 
Initial packaging constructs for these vectors maintained the accessory genes; however these 
proteins were shown to be dispensable for efficient transduction and integration of lentiviral 
vectors and were therefore deleted in second generation packaging constructs 157. The deletion 
of accessory genes also increased the safety of these vectors, since any replication competent 
virus generated during vector production would lack the essential factors for HIV-1 virulence 
in vivo. A further safety measure was achieved by the production of third generation packaging 
constructs in which the rev gene was placed on a separate plasmid to that of the gag-pol genes 
and the tat gene was removed altogether 158. (see Fig 11)  
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Figure 11: Lentiviral vector genomes and packaging constructs. (A) Genome of a wild-type HIV-
1. (B) Wild-type LTR lentiviral vector genome in which the cDNA of a therapeutic gene is regulated by an 
internal promoter (e.g. EF1α). (C) Genome of a self-inactivating (SIN) lentiviral vector containing a modified 
5’LTR in which the U3 region has been replaced by the constitutive RSV promoter. The vector contains a cPPT 
and WPRE to enhance vector potency and transgene expression. (D, E and F) First-, second- and third generation 
packaging constructs containing sequences from HIV-1 and the VSV-G envelope, used in conjunction with A, B 
or C. (ψ - packaging signal)  Adapted from 159 
 
 
 76
 
The viral tat protein acts as a potent transcriptional transactivator of the HIV-1 LTR and is  
therefore required for high titre virus production 160. High vector titre in the absence of tat was 
found to be possible however by replacement of the U3 region in the 5’LTR with a 
constitutively active heterologous promoter such as that from the Rous sarcoma virus  
(RSV)158. The viral rev gene product functions as a nuclear export factor; the protein binds to  
a RNA motif, the Rev-response element (RRE), and promotes cytoplasmic export of  
unspliced and spliced transcripts and hence must be provided during vector production160. To 
optimize LVs, the incorporation of central polypurine tract sequences (cPPT) and post 
transcriptional regulatory elements, such as woodchuck post transcriptional regulatory element 
(WPRE) have been shown to increase the infectivity of replication incompetent viral particles 
and augment gene expression 
 
One major limitation of lentiviral vectors is the lack of effective packaging cell lines, so that in 
general transient lentiviral supernatants are generated. The risk of insertional mutagenesis with 
lentiviral vectors may be lower than that of oncoretroviral vectors. Cattoglio and colleagues 
examined retroviral integration site (RIS) preferences in CD34+ cells and concluded that 
gamma-retroviruses carry a higher risk for insertional mutation than lentiviruses.161 
Retroviruses have integration-site preferences. Studies in HeLa and CD34 cells have shown a 
gamma-retroviral bias for transcriptional start sites (29% of total) and for actively transcribed 
genes. Lentiviral integrations were also biased toward actively transcribed genes, but for 
intragenic rather than transcriptional start sites.  Additionally, it was found that many of the 
recurrent gamma-retroviral integrations were cancer associated (i.e. proto-oncogenes). In 
contrast, recurrent lentiviral integrations did not involve a statistically significant number of 
cancer-associated genes. To improve the safety of LVs, more recent constructs have been 
developed called self inactivating vectors (SIN). These are characterised by a large deletion in 
the U3 region of 3′ long terminal repeat (LTR) of the DNA used to produce the vector RNA 
which is ultimately transferred to the 5′ LTR of the proviral DNA during reverse transcription, 
and leads to the inability of producing full length vector RNA. Thus, the risk of triggering 
cellular oncogenes by the enhancer activity of the LTR is diminished. Another advantage of 
SIN vectors is that the expression of the transgene can be restricted to specific cell targets 
depending on the internal promoter.162 A recent pilot study with lentiviral engineered T-cells 
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that expressed an anti-sense HIV vector in HIV infected patients showed no evidence for 
insertional mutagenesis after 21–36 months of observation.163 
 
Pseudo typing Lentiviral Vectors 
 
The glycoprotein of the Vesicular stomatitis virus (VSV-G) is most commonly used to pseudo 
type lentiviral vectors and expands vector tropism since the receptor for VSV-G, although still 
undetermined, appears to be ubiquitous in all cell types. Furthermore, VSV-G pseudo typed 
vectors can be efficiently concentrated by ultracentrifugation, enabling the production of 
serum-free, high-titre vector particles. However, VSV-G is associated with cytotoxicity 
limiting the concentrations of vector which can be used without reducing target cell viability.  
VSV-G pseudo typed late generation LVs can transduce T lymphocytes that have progressed 
from G0 into the G1 phase of the cell cycle without  becoming committed to proliferation.162 
The efficient transduction of human T lymphocytes by these vectors does not require cycling 
cells but a certain degree of activation. Stimulation with IL-2, -7 and -15 drives the 
progression to the G1 phase of the cell cycle without inducing further progression or 
proliferation. Gene transfer without TCR triggering reduces or eliminates the risk of selection 
or phenotypic alteration of cells in culture; 
 
 
Transduction of Human PBMCs with Lentiviral Vectors 
 
Qasim et al demonstrated that lentiviral vectors readily transduced peripheral blood 
lymphocytes (PBLs) cultured in IL-2 (100 IU/ml) or IL-7 (5 ng/ml) for 96 h at an efficiency of 
approximately 20–25% using a multiplicity of infection (MOI) of 20.107 There was no 
advantage combining cytokines or using higher MOI, but full activation using anti-CD3/CD28 
microbeads plus IL-2 (100 IU/ml) led to more efficient gene transfer (consistently above 50%). 
Cells cultured in IL-2 or IL-7 maintained their cell surface phenotypes, with preservation of 
the CD4 and CD8 subset proportions and naïve (CD27+CD45RO-) phenotype, whereas 
CD3/CD28-stimulated cells were highly activated (CD25+), with a memory phenotype 
(CD27+CD45RO+). 
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One concern arising from previous clinical trials of adoptive immunotherapy with suicide gene 
transduced T-cells, was the relatively high rates of viral infections following transplantation. In 
addition, the incidence of GVHD was lower than might have been expected, and questions 
have been raised about the functional potential of T-cells after full activation and extensive ex 
vivo expansion. Using the lentiviral vector system, Qasim et al found that cytokine-stimulated 
cells (in particular IL-7) showed preservation of responses against CMV-pulsed dendritic cells 
(DCs) at levels comparable to fresh PBMCs, whereas these responses were diminished in 
CD3/CD28-stimulated cells.107 Recent studies that have indicated that expansion of 
CD4+CD25+ regulatory T cells (Tregs) following activation with anti-CD3/CD28 may be 
partly responsible for suppression of effector function of transduced T-cells.107. Assessment of 
FoxP3 levels following transduction showed substantially increased levels in fully activated 
cells, with minimal alteration in IL-2- or IL-7-cultured cells. The increased numbers of 
FOXP3+ Tregs in CD3/CD28-activated cell cultures is consistent with the reduced 
proliferation detected in response to CMV or allo-stimulation.107 Thus, T-cells cultured in 
cytokines IL-2 or IL-7 are amenable to lentiviral-mediated gene transfer, and although the cells 
undergo division, they retain their phenotype, anti-viral responses, alloreactive potential and 
regulatory numbers.   
Haploidentical SCTs are compromised by a high rate of infectious death and malignant 
relapse. Allodepletion using CD25 based strategies has been shown to enhance immune 
reconstitution. However, the problems of leukaemic relapse and morbidity and mortality from 
adenoviraemia remain a problem. Our data has shown that increasing doses above 106/kg of 
allodepleted donor T-cells is effective against adenovirus. Furthermore, despite CD25 
allodepletion, there remains significant residual alloreactivity against host. Thus, by enhancing 
existing CD25 based allodepletion, this may enable us to give higher doses of allodepleted 
donor T-cells, and thus get better anti-viral and anti-leukaemic responses but without GVHD. 
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Statement of Aims 
 
The aims of this study are; 
 
1. To characterize the activation marker and cytokine profile of alloreactive T-cells 
identified using CFSE dye dilution. In particular we have focused on determining the 
phenotype of the CD25 negative, proliferating alloreactive cells to provide a rational 
basis for enhancing allodepletion with CD25-based strategies.  
 
2. Based on these studies, we have compared residual alloreactivity after depletion of 
alloreactive cells expressing these markers to determine if this leads to enhanced 
allodepletion compared to CD25-based strategies. We have also determined if anti-
viral T-cell responses are preserved following our refined allodepletion method.  
 
 
3. Using lentiviral transfer of chTCR CD19-CD3ζ transgene we have redirected the 
specificity of allodepleted T-cells generated using the optimal strategy identified from 
the above studies, to determine if this approach can augment anti-leukaemic activity of 
allodepleted T-cells. 
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MATERIALS AND METHODS 
 
Reagent Suppliers 
 
Chemicals were obtained from Sigma, Mo, USA, and media purchased from Invitrogen, unless 
otherwise stated. Restriction endonucleases and their appropriate buffers were purchased from 
Promega. Cytokines were purchased from R&D systems (Minneapolis, MN). 
 
Buffers and Solutions 
 
All buffers were prepared in double distilled water (ddH2o). Sterile solutions used ddH2o 
autoclaved at 121ºC for 15 min and filtered through a 0.22µm syringe tip filter (Millipore). 
Compositions of buffers and solutions are listed below.  
 
Buffer Ingredients 
Acetate Buffer 4.6 mls 0.1 M acetic acid, 11.0mls 0.1M sodium 
acetate, 46.9 mls Milli-Q water 
Cell Dissociation Buffer 
Invitrogen (13151-014) 
 
Orange G loading buffer  
 
 10Mm Tris Ph 7.5, 50Mm EDTA, 10% Ficol 
400, 0.4 % Orange G (Sigma (861286)) 
Flow Cytometry staining buffer (FACS 
buffer) 
PBS, 0.5 % (w/v) BSA (Sigma A9418) 
Flow cytometry fixing buffer (FACS fixing 
buffer)  
FACS buffer + 1 % Paraformaldehyde (Sigma 
441244) 
PBS 
Invitrogen (14190-094) 
 
Luira-Bertani Broth (LB) 1% (w/v) tryptone peptone, 0.5 %(w/v) yeast 
extract (Becton Dickinson), 170mM NaCL, pH 
7.0. Ampicillin  (Sigma A9393) was added at 10 
mg/ml where indicated (LB-Amp) 
 82
MACS Buffer PBS, 2mM EDTA, 0.5 % BSA 
TAE (X 50) 0.2M Tris, 1 M glacial acetic acid (BDH) 50mM 
EDTA, pH8.0 
PBS 0.05 % Tween 50 ul of Tween 20 (Sigma) per 100 mls of PBS 
APC Complex solution PBS/ 0.1 % Tween 20 
ELISPOT Coating buffer 1.59 g Na2CO3, 2.93g NaHCO3, 200mg NaN3, 
Up to 1 L with sterile water 9.6 pH, Sterile filter 
0.22µm 
 
Media and Solutions used for Tissue Culture  
 
Media and their supplementary ingredients used in tissue culture are presented. 
Medium Supplements 
AIM V 
Invitrogen (12055-091) 
 
Cell Genix DC media 
TCS Cellworks (2005) 
1% L-glutamine 
Complete DMEM 
Invitrogen (61965-026) 
10%(v/v) FCS (Sigma F7524) and 10µg/ml 
penicillin/streptomycin (Invitrogen 15140-
122) 
Complete RPMI with glutamax (RF10) 
Invitrogen (61870-010) 
10%(v/v) FCS and 10µg/ml 
penicillin/streptomycin 
Optimem  
Invitrogen (31985-047) 
 
CTL media 45 % RPMI hyclone (Hyclone SH30096.02), 
45 %clicks media (Irvine Scientific 9195), 1 
% L-glutamine, 10 % fetal calf serum hyclone 
(Hyclone SH30070.03) and 10µg/ml 
penicillin/streptomycin 
Trypsin 
Invitrogen 25300-062 
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Cell Lines used in Study 
 
Cell Line Origin Supplier Medium 
EBV- lymphoblastoid 
(LCLs) 
Normal donor B cells ICH, London RF10 
293Ts Human Embryonic 
kidney 
ICH, London Complete DMEM 
Ramos Human Burkitt’s 
lymphoma 
Baylor College of 
Medicine 
RF10 
K562 cells Human 
erythroleukaemia 
Baylor College of 
Medicine 
RF10 
K562 GFP+CD19+ K562 stably 
transduced with 
CD19 GFP vector 
Dr. Martin Pule RF10 
K562 GFP+ CD19- K562 stably 
transduced with a 
GFP vector 
Dr. Martin Pule RF10 
Cytokines used in Study 
 
Cytokine Source Catalogue Number 
Recombinant Human GM-CSF R&D 215-GM-010 
Recombinant Human IL-2 R&D 212-IL-010 
Recombinant Human IL-4 R&D 214-IL-010 
Recombinant Human interferon 
gamma (IFNγ) 
R&D 285-IF-100 
Recombinant Human Tumour 
necrosis alpha (TNFα) 
R&D 210-TA-010 
Recombinant Human IL-7 R&D 207-IL-005 
Prostaglandin E2 Sigma P5640 
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Antibodies Used in this study 
 
All antibodies were purchased from Becton and Dickinson unless otherwise stated. A list of 
the antibodies utilised in this study is listed below 
 
Antibody Use Clone 
Mouse Anti Human CD3 Fitc Functional Characterisation of 
alloreactive T-cells, assessing 
allodepletion efficacy and 
assessing lentiviral transduction 
SK7 
Mouse Anti human CD3 Pe Functional Characterisation of 
alloreactive T-cells, assessing 
allodepletion efficacy and 
assessing lentiviral transduction 
SK7 
Mouse Anti Human CD3 APC Functional Characterisation of 
alloreactive T-cells, assessing 
allodepletion efficacy and anti-
viral studies 
UCHT1 
CFSE (Invitrogen) Functional Characterisation of 
alloreactive T-cells 
Catal No. C34554 
Mouse Anti Human CD69 Pe Functional Characterisation of 
alloreactive T-cells 
FN50 
Mouse Anti Human CD71 Pe Functional Characterisation of 
alloreactive T-cells and 
assessment of allodepletion 
M-A712 
Mouse Anti Human CD71 
Biotinylated 
Performing CD71 allodepletion M-A712 
Mouse Anti Human HLA-DR 
PeCY5 
Functional Characterisation of 
alloreactive T cells 
TU36 
Mouse Anti Human OX40 
PeCY5 
Functional Characterisation of 
alloreactive T-cells 
ACT35 
Mouse Anti Human ICOS Pe Functional Characterisation of 
alloreactive T-cells 
DX29 
Mouse Anti Human CD95 
PeCY5 
Functional Characterisation of 
alloreactive T-cells 
DX2 
Anti Human CCR7 APC R&D 
systems 
Functional Characterisation of 
alloreactive T cells 
150503 
Anti Human CD45RA PeCY5 
R&D systems 
Functional Characterisation of 
alloreactive T-cells 
5H9 
Mouse Anti Human TNFα Pe Functional Characterisation of 
alloreactive T-cells 
MAb11 
Mouse Anti Human IFNγ APC Functional Characterisation of 
alloreactive T-cells 
B27 
Mouse Anti Human IL-2 APC Functional Characterisation of 
alloreactive T-cells 
5344.111 
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Mouse Anti Human CD25 Pe Functional Characterisation of 
alloreactive T-cells 
2A3 
 Mouse Anti Human CD25 
PeCy5 
Functional Characterisation of 
alloreactive T-cells and 
assessment of allodepletion 
M-A251 
Goat Anti Human IgG Fcγ Cy 
tm5 Jackson Laboratories 
Assessment of Lentiviral 
Transduction 
Catal No 109-176-008 
 Mouse Anti Human CD8 Fitc Anti-viral Studies SK1 
Anti Human CMV pp65 HLA2 
A2-NLV PE pentamer  
Proimmune 
Anti-viral Studies Catal No HCMVpp65 
495-504 
Anti Human CMV pp65 HLA2 
B7-TPR PE pentamer 
Proimmune 
Anti-viral Studies Catal No HCMV pp65 
417-426 
Anti Human EBV LMP-2 A2-
CLG PE pentamer Proimmune 
Anti-viral Studies EBV-LMP-2 426-434 
Mouse Anti Human CD14 Pe Assessment of Dendritic cell 
maturity 
M5E2 
Mouse Anti Human CD83 Pe Assessment of Dendritic cell 
maturity 
HB15e 
Mouse Anti Human CD86 Pe Assessment of Dendritic cell 
maturity 
IT2.2 
APC isotype IgG1 κ  MOPC-21 
Pe isotype IgG1 κ  MOPC-21 
Fitc isotype IgG1 κ  MOPC-21 
PeCY5 isotype IgG1 κ  MOPC-21 
Mouse Anti Human CD19 Pe Assessment of CD19 positivity 
on cell lines 
4G7 
 
7-AAD Assessment of viability of CD19 
positive targets 
 
Kits 
 
Plasmid Megaprep/Maxiprep Kit    Invitrogen (K2100-07) 
QIAquick gel extraction kit     Qiagen (287706) 
QIAquickPCR purification kit    Qiagen (28106) 
DNA Quick Ligase Kit     New England Biolabs (M2200S) 
 
PCR 
 
Primers       Invitrogen 
Taq DNA polymerase, dNTPs, buffer               Promega (M7660) 
Restriction enzymes      New England Biolabs(NEB) 
BamHI       NEB R0136L 
EcoR1        NEB R0101L 
Bgl II        NEB R0144S 
NotI        NEB R0189S 
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Buffer 1       NEB B7001S 
Buffer 2       NEB B7002S 
Buffer 3       NEB B7003S 
Buffer 4       NEB B7004S 
BSA        NEB B9001S 
 
Bacteria 
 
Escherichia coli strains used: 
DH5α Competent cells     NEB C2987H 
 
Centrifuges 
 
Microcentrifuge      Heraeus Biofuge Fresco 
Tabletop centrifuge      Sorvall Legend RT 
Superspeed centrifuge     Sorvall Evolution RC 
Ultracentrifuge      Sorvall Discovery SE 
 
 
Isolation of Responder and Stimulator Cells for MLR cultures and 
Generation of Epstein-Barr virus (EBV)–transformed lymphoblastoid cell 
lines (LCLs) 
 
Ethical approval for the study was obtained through the non-clinical institutional review board 
at University College London. T-cells and dendritic cells (DC) were isolated from peripheral 
blood or single donor buffy coat preparations from healthy donors with informed consent 
CD3+ T-cells were isolated by positive selection of peripheral blood mononuclear cells 
(PBMC) with CD3 microbeads (Miltenyi Biotec, Bergisch Gladbach, DE) according to 
manufacturer’s instructions. PBMCs were incubated with CD3 microbeads for 15 minutes at   
4° C (20 µl of beads/107 PBMCs), and washed in MACS buffer (PBS containing 2 mM EDTA 
and 0.5 % bovine serum albumin). Labelled cells were then passed over immunomagnetic LS 
columns, washed twice with MAC buffer and the positive fraction eluted after removal of LS 
columns from the MIDI MACS device. FACS analysis showed the cells to be 99 % routinely 
pure. 
 
Dendritic cells were generated from CD14+ PBMC isolated by immunomagnetic selection 
(Miltenyi Biotec). PBMCs were incubated with CD14 microbeads for 15 minutes at   4° C (20 
µl of beads/107 PBMCs), and washed in MACS buffer (PBS containing 2 mM EDTA and 0.5 
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% bovine serum albumin). Labelled cells were then passed over immunomagnetic LS columns, 
washed twice with MAC buffer and the positive fraction eluted after removal of LS columns 
from the MIDI MACS device. These were cultured at a concentration of 106 cells/ml in 
CellGenix DC Media  (CellGenix Technologies, Illinois) in 6 well plates supplemented with 
granulocyte-macrophage colony-stimulating factor (GM-CSF) (R & D systems, GM 215-010), 
(800U/ml final) and IL4 (1000 U/ml final) cytokines (R&D Systems, Minneapolis, MN 
systems, 214-IL-010). Cells were cultured for 1 week and matured with tumour necrosis factor 
(TNFα; 10 ng/mL final) (R&D Systems 210-TA-010) and prostaglandin E2 (1µg/mL final) 
(Sigma P5640) for 2 days. The phenotype and purity of the dendritic cells was verified by 
FACS staining using phycoerythrin (PE) conjugated monoclonal antibodies specific to human 
CD14, CD83 and CD86  (BD Biosciences CA, USA). Dendritic cells were irradiated at 30 Gy 
prior to being used as stimulators for MLRs. 
  
For LCL generation, 100µl (5 x 106 PBMCs) were infected with concentrated supernatant from 
the B95-8 EBV-producer cell line (100µl), in the presence of ciclosporin 1µg/ml (Sigma 
C3662) to inhibit EBV specific CTLs that would prevent LCL outgrowth. LCLs were cultured 
in RF10 medium consisting of RPMI 1640 (Biowhittaker, Walkersville, MD) supplemented 
with 10% fetal bovine serum (Hyclone, Logan, UT). The cells were plated on a 96 well plate at 
a density of 5 x 105/well. Cultures were fed with half volume medium exchange weekly. When 
clumps were seen, they were progressively transferred to a 24 well plate, and then a T25 flask. 
LCL were irradiated (70 Gy) prior to being used as stimulators for MLRs 
 
CFSE Staining and MLRs 
 
Purified CD3+ T-cells were labelled with 2.5 µM CFSE (Invitrogen, Carlsbad, CA C34554) for 
15 minutes at 37° C. The reaction was stopped by quenching with AB serum (Sigma Aldrich, 
Dorset, UK) and then the cells were washed twice in RPMI 1640 containing 10 % AB serum. 
CFSE-labelled T-cells were co-cultured with HLA-mismatched allogeneic irradiated DC at a 
responder: stimulator ratio of 5:1. A negative control consisting of CD3+ CFSE stained T-cells 
alone was used. Cells were cultured at a concentration of 2x106/ml in AIM V serum free media 
(Invitrogen, Carlsbad, CA).  
 
 88
Flow cytometric Staining and Analysis 
 
FACS were performed using PE/PerCP/APC- conjugated monoclonal antibodies specific for 
human CD3, CD25, CD69, CD71, HLA-DR, OX40, ICOS, CD95, CD45RA, CCR7, 
interferon-γ (IFN-γ), tumour necrosis factor alpha (TNFα), and interleukin-2 (IL-2). All 
antibodies were purchased from BD Biosciences (San Jose,CA, USA) except for CCR7 (R & 
D systems, Minneapolis, MN). Brefeldin (1 µg/ml) (BD Biosciences) was added for a period 
of 8 hours. All tubes were stained with CD3 and CD25, allowing gating on the CFSE-dim, 
CD3+, CD25-ve population. Staining was performed on samples taken from MLR cultures at 
days 0, 1, 3, 5, and 7. Voltages were determined by acquiring events on unstained co-cultures. 
Corresponding isotypic monoclonal antibodies were used to determine cut off points for 
positive populations. Co-cultures were stained with positive controls (either CD3 FITC, CD3 
PE, CD3 PeCy5, CD3 PERCP or CD3 APC) and isotypic monoclonal antibodies to determine 
appropriate compensation controls. All tubes contained CFSE, CD3 and CD25 except cells 
which were stained with CD45 RA and CCR7 PerCP, which were co stained with CD3 and 
CFSE. This allowed gating on the CFSE Dim CD25 negative population. 2x105 cells were 
incubated with human AB serum for 20 minutes at 4°C and then were stained with antibody 
for 30 minutes at 4 ° C and then washed twice in FACS buffer (PBS and 1 % calf serum) and 
were then resuspended in 1 % paraformaldehyde for 20 minutes. 
 
 To simultaneously analyse surface molecules and intracellular cytokines, samples were first 
stained for surface antigens, then fixed with 2% paraformaldehyde (incubated PBMCs for 20 
minutes in paraformaldehyde) to stabilize the cell membrane. They were then washed twice in 
FACS buffer and permeabilized with 0.5 % saponin to allow anti-cytokine antibodies to stain 
intracellularly (incubate PBMCs with saponin at room temperature for 10 minutes). PBMCs 
were then washed in saponin and were incubated with anti cytokine antibodies resuspended in 
a total of 50 µl of saponin. They were then incubated at 4ºC for 30 minutes and washed twice 
in saponin and resuspended in FACS buffer. Samples were acquired using 4-colour flow 
cytometry on a FACS LSR (BD biosciences). Analysis was done using WinList software 
(Verity Software House). The proliferative index and precursor frequencies were derived using 
ModFit LT software (Verity software House). For FACS analysis in allodepletion 
experiments, a CyAn flow cytometer (Dako, Fort Collins, CO) was used to acquire data and 
Summit v4.1 software (Dako) to analyze data.  
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Generation of Allodepleted Donor T cells and Comparison of 
Allodepletion Methods 
 
Normal donor peripheral PBMCs and HLA-mismatched irradiated (70Gy) recipient LCLs 
were resuspended at 2 x106/ml in AIM V media. PBMCs were co-cultured with or without 
LCLs at a responder: stimulator ratio of 40:1 in T-175 flasks for 3 days. For comparison of 
CD25 immunomagnetic bead and CD25 IT depletion, on day 3 of the MLR, co-cultures were 
split into 2 arms. Anti-CD25 microbeads (20 µl microbeads/107 PBMCs, Miltenyi Biotec, 
Bergisch Gladbach, Germany 130-092-983) were added to half the co-culture and 4 µg/ml 
CD25 IT (RFT5-SMPT-dgA) was added to the other half. CD25 immunomagnetic negative 
selection was performed according to manufacturer’s instructions using LD columns and 
depletion using CD25 IT was performed overnight as follow; co cultures were harvested and 
resuspended at 107/mL in immunodepletion medium consisting of AIM V supplemented with 
20 mM ammonium chloride (Sigma, St Louis, MO) to improve the bioactivity of the 
immunotoxin with pH adjusted to 7.75 using Na HEPES (N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid) (Sigma). 0.22 µm filtered RFT5-SMPT-dgA anti-CD25 immunotoxin was 
then added and the next morning co-cultures were washed twice and then resuspended at 2 x 
106/mL in AIM V. The CD25-ve fractions were resuspended at 2 x 106/ml in AIM V. 
Unmanipulated donor PBMC:LCL co-cultures and donor PBMCs alone were used as controls. 
2x105 cells from unmanipulated and allodepleted day 3 co-cultures were sampled in triplicate 
for FACS analysis and primary proliferation assays. The remaining cells were rested in AIM V 
medium in 24 well plates at 2 x 106 per well for 2 days prior to secondary stimulation in 
secondary MLRs and enzyme-linked immunospot (ELISPOT) assays.  
 
For combined CD25/71 allodepletion, day 3 PBMC:LCLs co-cultures were washed and 
resuspended in 60 µl of FACS buffer (PBS with 1 % calf serum)  per 107 PBMCs. Biotinylated 
anti-CD71 antibody (BD Biosciences 555535) was added (20 µl of antibody/107 PBMCs) for 
15 minutes at 4ºC. Cells were then washed and labelled with anti-CD25 beads and anti-biotin 
beads (Miltenyi Biotec 130-090-485) using 20 µl of antibody/107 PBMCs for 15 minutes at 
4ºC. Immunomagnetic depletion of CD25/71 labelled cells was then performed on LD 
columns according to manufacturer’s instructions. For combined CD25/45RA depletions, 
PBMCs were labelled with CD25 and CD45RA beads (Miltenyi Biotec 130-091-092), and 
depletions were done according to manufacturer’s instructions. Aliquots from the allodepleted 
negative fractions were analysed flow cytometrically.  The remainder of the negative fraction 
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was resuspended in AIM V media at 2 x 106/ml and rested for 2 days and were then analysed 
for residual alloreactivity in secondary MLRs or IFN-γ ELISPOT assays. 
Scale Up studies 
 
In order to optimize our scale up studies of CD25/71 allodepletion we first compared 
allodepletion between clinical grade CD25 immunomagnetic beads (Miltenyi 274-01) with a 
biotinylated CD25 and clinical grade anti biotin beads (Miltenyi 173-01). Day 3 PBMC: LCLs 
co-cultures were split into 2 arms: CD25/71 allodepletion was performed as above for one half 
of the co-culture. The remaining half was washed and resuspended in PBS (60µL/ 107 
PBMCs). Biotinylated anti-CD25 (gift of Dr. Marina Cavazzana-Calvo, 2 µg/108 PBMCs) and 
biotinylated anti-CD71 (BD biosciences) were added to the remainder for 15 minutes at 4ºC. 
The co-culture was washed and antibiotin beads were added and the depletion was performed 
using LD columns as described above. 
 
In order to determine if our data using CD25/71 allodepletion could be replicated using 
CliniMACs device (Miltenyi 151-01), we performed scale up studies in the cell therapy 
laboratories at Great Ormond Street Hospital. Donor PBMCs were co cultured with irradiated 
host DCs (R:S 10.1) in cell culture bags (Miltenyi Biotec 200-074-301) and a combined 
CD25/71 allodepletion (using biotinylated CD25+71) was done on day 4 using a CliniIMACs 
device using depletion programme 1.2. Two sets of CliniMACs tubing were used to perform 
the depletion; CLINIMACS depletion tubing set (Miltenyi 266-01) and TS tubing (Miltenyi 
Biotec 161-01). Samples were taken after depletion for FACS to determine the efficacy of 
depletion, and for sterility testing. The allodepleted cells were rested for 2 days and 
restimulated to host/3rd party in a 2º MLR. 
 
 
Proliferation assays  
 
Primary proliferation assays were performed by pulsing unmanipulated or allodepleted co-
cultures on day 5 with 1 µCi 3H-thymidine (Amersham Pharmacia Biotech, Little Chalfont, 
UK) per well for 16 h. 3H-thymidine incorporation was measured with a MicroBeta TriLux 
(Perkin-Elmer Weiterstadt, Germany). Data are presented with the mean cpm of triplicate 
responder alone and stimulator alone subtracted from mean cpm of test cultures.  
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To assess residual alloreactivity in secondary MLRs, 5 days after the initial co-culture 2 x 105 
allodepleted T-cells were restimulated with 5000 irradiated LCLs from either the original 
stimulator or HLA mismatched 3rd party. Controls consisted of unmanipulated PBMC which 
were frozen on day 0 and thawed on the day of plating, allodepleted T-cells alone or LCLs 
alone. After 5 days, cells were pulsed with 3H-thymidine and uptake assayed the next day 
 
IFN-γ ELISPOT assay 
 
To further assess residual alloreactivity, on day 5 after primary stimulation, 2 x 105 
allodepleted donor T-cells or thawed, unmanipulated donor PBMCs were plated per well in the 
presence of 2 x 105 irradiated (30 Gy) host or 3rd party LCL stimulators in triplicate for 18 - 24 
hours at 37°C. Controls consisting of 2 x 105 responders or stimulators alone were also plated. 
MAHAS4510 plates (Millipore, Billerica, MA) were coated with anti–IFNγ capture antibody 
MAB91 DIK (Mabtech, Cincinnati, OH) overnight and blocked with RF10 medium for 1 hour 
at 37°C. 2 x 105 allodepleted donor T cells or thawed donor PBMCs per well were plated in the 
presence of 2 x105 irradiated stimulators in triplicate wells for 18 to 24 hours at 37°C. Controls 
consisting of 2 x 105 responder alone, and 2 x 105 stimulators alone were also plated. Plates 
were cultured for 18-24 hours and then washed and incubated for 2 hours at 37°C with 
biotinylated–anti-IFNγ detection antibody 7-B6-1 (Mabtech). Avidin-peroxidase complex 
(Vector Laboratories, Burlingame, CA) was added for 1 hour at room temperature and spots 
developed with 3-amino-9-ethylcarbazole (AEC, Sigma) substrate mix. The numbers of spots 
were counted using a plate reader (Bioreader 3000, Bio-Sys GmbH, Karben, Germany), the 
means of triplicate wells calculated and expressed spot-forming cells per 105 cells. The mean 
number of specific spot-forming cells was calculated by subtracting the mean number of spots 
produced by responder alone and stimulator-alone wells from the mean number of spots in test 
wells for each dilution. 
 
Assessment of Antiviral Immunity 
 
For pentamer analysis, 106 PBMC or allodepleted T-cells were co-stained with CD8 FITC, 
CD3 PerCP and either isotype PE control antibody or PE-conjugated pentamer appropriate to 
the donors’ HLA restriction. The following pentamers were used to detect virus-specific CD8+ 
T cells (ProImmune, Oxford, United Kingdom): CMV pp65- HLA-A*0201-NLVPMVATV 
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(A2-NLV), and HLA-B*0702-TPRYTGGGAM (B7-TPR); EBV- LMP-2- HLA-A*0201-
CLGGLLTMV (A2-CLG). The PBMCs were stained with 5 µl PE-labelled pentamer for 15 
min at room temperature, washed and co-stained for surface expression of CD8-APC and 
CD3-PerCP. PBMCs from donors with known positive populations served as positive controls 
and PBMCs from normal donors negative for the restricting HLA-type were used as additional 
negative controls. A total of 200 000 events in the lymphocyte gate were analyzed where 
possible and the percentage of tetramer-positive cells in the CD3+/CD8+ lymphocyte gate was 
expressed as a proportion of the CD8+ cells with the isotype control subtracted. For a 
population to be labelled as positive, at least 50 CD3+CD8+ tetramer-positive cells with the 
staining characteristics of the positive control population had to be acquired. The percentage of 
tetramer-positive cells in the CD3+/CD8+ lymphocyte gate was expressed as a proportion of 
the CD8+ ve cells.  
 
Functional responses to CMV, EBV and adenovirus were analyzed in IFN-γ ELISPOT assay. 
The following stimulators were used to monitor antiviral responses of the allodepleted 
PBMCs: To assess EBV responses, unmanipulated PBMCs or allodepleted PBMCs were co- 
cultured with irradiated (70Gy) autologous LCLs. To assess CMV responses, unmanipulated 
PBMCs or allodepleted PBMCs were co-cultured with irradiated autologous PBMCs pulsed 
with pp65 pepmix (1 µg/ml).The pp65 pepmix was purchased from JPT Peptide Technologies 
GmbH (Berlin, Germany) and consists of 138 different pp65 peptides. Autologous PBMCs 
were co incubated with pp65 pepmix for 1 hour at 37ºC, washed twice, then resuspended at 2 
x106/ml in AIM V and then irradiated to 30Gy.  We examined the response to adenovirus by 
stimulating unmanipulated PBMCs or allodepleted PBMCs with autologous PBMC transduced 
with Ad5f35-GFP; The Ad5f35-GFP vectors were purchased from Baylor College of Medicine 
(Houston, TX). Autologous PBMCs were transduced with the Ad5f35GFP (Multiplicity of 
infection MOI 20) for 2 hours at 37ºC washed twice, resuspended at 2 x106/ml in AIM V and 
then irradiated at 30Gy. The titre of the AD5f35GFP was 1 x 1010 plaque forming units/ml. To 
control for GFP responses, autologous PBMCs were pulsed with Vaccinia-GFP (MOI 3) 
PCR amplification of CD19 chTCR Sequences 
 
The ScFv CD19ζ plasmid was supplied by Dr. Martin Pule. The CD19 chimeric TCR 
(CD19R) transgene consists of the variable domains of the CD19 specific murine monoclonal 
antibody FMC-63 assembled as a single chain variable fragment (ScFv), in frame with a 
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sequence encoding the human IgG1 hinge CH2-CH3, the human CD28 transmembrane 
domain, and the cytoplasmic signalling domain of the human CD3ζ. The CD19R transgene 
was subcloned into the Not 1 and Bam H1 sites of the pHR –SIN-SE lentiviral vector164 to 
create the construct CD19R/ pHR –SIN-SE (Fig 39).  
 
The 1946 base pair fragment of the CD19 chTCR was amplified by PCR.  Not 1 restriction 
restriction sites were added to the 5′ end of the reverse primer, and a Bgl II restriction site was 
added to the 5′ of the forward primer so that the fragment could be subcloned into the Not 1 
and Bam H1 sites of the pHR –SIN-SE lentiviral vector (gift of Dr. Martin Pule).  
Forward 5′GATTCGGCACTGAGATCTGCCACCATGGAGACCGACACCCTGCTGC 3′ 
Reverse 5′AGCCTGGACACTGCGGCCGCACGCGTCATCTGGGTGGCAGGGCCTG 3′ 
 
PCR 
 
PCR reactions were performed in a total volume of 25µl containing 100ng template DNA, 
forward and reverse primers at 0.5µm, dNTPs, each dNTP at 200µM and 2.5U of Taq DNA 
polymerase in the appropriate buffer (Promega). The PCR was performed using an Eppendorf 
AG 22331 Themocycler utilising the following programme set at 35 cycles: 98ºC for 2 
minutes, 98ºC for 30 seconds, 67ºC for 2 minutes, and 72ºC for 3 minutes, and then hold at 
4ºC. PCR products to be used for cloning procedures were purified using a QIAquick PCR 
purification kit (Qiagen) as per the manufacturer’s instructions. 
 
Enzyme digestion of Plasmid DNA 
Plasmid DNA (typically 0.5-5µg) was digested in a final volume of 25-50 µl of 10 x buffer 
(supplied by manufacturer and diluted x1 with distilled water) and bovine serum albumin (0.1 
mg/ml). The amount of enzyme used contained an excess of 5-10 units/µg DNA according to 
manufacturer’s instructions (Promega). The digest was incubated at 37ºC for 3 hours. The pHR 
–SIN-CSGW lentiviral vector was digested with BamH1 and Not1 excising the GFP sequence 
and creating overlapping ends for the CD19 chTCR. The amplified CD19 chTCR fragment 
was digested with Not 1 and Bgl II. The DNA digestion was verified by agarose gel 
electrophoresis. 
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Agarose Gel Electrophoresis and Gel Purification of Fragments 
DNA fragments were resolved by electrophoresis thorough 1 % agarose gels in 1 x TAE buffer 
(40 mM Tris-acetate, 5mM EDTA). To prepare the gels, agarose was dissolved in 1x TAE 
buffer by boiling in a microwave, and after cooling, ethidium bromide was added at 0.5µg/ml 
for visualisation of DNA. DNA samples were mixed with Orange G loading buffer (10Mm 
Tris Ph 7.5, 50Mm EDTA, 10% Ficol 400, 0.4 % Orange G) before loading onto agarose gels. 
A 1kb plus ladder DNA ladder (bioline) was loaded onto each gel to enable size determination 
of DNA fragments. Gels were electrophoresed using a voltage of 50-100 V (up to 150 mA) 
and the separated DNA fragments subsequently visualised by exposure to ultra-violet light 
using the UVIdoc gel documentation system. Following electrophoresis DNA fragments were 
excised from agarose gels using a clean scalpel blade under ultra-violet light. The DNA was 
extracted from agarose using a QIAquick gel extraction kit (Qiagen) as per manufacturer’s 
instructions. 
 
Ligations 
 
Ligations were performed using a vector to insert ratio of ratios of 1:3 or 1:6 (100 ng vector 
DNA) in a final volume of 20 ul with 1.5 ul of quick ligase (NEB). The reaction was incubated 
for 5 minutes at room temperature. A vector only control sample was also included to provide 
an estimate of the re ligated plasmid. The ligation reaction was immediately transformed into 
competent E.Coli DH5 alpha cells (NEB) 
 
Bacterial Transformation 
 
Competent DH5α E.Coli were transformed by heat shock. 25 µl of competent cells were 
slowly thawed on ice and mixed with 1-10ng of DNA from the ligation mix. The cells/DNA 
were incubated on ice for 30 minutes and then heat shocked by placing the mixture for 35 
seconds at 42ºC and then transferred back onto ice. 250 µl of LB media was then added to the 
cells, and the mixture was transferred to a 5ml tube. The cells were shaken at 250 rpm at 37ºC 
for 1 hour, after which they were diluted in LB media and spread on LB ampicillin agar plates. 
The plates were incubated overnight at 37ºC, after which colonies were picked using sterile 20 
µl pipette tips and grown overnight in 5 ml liquid cultures. 
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Small Scale Plasmid DNA Preparation 
 
Plasmid DNA was prepared using Qiagen Mini-Prep kits as per manufacturer’s instructions 
from overnight single colony inoculums. Test cuts with EcoR1/Not1 (predicted size 2.5 kb and 
8.5 kb), EcoR1/BamH1 (predicted size 1.3 kb and 9.7 kb) and Not1/BamH1 (predicted size 
1.15 kb and 9.86 kb) were done to determine clones with the correctly inserted CD19R 
fragment.  
 
Large Scale Plasmid DNA Preparation 
 
For large scale plasmid DNA preparation 500 ml LB media containing ampicillin (50µg/ml- 
Sigma) was inoculated with 500 ul of a fresh 5 ml culture and incubated overnight at 37ºCwith 
agitation (250 rpm). Plasmid DNA was subsequently prepared using Qiagen Mega-Prep kits as 
per manufacturer’s instructions. After overnight culture at 37ºC with shaking, bacteria were 
pelleted, by centrifugation at 4000xg for 10 minutes and resuspended in the presence of 
100µg/ml RNAase. Plasmid was purified by alkaline lysis of bacteria, followed by binding of 
plasmid DNA to anion exchange resin columns under appropriate low salt and pH 
conditions (Qiagen Maxi/Mega Prep Kits). The columns were washed to remove non-DNA 
fractions and the plasmid DNA was eluted using a high salt solution and then desalted by 
precipitation with isopropanol. The plasmid DNA pellets were washed in 70 % ethanol and 
then resuspended in pyrogeneic-free water. Correct assembly of the CD19 chTCR was verified 
by DNA sequencing. Plasmid DNA concentration was calculated by measuring the absorbance 
of light at a wavelength of 260nm (A260) using a nano dropND-1000 spectrophotometer with a 
0.2 mm path length. At this wavelength 50µg/ml of double stranded DNA has an absorbance 
of 1. 
 
Lentivirus Preparation and Transductions 
 
Lentivirus Production 
 
1.2 x 107 293 T cells grown in complete DMEM were seeded in 175 cm2 tissue culture flasks 
the day before transfection. Lentiviral vector DNA (40µg) and packaging plasmids pMDG.2 
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carrying the envelope transgene (VSV-G) (10µg) and pCMV∆8.74, carrying the lentiviral 
transgene (gag-pol)(30µg) were added to 5 mls OPTI-MEM, filtered through a 0.22µm filter, 
and combined with 5 ml filtered OPTI-MEM supplemented with 1 ul 10mM polyethylenimine 
(PEI) transfection reagent. The transfection reaction was incubated at room temperature for 20 
minutes during which time the 293T cells were washed once with OPTI-MEM media. The 10 
mls DNA/PEI complexes were subsequently added to the cells and they were then incubated at 
37ºC/5%CO2 for 4 hours, after which the media was replaced with 14 mls of complete DMEM. 
Viral supernatant was harvested at 48 and 72 hours post transfection, filtered through a 
0.22µm filter and concentrated by ultracentrifugation at 23,000 rpm for 2 hours. Lentiviral 
pellets were resuspended in 100µlm serum free media (OPTI-MEM), stored on ice for 20 
minutes and then snap frozen in aliquots at -80ºC.  
 
Titration of Lentiviral Supernatants 
 
Virus transduction was determined by transduction of 293 T cells. 1 x 105 cells were seeded in 
complete DMEM in 24 well plates and left to adhere overnight. The media was subsequently 
aspirated and serial dilutions of lentiviral supernatant in a total volume of 100µl of optimem 
were added. 72 hours post transduction cell dissociation media was added to the 293 T cells 
and the infectious viral titre was determined by analysis of transgene positive cells by flow 
cytometry. The titre of the virus was determined as below: 
 
No of virus agents/ml= % of transduced cells x no of cells in the well 
     
    Vol of virus used to infect cells 
 
 Wells giving 5-15 % transduction was used to determine titre. 
 
 
 
Transduction of PBMCs and Allodepleted T cells 
 
PBMCs were resuspended at a concentration of 1 x 106 /ml in CTL media (45% Click’s 
medium, Irvine Scientific, Santa Ana, CA, 45% RPMI 1640, Hyclone, Logan, UT and 10% 
FCS, Hyclone) in 24 well plates. IL-2 (R&D Systems 212-IL-010) was added on day 0 only at 
100 u/ml and incubated at 37ºC/5 % CO2 for 4 days. At 96 hours concentrated lentiviral 
supernatant (MOI 150, volume 7.5 µl- from soups which have given titre of >1010 viral 
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agents/ml) was added directly to 1ml of cell culture and the cells were subsequently analysed 
for transgene expression 96 hours later. 
 
For positive controls, PBMCs were transduced after polyclonal stimulation with agonistic anti 
CD3 (1µg/ml) (eBiosciences 16-0037) and agonistic anti CD28 monoclonal antibodies 
(1µg/ml) (caltag laboratories CD2800). They were resuspended in CTL media at a 
concentration of 1 x 106/ml in 24 well plates. On day 1, IL-2 was added at 50u/ml, and then on 
day 2 further IL-2 was added at 100u/ml and concentrated lentiviral supernatant was added at a 
multiplicity of infection (MOI) of 20. 
 
To transduce allodepleted PBMCs, Day 3 CD25/71 allodepleted donor T cells were 
resuspended in CTL media165 at a concentration of 106/ml supplemented with IL-2 100 u/ml (R 
&D systems) in 24 well plates. On day 7, the PBMCs were transduced using a multiplicity of 
infection (MOI) of 150 and were harvested on day 11. Expression of the CD19R transgene was 
determined flow cytometrically as described below. Mock transduced allodepleted cells were 
treated in the same way except no lentiviral soup was added on day 7. 
 
 
 
 
Flow cytometric Analysis of Transgene Expression 
  
A goat anti-human IgG Fc  Cytm5 antibody (Jackson ImmunoResearch, West Grove, PA) was 
used to detect cell surface expression of CD19chTCR. This antibody binds to the human IgG1 
CH2-CH3 hinge of the CD19R. 1.5 µg of antibody was added to 2 x 105 PBMCs for 30 
minutes at 4ºC followed by two washes before acquisition. For positive controls PBMCs 
polyclonally stimulated with agonistic anti CD3/28 antibodies were used, whilst allodepleted 
PBMCs which were mock transduced were used as negative controls. For FACS analysis, a 
CyAn flow cytometer (Dako, Fort Collins, CO) was used to acquire data and Summit v4.1 
software (Dako) to analyze data.  
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Functional Assays of Anti-Leukemic Responses 
Measurement of Granzyme B and IFNγ production 
 
MAHAS4510 plates (Millipore, Billerica, MA) were coated with anti–granzyme B capture 
antibody GB10 (Mabtech, Cincinnati, OH) or IFNγ capture antibody overnight (described 
above). They were then washed and blocked with RF10 medium for 2 hour at 37°C. Triplicate 
samples of αCD19ζ TCR transduced or mock transduced allodepleted donor T cells were co 
cultured with CD19+/- tumor cell lines (K562, K562 stably transduced with GFP or a CD19-
GFP transgene, Ramos), autologous/allogeneic LCLs or 1o ALL blasts at a responder: 
stimulator ratio of 1:1. After 18 hours granzyme B production or IFNγ was assessed in a 
granzyme B ELISPOT/IFNγ ELISPOT assay. Controls consisting of 1 x 105 responders or 
stimulators alone were also plated. Plates were cultured for 18-24 hours and then washed and 
incubated for 2 hours at room temperature with biotinylated–anti-granzyme B detection 
antibody GB11 (Mabtech) or IFNγ detection antibody. Avidin-peroxidase complex (Vector 
Laboratories, Burlingame, CA) was added for 1 hour at room temperature and spots developed 
with 3-amino-9-ethylcarbazole (AEC, Sigma) substrate mix. The plates were read and the 
number of specific spot forming cells was determined. 
 
Cytotoxicity assays 
Cytotoxic specificity was determined in a standard 51Cr release assay. 3 x 106 target cells were 
labelled with 100 µCi 51Cr (Amersham Pharmacia Biotech, Piscataway, NJ) for 2 h at 37°C. 
51Cr-labelled K562 cells (CD19 positive, negative and non transduced) and LCLs were plated 
at 5 × 103 cells per well, respectively, and cultured with transduced and non transduced 
PBMCs at different concentrations (effector to target ratios: 30:1, 5:1 and 1:1) in 96-well U-
bottom plates. One percent Triton X-100 (Sigma-Aldrich) was added to measure maximum 
release and target cells were incubated alone to assess spontaneous release. After 4 h of 
incubation at 37°C, plates were spun and 25 µl supernatant were harvested and transferred to 
96-well Wallac isoplates (Perkin-Elmer, Weiterstadt, Germany) and mixed with 150 µl 
OptiPhase Supermix Cocktail (Perkin-Elmer). Counts were measured on a MicroBeta TriLux 
(Perkin-Elmer) and the percent specific lysis was calculated as ([experimental release - 
spontaneous release] / [maximum release - spontaneous release]) × 100. 
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Flow Based Cytotoxicity assay 
 
An alternative cytotoxicity assay was based on assessment of cell viability using FACS. 
Normal donor PBMCs were transduced/mock transduced in media supplemented with OKT3 
(1µg/ml) anti CD28 (1µg/ml) and IL-2 (100U/ml) to serve as a positive control, or IL-2 
100u/ml only as described. Transduced/mock transduced PBMCs were co-cultured with an 
equal number of K562 GFP+CD19+ or K562GFP+CD19- cells. After a week, the number of 
viable GFP+ cells was determined by staining with 7AA-D. A fixed number of trucount beads 
(BD biosciences) was acquired to ensure that comparison could be made between the different 
co-cultures. The number of GFP+ viable (7AA-D negative) cells was then determined in each 
co-culture and the percentage cytotoxicity was determined by dividing the number of viable 
targets cells in the presence of transduced PBMCs by the number in the mock transduced 
control co-culture. 
 
Statistical Analysis 
A Wilcoxon matched pairs test was used to determine statistical differences between samples 
(GraphPad Software Version 5.0, San Diego, CA). Data pertaining to flow cytometry is 
expressed as mean ± SD, whilst ELISPOT and MLR data is expressed as median and range.  
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Chapter 3 
 
 
Functional Characterisation of Alloreactive T cells 
 
 101
 
Aims 
1. To characterize the activation marker and cytokine profile of proliferating alloreactive 
T-cells identified using CFSE dye dilution.  
 
2. To determine the phenotype of the CD25 negative proliferating alloreactive cells to 
provide a rational basis for enhancing allodepletion with CD25 based strategies  
 
Introduction 
 
Adoptive immunotherapy with allodepleted donor T-cells generated using CD25 IT 141 at a 
dose of 3 x 105/kg accelerated T-cell reconstitution and recovery of CMV and EBV-specific 
immunity after haplo-SCT. However, the rate of leukaemic relapse rate was high, resulting in 
an overall survival of only 5/16 patients. This may be explained by the high-risk nature of this 
patient group and the low precursor frequency of leukaemia-reactive T-cells within the infused 
allodepleted T-cells. Additionally, 2 patients died of adenovirus associated complications, 
including 1 who had persistent adenoviraemia despite 3 infusions of allodepleted donor T-cells 
at 105/kg, which cleared after a single infusion at 2.5 x 106/kg. Importantly, no patient had 
detectable T-cell responses to this virus before 9 months post-SCT. These data suggest that 
larger doses of allodepleted T-cells may be necessary to confer protective responses to 
pathogens which evoke low frequency T-cell responses in the donor and for a graft-versus-
leukaemia (GVL) effect. Our in vitro data indicates that significant residual alloreactivity 
persists after CD25 IT mediated allodepletion125. While the incidence of significant acute and 
chronic GVHD was low in the clinical study, this was nonetheless observed in 2 cases, raising 
concerns about the safety of administering larger doses of allodepleted donor T-cells in the 
haploidentical setting. Thus in order to develop this approach further, there is a pressing need 
to enhance the degree of depletion of alloreactive cells, to enable add back of sufficient T-cells 
for protective anti-leukemic and anti-infective responses without causing GVHD.  
 
Activated T-cells express a variety of surface markers, including CD25, CD69, CD71, CD95, 
CD137, CD147, OX40, ICOS, HLA-DR, and secrete Th1 cytokines IL-2 and IFN-γ. As such, a 
plethora of potential targets and methods now exist for allodepletion strategies59,114-118 but 
there is no data on the relative expression of these targets on alloreactive T-cells to enable 
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identification of the optimal targets for allodepletion. The data above suggest that a significant 
minority of alloreactive T-cells are retained after CD25-based allodepletion, suggesting that 
CD25 may be expressed only in a subset of alloreactive T-cells and raising the possibility that 
targeting other molecules, perhaps in combination with CD25, could enhance allodepletion. In 
order to rationally design strategies for enhanced allodepletion, we have functionally 
characterized the phenotype of alloreactive T-cells. While alloreactive T-cells have multiple 
phenotypes, proliferation in response to alloantigens is their most basic hallmark. We have 
identified proliferating alloreactive T-cells using CFSE dye dilution. Godfrey et al24 have 
shown that flow cytometric depletion of CFSE-dim T-cells almost completely abrogates in 
vitro alloreactivity in secondary MLRs and markedly reduces GVHD in an MHC Class II 
disparate murine model. While it is not practical to use this approach clinically, we have used 
this method to systematically characterise the expression of cytokines, effector molecules and 
activation markers on proliferating alloreactive T-cells, in particular those that are CD25 
negative.  
 
In this chapter we have characterised the phenotype of proliferating alloreactive T cells against 
a wide range of activation markers and intracellular cytokines. In particular we went onto 
examine the phenotype of proliferating CD25-ve  alloreactive T-cells. 
 
 
Optimisation of Intracellular Cytokine Staining 
 
To simultaneously analyse surface molecules and intracellular cytokines, samples were first 
stained for surface antigens, then fixed with 2% paraformaldehyde to stabilize the cell 
membrane. They were then washed twice in FACS buffer and permeabilized with 0.5 % 
saponin to allow anti-cytokine antibodies to stain intracellularly. PBMCs were then washed in 
saponin and were incubated with anti cytokine antibodies resuspended in a total of 50 µl of 
saponin. They were then incubated at 4ºC for 30 minutes and washed twice in saponin and 
resuspended in FACS buffer before acquisition. Optimisation of intracellular staining required 
careful dose titration of anti human IFNγ, TNFα and IL-2 antibodies. To determine this, 
human PBMCs were stimulated for 6 hours with PMA 0.1µg/ml (Sigma Aldrich), and 1µg/ml 
of ionomycin (Sigma Aldrich). Brefeldin (a golgi inhibitor which leads to an accumulation of 
intracellular cytokines, preventing their secretion) at 1µg/ml (BD biosciences) was also added 
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to culture. Optimal staining was achieved at the following concentrations of antibodies: IFNγ 
(B27 clone) at 0.2µg/106 PBMCs, TNFα (MAB11 clone) at 0.5 µg/106 PBMCs, and IL-2 
(5344.111 clone) at 0.02 µg/106 PBMCs. 
 
After optimizing the intracellular cytokine antibody dose titration, we then went onto compare 
golgi inhibitors, brefeldin and monensin to determine which one was superior for detecting 
intracellular TNFα, IL-2 and IFNγ. PBMCs were incubated with PMA/ionomycin for 6 hours, 
with brefeldin or monensin added at the beginning of culture. The percentage of CD3 positive 
cells staining for each cytokine was then determined. (See Table 2) 
 Brefeldin 1µg/ml Monensin 2µM 
CD3 IL-2 13.3 16.8 
CD3 TNFα 31.5 22.6 
CD3 IFNγ 15.6 14.7 
Table 2: Golgi inhibitor Brefeldin is superior to monensin in detecting intracellular TNFα 
in activated PBMCs. % of T cells expressing each cytokine is shown. n=3 (mean of the three values shown) 
 
As can be seen from table 2, brefeldin led to far more TNFα significantly improved detection 
of TNFα with little difference between IL-2 and IFNγ accumulation between the different 
golgi inhibitors.  Therefore for future experiments, brefeldin was used. 
 
Subsequently, the optimal duration of incubation of brefeldin was determined. PBMCs were 
stimulated with PMA/ionomycin and co-cultured with brefeldin for 4, 6, or 8 hours and the 
percentage of CD3+ T-cells staining for each cytokine and cell viability (by trypan staining) 
was determined. (See Table 3). 
 
 4 hours 6 hours 8 hours 
CD3 IL-2 4.3 12.5 20.5 
CD3 TNFα 10.2 30.8 38.9 
CD3 IFNγ 12.3 14.8 23.8 
Viability 96 % 94 % 91 % 
Table 3: 8 hour incubation with brefeldin maximized intracellular cytokine detection 
without compromising cell viability % of T cells expressing each cytokine is shown n=3 (values shown 
are mean) 
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As can be seen from Table 3, incubation for 8 hours leads to far more intracellular cytokine 
being detected, without the viability being affected. Increasing the time of incubation with 
brefeldin beyond 12 hours significantly affected the viability as did increasing the 
concentration above 1µg/ml. Thus, for future experiments an incubation time of 8 hours with 
brefeldin was chosen. 
 
 
Finally a comparison was made between the efficacy of different cell permeabilization agents, 
the commercial PD wash (BD biosciences, CA, USA) and saponin 0.5 % (PBS and 1 % calf 
serum and 0.5 % saponin, filtered through 0.22 µm filter). 
  
 
 
 
 
Figure 13: 0.5 % saponin led to superior detection of intracellular TNFα than with PD 
wash n=2 
 
PBMCs were stimulated with PMA/ionomycin for 8 hours with brefeldin, fixed with 2 % 
paraformaldehyde and then permeabilized with either PD wash or 0.5 % saponin and the 
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percentage of lymphocytes expressing TNFα, IL-2 and IFNγ was determined. As can be seen 
from Figure 12, 0.5 % saponin was superior to PD wash in detecting intracellular TNFα. 
Similar results were obtained for IL-2 and IFNγ. 
 
Thus in summary, in order to optimize our intracellular cytokine staining in alloreactive T- 
cells, we co-cultured PBMC with brefeldin 1µg/ml, for an incubation period of 8 hours and 
then after fixing, permeabilized the cells with 0.5 % saponin. 
 
 
Kinetics of expression of Activation Markers and Cytokines during Allo-
MLR 
We initially determined expression of surface and cytokine markers in immunomagnetically 
selected CD3+ lymphocytes cultured with HLA-mismatched mature DC over the course of a 7 
day allogeneic MLR flow cytometrically. As controls, unmanipulated PBMCs from the same 
donors were cultured under identical conditions. The mean purity of CD3+ selected cells was 
99.15 %. DCs showed the characteristic morphology and marker profile (mean % CD83- 97.35 
%). Co-cultures were sampled for flow cytometric analysis of the CD3+ T cells in the 
lymphocytes gate on days 0, 1, 3, 5,and 7 of co-culture. Figure 13 summarizes the cumulative 
data from 5 donor-recipient pairs on up regulation of these markers on donor T-cells with 
unstimulated controls subtracted. CD25 was up regulated within 24 hours of an allogeneic 
MLR, peaking on days 3 (mean 47 % of total T-cells) and then plateaued. CD71 showed 
similar kinetics, peaking on day 3 (mean 39.3 % of total T-cells). This high level of expression 
was consistent cross all 5 donor-recipient pairs. There was little expression of CD25 or CD71 
in the unstimulated T-cells (mean 1.4% and 2.6 % respectively on day 3). CD69 showed rapid 
up regulation on day 1 (mean 19 % of T-cells) but expression subsequently declined. HLA-
DR, ICOS, and CD95 all showed similar patterns of expression, progressively increasing their 
expression with time during culture and peaking on day 7, but were all expressed on lower 
proportions of total T-cells. There was a strong up regulation of the Th1 cytokines IL-2 and 
IFN-γ, with over 20 % of total T-cells secreting these cytokines by day 3-5 of co-culture. In 
contrast, TNFα secretion was only weakly up regulated throughout the period of co-culture. 
 
 
 
 106
0
10
20
30
40
50
60
70
CD25 HLA-DR CD71 CD69 ICOS OX40 CD95 IL-2 IFNγ TNFα
%
 T
 c
el
ls
D0
D1
D3
D5
D7
 
                             
  
Figure 14: Kinetics of Surface Markers and Cytokine Expression in alloreactive T- cells. 
(n=5) FACS analysis of expression of surface markers and intracellular cytokines in CFSE labelled T cells co-
cultured with HLA- mismatched DCs. Results are mean + SD. Unstimulated control data has been subtracted 
from the stimulated data. As CCR7 and CD45RA showed high expression in unstimulated PBMCs they are not 
shown  
 
As outlined above a key hallmark of an alloreactive T-cell is its ability to proliferate in 
response to alloantigen. In order to identify these alloreactive T-cells we labelled donor T-cells 
with CFSE and then co-cultured them with or without HLA mismatched dendritic cells. We 
then quantified the CFSE Dim (the alloreactive proliferating T-cell) population on days 0,1,3,5 
and 7 allowing us to determine the precursor frequency and the kinetics of alloreactive T-cell 
proliferation in a MLR.  
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Figure 15: Kinetics of CFSE Florescence in Allogeneic MLR and Unmanipulated T-
cells.(n=5)  FACS analysis of a representative example of the kinetics of CFSE fluorescence in the allogeneic 
MLR after CFSE labelled T-cells were cultured with/without HLA-mismatched DCs. Proliferation of alloreactive 
T-cells results in reduction in CFSE fluorescence intensity. Gating on the CFSE dim region, which selectively 
identifies the proliferating T cell population is shown on the day 7 FACS plots.  
 
Identification of Proliferating Alloreactive T-cells using CFSE Dye Dilution 
 
In order to characterize the phenotype of proliferating alloreactive T cells population we 
labelled donor T-cells with CFSE and then co-cultured them with or without HLA-mismatched 
DC. Gating on the CFSE-dim population enabled us to track the proliferating alloreactive T-
cell population. We initially quantified the CFSE-dim population on days 0,1,3,5 and 7. Figure 
14 shows the progressive dilution of CFSE fluorescence with time in an allogeneic MLR. By 
day 7 of the MLR culture, 70 % of the T-cells in the culture were CFSE-dim. The mean 
alloreactive precursor frequency (calculated using ModFit LT software (Verity software 
House) was 4.2 % ± 1.5 % and there was a mean of 8 cell divisions. In contrast, there was very 
little shift in fluorescence in the unmanipulated PBMCs. Figure 14 shows our gating strategy 
for identifying CFSE-dim cells, taking into account the shift in CFSE fluorescence of 
unmanipulated PBMC with time. To validate this gating strategy, we compared CFSE dye 
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dilution in CFSE-labelled unstimulated PBMCs and PBMCs co-cultured with autologous DC 
in 5 normal donors. (See Fig 15)  As previously reported166,167, T-cells cultured with 
autologous DC showed minimal proliferation (mean 1.3 % ±  1.19 % of CFSE-dim T-cells, at 
day 7 of co-culture) and little up regulation of CD25 or CD71. We are thus confident that the 
CFSE-dim population truly represents proliferating alloreactive T-cells.  
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Figure 16: T-cells cultured with autologous DC showed minimal proliferation and little up 
regulation of CD25 or CD71. Activation marker Expression and Kinetics of CFSE Fluorescence in T cells 
co cultured with Autologous Dendritic Cells.(a) CFSE Fluorescence (b) CD25 expression (c) CD71 expression. 
Data is the mean ± SD of cultures from 4 donors 
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As shown in Fig 16, which illustrates the % of CFSE-dim T-cells in the MLR, proliferation 
was greatest between Days1-3 of culture, and then plateaued between days 5-7.  
This suggests that strategies targeting proliferating alloreactive T cells e.g. chemotherapy 
agents would be most successful between days 1-3 of the MLR. 
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Figure 17: Time course of Proliferation in Allogeneic MLR. (n=5) FACS analysis demonstrating 
the percentage of T cells which are CFSE dim proliferating alloreactive T cells in the MLR, serially assessed over 
a week. Results are the mean + SD .The percentage of CFSE dim populations in the unstimulated control has 
been subtracted from the results obtained in the MLR. 
 
Phenotypic Characterization of Proliferating Alloreactive T-cells 
 
To determine the phenotype of alloreactive T-cells, we then analyzed surface marker and 
cytokine expression in the proliferating alloreactive T cell population by gating on the CFSE-
dim population on days 3, 5, and 7 of the MLR. The cumulative data for 5 HLA- mismatched 
pairs is shown in Fig 17. 
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Figure 18: Kinetics of Surface Marker and Cytokine Expression in Proliferating 
Alloreactive T cells. (n=5) Normal donor PBMCs were co-cultured with HLA-mismatched DCs and the 
expression of surface markers and intracellular cytokines in the proliferating alloreactive T-cell population was 
determined by gating on the CFSE dim population using FACS analysis. Data shown is mean + SD. 
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CD25  
 
 
  
Figure 19: Up regulation of CD25 is seen in the CFSE-dim T cells but a Significant CFSE 
Dim CD25 negative population is discernible.   Data is representative of CD25 expression in all 5 
experiments 
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Figure 20: Mean Fluorescence Intensity of CD25 Expression on the Proliferating 
Alloreactive T cells peaks on day 3. Data is mean ± SD of 5 donor recipient pairs.  
 
As seen in Fig 18, CD25 (IL-2 receptor α) shows little expression in resting PBMCs. However, 
in PBMCs co cultured with HLA mismatched DCs, it is up regulated within 24 hours, peaks on 
days 3 and then plateaus. Thus CD25 is strongly and consistently expressed on the 
proliferating alloreactive T-cells. In 5 donor recipient pairs a mean of 83 % ± 8 % of the 
proliferating T-cells express CD25 on day 3 (Fig 17). The mean fluorescence intensity of 
CD25 peaks on day 3 (see Fig 19) thus confirming that the optimal time for CD25 
allodepletion is on days 3 of a MLR. This data validates the strategy of using a day 3 CD25 
allodepletion. However, as can be seen in the representative donor shown in Figure 18, a 
significant population of CFSE dim T-cells do not express CD25 .Therefore CD25 based 
negative selection strategies alone will not deplete a significant proportion (mean 17 % on day 
3 see Fig 17) of proliferating alloreactive cells.  
 
 
 
 
 
 
Time of MLR 
←Coculture 
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CD71  
 
CD71 (transferrin receptor) expression had similar kinetics to CD25, being unregulated on the 
majority of proliferating T-cells by day 3 of MLR (mean 65 ± 23 % of the CFSE-dim T-cells), 
with some subsequent down regulation at later time points and somewhat more variability than 
CD25 (see Fig 17). 
 
 
Figure 21: CD71 is strongly up regulated on proliferating alloreactive T cells but shows 
little expression on resting T cells. CD71 is up regulated on day1 and peaks on day 3 of the MLR. Data is 
representative of CD71 expression in all 5 experiments 
 
There is very little expression of CD71 in the unstimulated T-cells, and thus allodepletion 
strategies targeting CD71 should preserve desirable antiviral and anti-leukaemic responses. 
(See Fig 20). Analysis of the mean fluorescence intensity of CD71 expression demonstrated 
this to be highest on day 3 of co-culture (Figure 21) 
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Figure 22: Mean Fluorescence Intensity of CD71 Expression on Proliferating Alloreactive 
T cells is highest on day 3. Data is mean ± SD for 5 donor recipient pairs 
 
These data identify CD71 as a promising novel target antigen for depleting alloreactive T-cells 
and demonstrate that the optimal time point for CD71 allodepletion is on day 3 of a MLR. (See 
Figs 17 & 21) 
 
 
 
 
 
 
 
 
 
Time of MLR 
←Coculture 
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CD69  
 
                         
Figure 23: CD69 is the strongly up regulated on day 1 in the allogeneic MLR, but then 
rapidly declines. Data is one of a representative sample 
 
As shown in Figure 17, the other activation markers analyzed were only expressed on a 
minority of proliferating CFSE-dim T-cells.  CD69 was expressed on only 4 ± 5 % of CFSE-
dim cells at day 3 of MLR. As a CFSE-dim population was only discernible from day 3 
onwards (Fig 16), it was not possible to determine if the higher expression of CD69 on total T-
cells at day 1 of the MLR (Fig 13) represents a truly alloreactive population.  
 
As shown in the representative FACS plot in Fig 22, CD69 is the earliest marker to be up 
regulated, in an allogeneic MLR demonstrating significant up regulation by day 1. Up to 20 % 
of CD3+ve lymphocytes express this marker in the alloreactive MLR, with little or no 
expression in unstimulated control co-cultures.  However, expression of CD69 decreases 
progressively with time of co-culture. In this regard, it is of note that groups who have used 
CD69 based strategies to deplete alloreactive T-cell on day 3 which may not be the optimal 
time point. As illustrated in Fig 17, the majority of the CFSE dim population do not express 
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CD69. This is likely to reflect down regulation of CD69 by the time appreciable CFSE dye 
dilution occurs, so that it is difficult to use the latter to identify alloreactive cells expressing 
CD69. Furthermore, compared to molecules such as CD25 and CD71, CD69 expression during 
allo MLR showed significantly more variability (Fig 17) limiting the usefulness of this marker 
as a target for allodepletion strategies. In this regard, it is of note that  groups who have used 
CD69 to deplete alloreactive T cells have done so on day 3.126 
 
Activation Markers 
 
Inducible co stimulator (ICOS) was not expressed on unstimulated T-cells and was 
progressively up regulated over time in the allo-MLR, but only on a minority of proliferating 
alloreactive T cells (mean 15 ± 12 % at day 7) (see Figs 17) at day 7 with significant 
variability. Fas (CD95) was expressed on a higher proportion of unstimulated T cells. Like 
ICOS, CD95 showed a progressive but more variable increase over time in the allo-MLR with  
expression on proliferating alloreactive T cells peaking on day 7 (a mean of 27 ± 24 % at day 7 
Fig 17). This is consistent with groups targeting Fas +ve alloreactive T-cells, who have shown 
that optimal timing for Fas mediated allodepletion is between days 5-7 of an allo- MLR. 66 
However, the significant variability between donor recipient pairs, limits the usefulness of 
targeting this marker. 
 
CD134 (OX40) was not expressed on unstimulated control, but showed little up regulation on 
the alloreactive T-cells, with maximal expression on day 7 of the allo-MLR (1.64±1.42 % Fig 
17). Our data indicates that targeting OX40 would not be a successful allodepletion strategy. 
HLA-DR showed low levels of baseline expression in the unstimulated control but was only 
expressed in small subpopulations of proliferating alloreactive T-cells (mean 8% ±5.87of 
CFSE-dim T-cells at day 7, Fig 17). Unlike ICOS and CD95, HLA-DR expression did not 
show any significant increase in expression with time during the MLR. 
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Memory Markers (CD45RA and CCR7) 
 
In light of the recent murine data suggesting that alloreactive T-cells recognising minor 
histocompatibility antigens28,29 in murine models, reside predominantly in the naïve T cell 
compartment, we next examined expression of the CD45RA isoform and the chemokine 
receptor (CCR7) on proliferating alloreactive T-cells. We observed strong expression of CCR7 
(mean 54 ± 20 % on day 3) and CD45RA (mean 25.9 % on day 3) in the CFSE-dim population 
(Fig 17), but there was also high expression on the unstimulated PBMCs at the same time-
points (CCR7 mean of 52.7 % and CD45RA 12.3% of total T-cells on day 3) (see Fig 23 for 
representative example). The intensity of expression of CD45RA was greatest on day 3 (Fig 
24) suggesting this would be the optimal time point for allodepletion. As time progressed, the 
percentage of CFSE-dim T-cells expressing CCR7 and CD45RA declined, consistent with a 
progressive increase in T-cells of effector memory phenotype (mean 62 ± 8% by day 7 of co-
culture).   
(a) CD45 RA  
 
 
. 
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(b) CCR7 
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Figure 24: (a) CD45 RA Expression shows significant expression on resting lymphocytes 
and progressively decreases during the time course of the MLR co culture. (b) Significant 
Expression of CCR7 on resting lymphocytes limits its usefulness as an Allodepletion 
Target. Data is from a representative sample 
 
While CCR-7 is expressed on approximately half of proliferating, alloreactive T-cells, 
CD45RA is only expressed on a minority of such cells, limiting its usefulness as a target of 
allodepletion. Further, as shown in Fig 23, these markers are expressed in a significant 
proportion of unstimulated PBMCs, and thus allodepletion approaches targeting CD45RA or 
CCR7 would lead to a large cell loss and could adversely affect desirable third party responses, 
anti-viral and anti leukaemic responses. 
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Figure 25: Mean Fluorescence Intensity of CD45RA Expression on Proliferating 
Alloreactive T cells peaks on day 3 Data is mean ± SD in 5 donor recipient pairs. 
 
The intensity of expression in proliferating alloreactive T cells of CD45RA is greatest on day 
3, (Fig 24) suggesting that this would be the optimal time point for an allodepletion.  
Intracellular Cytokines 
 
The presentation of alloantigen induces a response involving proliferation of donor T cells and 
secretion of interleukin-2 (IL-2) and interferon γ (IFNγ) leading to the generation of T 
cytotoxic clones. The central importance of IL-2 signalling in GVHD is illustrated by the use 
of ciclosporin and FK506, in GVHD prophylaxis, which inhibit IL-2 production. The 
presumed contribution of tumor necrosis factor-alpha (TNFalpha) to acute GVHD provides  
the rationale for the use of anti-TNFalpha antibodies (e.g. infliximab) in the treatment of 
GVHD43. We therefore next determined Th1 cytokine expression on proliferating CFSE-dim T-
cells using intracellular cytokine staining. As shown in Figure 17 & 25, there was little 
baseline expression of IL-2 in the unstimulated control T-cells, whereas IL-2 was up regulated 
in the alloreactive T cells in the allo- MLR.  IL-2 expression peaked on day 3 of co-culture 
(mean 34 ± 6% of CFSE-dim T-cells), and progressively decreased thereafter.  
 
Time of MLR 
←Coculture 
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IL-2 
 
 
Figure 26: IL-2 is expressed in a minority of proliferating alloreactive T-cells Data is from a 
representative sample 
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IFNγ 
 
 
 
 
Figure 27: IFNγ is expressed on a minority of proliferating alloreactive T-cells. Data is from a 
representative sample. 
 
IFN-γ was expressed in a similar proportion of the CFSE-dim population as IL-2. Expression 
of IFN-γ peaked on day 5 (mean 33 ± 13 %) and then decreased slightly by day 7 (Fig 17 & 
26). Thus around a third of proliferating alloreactive T-cells express the Th1 cytokines.  
TNFα 
 
In contrast to IL-2 and IFNγ, we observed little up regulation of TNFα in alloreactive T-cells 
at any time point during co-culture (mean 1 % on day 7 Fig 17). Thus any strategy targeting 
TNFα producing T-cells as a single step allodepletion procedure would be unlikely to be 
successful. 
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Overall, the majority of phenotypic markers analysed appear to be expressed only in small 
subpopulations of alloreactive T-cells, limiting their usefulness as potential targets for 
allodepletion strategies. Only CD25 and CD71 were expressed in the majority of T-cells 
proliferating in response to alloantigens. These data provides strong support for targeting 
CD25 in allodepletion strategies, and identify CD71 as a promising novel target for similar 
approaches. 
 
 
Characterization of CD25-negative alloreactive T-cells 
 
While the majority of proliferating alloreactive T-cells express CD25, a significant population 
(17 ± 8 % at day 3 of co-culture, Figure 17) does not and would be retained by strategies 
targeting this molecule alone. We therefore gated on the CFSE- dim, CD25-ve T-cell 
population in order to determine phenotypic markers that could be used to target this CD25- 
population. Data on the expression of surface markers and cytokines by this population are 
shown in Figure 27. Our studies identified CD71 and CD45RA as the markers expressed on 
the majority of CD25-ve proliferating alloreactive T- cells (mean 69 ± 21 % and 62 ± 12 % 
respectively at day 3 of MLR). In 5 donor-recipient pairs, a mean of 94%/93% of proliferating 
alloreactive T-cells could potentially be deleted by effective depletion of cells expressing 
either CD71/CD25 or CD45RA/CD25 (Table 4). Other surface markers including CD69, 
ICOS, OX40, CD95, HLA-DR, CCR7, and the cytokines IL-2, IFN-γ, and TNFα were only 
expressed on a minority of cells in this population and thus would be of limited value in 
enhancing the depletion of alloreactive T-cells achieved with CD25-based approaches. 
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Figure 28: CD71 and CD45RA are highly Expressed in Proliferating CD25 negative 
Alloreactive T-cells. (n=5) CFSE labelled T-cells were co-cultured with HLA mismatched DCs and the 
kinetics of expression of surface markers and intracellular cytokines in the proliferating alloreactive CD25- 
population determined flow cytometrically by gating on the CFSE dim CD25- cells. Results are mean+ SD. 
 
Table 4: Percentage of proliferating alloreactive T-cells expressing markers 
 % of Proliferating Alloreactive T Cells 
Expressing Marker 
CD25 83 % 
CD25+ CD71 94 % 
CD25+ CD45RA 93 % 
 
Percentage of proliferating  alloreactive T expressing CD25 alone, CD25 and CD71, and 
CD25 and CD45RA on day 3 of the MLR was determined by FACS analysis of CFSE Dim 
CD3 positive cells. N=5 
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Conclusions 
 
We systematically characterized the activation and cytokine marker profile in proliferating 
alloreactive T-cells. While alloreactive T-cells can be identified by a number of phenotypes, 
we focused on proliferation in response to alloantigen as the most fundamental. Further, given 
the numbers of allodepleted T-cells infused in the clinical setting, alloreactive T-cells would 
need to proliferate in order to cause clinical sequelae. We co-cultured CFSE labelled T-cells 
with HLA- mismatched DCs, and tracked proliferating alloreactive T-cells by gating on the 
CFSE dim T-cell population. In our model, there was a mean of 8 cell divisions with up to 70 
% of day 7 PBMCs becoming CFSE dim, with a precursor frequency to alloantigen of 4 %. 
Our data showed that CD25 was expressed in over 80 % and CD71 in 65 % of proliferating 
alloreactive T-cells on day 3 of MLR. In contrast, CD69, CD45RA, ICOS, OX40, CD95, 
HLA-DR, IL-2, IFN-γ, and TNF α were all expressed only in a minority of proliferating 
alloreactive T-cells, indicating that these are poor targets for allodepletion. CD69 is a well-
established T-cell activation marker but was poorly expressed in the CFSE-dim population. 
This may in part reflect down regulation of CD69 by the time appreciable CFSE dye dilution 
has occurred (day 3 of MLR). Recent studies suggest that alloreactivity may reside 
predominantly in the CD45RA+ naïve T-cell compartment.29,33 However, the expression of this 
marker only on a minority of alloreactive T-cells and on bystander T-cells as well as the 
progressive maturation of alloreactive T-cells to a memory phenotype during MLR suggest 
that targeting this molecule as a sole strategy for allodepletion is unlikely to be successful. 
 
In contrast, our data provide strong support for targeting CD25 in allodepletion strategies and 
identify CD71 as a novel target that is highly expressed on proliferating alloreactive T-cells. 
While our data confirm CD25 as an excellent target for allodepletion strategies, a mean of 17 
% of proliferating alloreactive T-cells do not express CD25.  Therefore, we studied the 
phenotype of proliferating CFSE-dim T-cells not expressing CD25. We have identified CD71 
and CD45RA as the markers most highly expressed on proliferating alloreactive T-cells that 
do not express CD25. CD71 (transferrin receptor) is essential for iron transport into 
proliferating T-cells but is not expressed on resting lymphocytes, whereas CD45RA was 
expressed on a higher percentage of unstimulated T cells, and hence has a lower specificity for 
the alloreactive T-cell population. We found that 70 % of the CFSE-dim CD25-ve population 
express CD71 and 62 % expressed CD45 RA. Potentially, this enables us to target 2 
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independent phenotypes of alloreactive T-cells at the same time-point within a single co-
culture. We showed that the combination of CD25/CD71 and CD25/45RA is expressed in 94 
% and 93 % respectively on proliferating alloreactive T-cells. Based on these data we then 
went on to compare CD25 based allodepletion strategies with CD25/71 allodepletion, to 
determine if depletion of CD71+ve T-cells would enhance the reduction of alloreactivity seen 
with CD25 based allodepletion. 
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Chapter 4 
 
 
Enhancing CD25 based allodepletion strategies 
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Aims 
1. To compare residual alloreactivity to host and 3rd party after CD25 based allodepletion 
with CD25/71 combined allodepletion 
 
2. To compare residual alloreactivity to host and 3rd party after CD25/45RA  based 
allodepletion with CD25/71 combined allodepletion  
 
3. To develop a clinically applicable system for CD25/71 allodepletion under GMP 
conditions 
 
Introduction 
 
Adoptive immunotherapy with allodepleted donor T-cells generated using CD25 IT has been 
shown to enhance T-cell and anti-viral immune reconstitution in the haploidentical setting. 
138,141 However, this and other studies have demonstrated the need to enhance allodepletion 
beyond CD25 based existing strategies as leukaemic relapse and infections with pathogens 
evoking low frequency T-cell responses, such as adenovirus remain problematic. 141 Higher 
doses of allodepleted donor T-cells need to be infused to enhance anti-viral and anti-leukaemic 
effects but this would require enhancement of CD25-based allodepletion if GVHD is to be 
avoided. Our data from Chapter 3 validate the use of CD25 as an excellent target for 
allodepletion and identified CD71 and CD45RA as the optimal markers to target CD25 
negative proliferative alloreactive T-cells. These data suggest that a combined CD25/71 
allodepletion might enhance allodepletion compared to existing CD25-based strategies. In this 
chapter we examined residual alloreactivity between combined CD25/71 immunomagnetic 
allodepletion against CD25 allodepletion. 
 
 
Optimization of allodepletion 
 
Prior to comparison of CD25 vs. combined CD25/71 allodepletion we initially optimised 
conditions for CD25-based depletion and measurement of residual alloreactivity.  
Comparison of Dendritic cells, LCLs and PBMCs as APCs 
 
In order to determine the optimum APC, in 4 donor recipient pairs, PBMCs were co-cultured 
with either HLA mismatched mature DCs, LCLs or cytokine pre-treated PBMCs The APCs 
were from the same donor for each experiment. The PBMCs were pre-treated with 
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recombinant human TNFα and IFNγ at 1000 iu/106 PBMCs in order to up regulate HLA class 
I and II expression and hence optimize presentation of alloantigen. Normal donor PBMCs 
were thus co-cultured with irradiated APCs [DC(R: S 10.1), LCLs(R: S 40.1) or cytokine 
treated PBMCs (R.S 1.1) from the same recipient]. As can be seen in table 5, flow cytometric 
analysis showed stronger up regulation of CD25 and CD71 in T cells co-cultured with 
allogeneic DCs or LCLs compared with cytokine treated PBMCs from the same donor. Similar 
results were obtained for the MFI of CD25 and CD71 (Table 6). In view of these results and 
our previous data showing that using LCLs rather than PBMCs as stimulators resulted in more 
consistent depletion of alloreactivity, LCLs were used as stimulators in subsequent 
experiments. 
 
 CD3 CD25 CD3 CD71 
Unmanipulated  2.44 ± 0.01 1.47 ± 0.24 
BC +PBMCs 7.13± 2.32 1.91±1.22 
BC + DCs 9.26± 4.72 5.71±4.37 
BC + LCLs 10.9± 5.54 4.24±3.43 
 
Table 5: Increased up regulation of CD25 and CD71 in co cultures with allogeneic DCs 
and LCLs compared with PBMCs. Normal Donor PBMCs were co cultured with irradiated 
HLA mismatched PBMCs or LCLs or Dendritic cells. FACS for % CD3+ CD25+ and CD3+ 
CD71+ population was performed on day 3 co cultures and unmanipulated control (N=4) 
Mean % ± 1SD 
 
 
 
 CD3 CD25 CD3 CD71 
Unmanipulated  39.23±0.99 65.30±5.9 
BC +PBMCs 104.12±8.97 139.04±40.5 
BC + DCs 216.64±99.53 175.87±36.29 
BC + LCLs 143.70±28.79 148.2±54.48 
Table 6: Increased MFI of CD25 and CD71 in co cultures with allogeneic DCs and LCLs 
Compared with PBMCs Normal Donor PBMCs were co cultured with irradiated HLA 
mismatched PBMCs or LCLs or Dendritic cells. FACS for MFI in the CD3+ CD25+  and 
CD3+ CD71+ populations was performed on day3 co cultures and unmanipulated control 
(N=4) Mean MFI± SD 
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Optimization of CD25 immunotoxin dose 
 
To determine the optimum dose of our existing CD25 immunotoxin (RFT5-SMFT-dgA) for 
depletion of CD25+ alloreactive T-cells, donor PBMCs were co cultured with HLA- 
mismatched LCLs and then on day 3 the co cultures were exposed to varying concentration of 
CD25 immunotoxin (0 µg/ml, 3µg/ml, 3.5µg/ml, 4µg/ml, 4.5µg/ml, and 5 µg/ml). Co-cultures 
in the presence and absence of immunotoxin were incubated overnight at 37°C. The next 
morning co-cultures were washed twice and then resuspended at 2 x 106/mL in AIM V. 
Aliquots from the different co cultures were then analysed by Trypan blue staining for viability 
and FACS for the residual CD3+CD25+ (see Table 7) .  
 
 
 CD3+ CD25 + Viability 
0 µg/ml 10.25 83.25  
3 µg/ml 1.34 81.25 
3.5 µg/ml 1.1  80.27 
4 µg/ml 0.63  77.32 
4.5 µg/ml 0.59 61.2 
5.0 µg/ml 0.54  52.3 
Table 7: Progressive increase in CD25 depletion with increasing concentrations of CD25 
IT, but at cost of decreased viability. (n=1) Normal donor PBMCs were co cultured with HLA 
mismatched LCLs and a day 3 CD25 depletion was done with varying concentrations of CD25 immunotoxin. The 
residual CD3+CD25 + T cells were assessed by flow cytometry on day 4 and viability by trypan staining. 
 
As can be seen in Table 7, progressive increases in CD25IT dose led to an increased depletion 
of CD3+ CD25 + T cells, but at a cost of decreasing cell viability. A dose of 4 µg/ml was 
chosen, as this led to an acceptable level of CD25+ depletion with reasonable preservation of 
cell viability. 
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Conditions for Resting Allodepleted cells prior to restimulation 
 
Our group has previously shown that proliferative and cytokine responses to cytokine 
stimulation with host APCs are highly dependent on the timing of 2º stimulation in relation to 
allodepletion with negligible responses if restimulation was done immediately after 
depletion.125 In order to skew our assays to optimize our assays detection of residual anti host 
responses, we rested cell for 2 days prior to restimulation. We next went on to compare the 
media in which allodepleted donors T cells should be rested in. Donor PBMCs were co- 
cultured with HLA mismatched LCLs and a day 3 CD25 immunomagnetic allodepletion was 
done. The allodepleted T-cells were then rested in AIM V (serum free) medium with or 
without IL-2 (100 U/ml). On day 5 the allodepleted T cells were then harvested and then 
restimulated with host or 3rd party LCLs in a 2º IFNγ ELISPOT assay. 
 
 Host LCLs 3rd Party LCLs 
AIM V 21.1 61.3 
AIMV +IL-2 108.4 162.3 
Table 8: Residual alloreactivity to host is enhanced when allodepleted donor T cells are 
rested in media supplemented with IL-2. Donor PBMCs were co cultured with HLA mismatched 
LCLs and a day 3 CD25 immunomagnetic allodepletion was done. The allodepleted T cells were then rested in 
AIMV with or without IL-2. Day 5 allodepleted donor T cells were then co cultured with host/3rd party LCLs in 
2º IFNγ ELISPOT assay. Results show the percentage of spot forming cells compared to the response to 
unmanipulated PBMCs from the same donor. n=1 
 
The residual IFNγ response to host was over 5 xs higher when the cells were rested in media 
supplemented with IL-2. (Table 8) This would imply that the IL-2 promotes the proliferation 
of alloreactive donor T cells that were not deleted by the allodepletion, and therefore lead to a 
higher residual alloreactivity. Therefore, for future experiments, the allodepleted donor T-cells 
were rested in AIM V media without IL-2. 
Assaying Residual Alloreactivity 
 
We next compared LCLs vs. PBMCs as secondary stimulators in MLRs and IFNγ ELISPOTS. 
Donor PBMCs were co-cultured with HLA- mismatched LCLs and a CD25 or CD25/71 
immunomagnetic allodepletion was done on day 3. The allodepleted donor T-cells were rested 
for 2 days in AIM V media and then co cultured with host LCLs/PBMCs or 3rd party 
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LCLs/PBMCs in a 2º MLR. Results from allodepleted T-cells were compared with thawed 
unmanipulated PBMC from the same donor after stimulation with LCLs from the original 
stimulator or a 3rd party. To compensate for the variability in absolute counts, due to the degree 
of mismatch, results were standardized by calculating the residual proliferation as below:  
 
cpm (donor PBMC+ Host LCL + Allodepletion)- cpm (donor PBMC + Allodepletion) 
cpm(donor PBMC alone +LCL; no allodepletion) – cpm (donor PBMCs alone; no 
allodepletion) 
 
 Host LCLs 3rd Party LCLs Host PBMCs 3rd party LCLs 
CD25 0 71.1 0 68.5 
CD25/71 0 78 1.25 84.6 
Table 9: Mean residual alloreactivity to host and third party is not significantly affected by 
using LCLs or PBMCs as 2 º stimulators. Donor PBMCs were co-cultured with HLA mismatched 
LCLs and a CD25 or CD25/71 immunomagnetic allodepletion was preformed. The rested cells were then 
restimulated to host or Third party LCLs/PBMCs in a 2º MLR. n=2 
 
There was no significant difference in residual alloreactivity to host or 3rd party when either 
LCLs or PBMCs were used as stimulators in 2º MLRs (see Table 9). In IFNγ ELISPOT 
assays, the response of unmanipulated PBMCs to primary stimulation with allo LCLs was 
much greater than with allo PBMCs, so again LCLs were used as secondary stimulators in 
order to facilitate comparison between allodepleted and unmanipulated PBMCs (data not 
shown). 
 
 
Comparison of CD25 Immunomagnetic Beads and CD25 
Immunotoxin 
 
To determine an optimum baseline allodepletion method, we first compared residual 
alloreactivity following allodepletion using CD25 immunomagnetic beads or IT in 6 donor-
recipient pairs. In these and subsequent experiments, LCL were used as stimulators. Normal 
donor PBMCs were co-cultured with HLA-mismatched LCLs and at day 3 of MLR, cultures 
were split into 2 arms and allodepletion performed using anti-CD25 beads or IT as described 
in Methods. FACS analysis confirmed very effective depletion of CD25+ cells with both 
methods (mean CD3+CD25+ 0.19 ± 0.17% after bead depletion, 0.97 ± 0.38% after IT p=NS). 
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Aliquots were sampled for the primary MLR to determine the median residual response to host 
calculated using the formula below. 
  
Aliquots of the 1o MLR co-cultures were sampled to determine residual proliferative 
responses. To compensate for the variability in absolute counts due to the degree of mismatch, 
results were standardized by calculating the residual proliferation as below:  
cpm (donor PBMC+ Host LCL + Allodepletion)- cpm (donor PBMC + Allodepletion) 
cpm(donor PBMC alone +LCL; no allodepletion) – cpm (donor PBMCs alone; no 
allodepletion) 
 
As shown in Figure 28a, in primary MLR residual proliferative responses to host were 
undetectable using either anti-CD25 bead or IT (median residual proliferation 0 ± 0 % for 
both). This reduction in proliferation compared to unmanipulated PBMCs was significant for 
both methods (p<0.05). However, our previous data125 indicated that this assay may 
significantly underestimate residual alloreactivity. To skew our experimental system to detect 
such responses, allodepleted cell fractions were rested for 2 days and restimulated with LCLs 
from either the original stimulator or a 3rd party and residual responses assessed using IFNγ 
ELISPOT or 2° proliferation assays. To compensate for variability in responses between 
donor-recipient pairs, results from allodepleted T-cells were compared with thawed 
unmanipulated PBMC from the same donor after stimulation with LCLs from the original 
stimulator or a 3rd party. 
 
In IFN-γ ELISPOT assays (Fig 28b), the median residual number of specific spot forming cells 
(SFC) after stimulation with host LCL was 38.3 % (range 17.6 – 110.7%) of the response of 
unmanipulated PBMC after anti-CD25 bead and 54.5 % (range 11.7 – 159.3%) after CD25 IT 
allodepletion ( comparison between beads and IT p=NS). Third party responses were 
equivalent to unmanipulated PBMCs for both forms of allodepletion. There was no significant 
difference in the residual response to host following CD25 bead and IT allodepletion in these 
assays. In the 2º MLR (Fig 28c), the median proliferation to host stimulators was 27.8 % 
(range 0.05 – 91.5%) of the response of unmanipulated PBMC from the same donor after 
CD25 bead allodepletion, whilst for CD25 IT it was 16.5 % (range 0.03% - 62.2%) 
(comparison between beads and IT p=NS). Both depletion methods significantly reduced 
proliferation to host compared to unmanipulated PBMC s (p<0.05) but again there was no 
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significant difference in residual proliferative responses to host between CD25 beads and 
CD25 immunotoxin. Third party responses were equivalent to unmanipulated PBMC for both 
forms of depletion.  
 
Since there was no significant difference in residual alloreactivity to the original host between 
the CD25-based methods, we used anti-CD25 immunomagnetic bead depletion in further 
experiments to minimise cell manipulation in combined depletion methods. 
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Figure 29:( a) Comparison of Residual Alloreactivity after CD25 Beads vs. CD25 
Immunotoxin allodepletion in Primary MLR. Residual proliferation to host stimulators in 6 donor-
recipient pairs after allodepletion with anti-CD25 beads or immunotoxin following stimulation of donor PBMCs 
with LCLs (R/S 40:1) Residual proliferation was calculated using the formula on page 142 and was significantly 
reduced for both forms of CD25 allodepletion compared to unmanipulated PBMCs (p<0.05) Line = median, box 
=25th-75th centile, error bars = min, max values.  
 (b) Comparison of Residual Alloreactivity after CD25 bead vs. CD25 Immunotoxin 
Allodepletion in IFNγ ELISPOT n=6 This figure shows the frequency of cells secreting IFN-  in 
response to stimulation with original/3rd party LCL in ELISPOT assays. The responses of allodepleted PBMCs 
generated using CD25 beads or immunotoxin were compared. There was no significant difference in residual 
response to host between both forms of CD25 allodepletion. 
 (c) Comparison of Residual Alloreactivity between CD25 beads and CD25 immunotoxin 
in 2º MLR  n=6 Allodepleted PBMCs generated using CD25 beads or immunotoxin were rested and then 
stimulated with either original host LCLs or 3rd party in a 2º MLR. Residual proliferation to host was significantly 
reduced after allodepletion with CD25 beads and CD25 immunotoxin (marked with asterisk) compared to 
unmanipulated PBMCs but there was no significant difference in residual responses to host between these 2 
methods.  
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Comparison of CD25 vs. CD25/71 Immunomagnetic Depletion 
 
Based on our phenotypic characterisation of CD25 proliferating alloreactive T-cells, we then 
compared residual alloreactivity and 3rd party responses after CD25 and combined CD25/71 
immunomagnetic depletion, to determine if the latter combination enhanced the degree of 
selective allodepletion achieved with CD25-based methods. Normal donor PBMCs were co-
cultured with HLA-mismatched allogeneic LCLs in 8 donor-recipient pairs and at day 3 of the 
MLR, co-cultures were split into 2 arms and negative selection for CD25+ or CD25+ and 
CD71+ cells performed (using anti CD71 biotin and anti biotin/antiCD25 beads). Figure 29 
shows a representative FACS plot of CD3/CD25 and CD3/CD71 expression in unmanipulated 
PBMCs, in undepleted co cultures and post CD25 and CD25/71 depletion.  Table 10 shows 
flow cytometric data on the expression of CD25 and CD71 on T-cells before and after CD25 
and CD25/71 immunomagnetic depletions. Both CD25 and CD25/71 immunomagnetic 
depletions effectively deplete CD3+ CD25+ T-cells with no significant difference between the 
methods (mean < 0.2% after both methods p=NS). However, there was a small CD3+ CD71+ 
population remaining after CD25 allodepletion (mean 0.62 %), which was effectively removed 
with combined CD25/CD71 immunomagnetic depletion.  
Table 10: Effective depletion of alloreactive T-cells by CD25 and CD25/71 beads 
 Unmanipulated 
PBMCs 
Day 3 
PBMCs 
+Allo LCL 
Day 3 PBMCs 
+Allo LCL+25 
Beads 
Day 3 PBMCs +Allo 
LCL+25/71 Beads 
CD3 CD25 1.51 ± 0.7 10.78 ± 4.11 0.15 ± 0.08 0.06 ± 0.01 
CD3 CD71 0.84 ± 0.71 7.43 ± 3.43 0.62 ± 0.31 0.05 ± 0.05 
 
The percentage of T-cells expressing CD25 and CD71 by FACS analysis in the non-depleted 
and allodepleted co-cultures is shown. Data represent mean ±SD. N=8 
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12.97 %
60.88 %
7.86 %
66.08 %
6.72 %8.23 %
73.38 %
0.26 %2.55 %
CD3 FITC
CD25
CD71
Unmanipulated PBMCs+ Allo
LCLs
PBMCs +Allo LCL + 
CD25 Depletion
PBMCs +Allo LCL + 
CD25/CD71 DepletionUnmanipulated PBMCs+ Allo LCLs
0.81 %0.53 %
77.27 %
0.01 %
77.23 %
0.02 %
0.26 %
73.38 %
2.55 %
 
Figure 30: CD25/71 immunomagnetic allodepletion effectively removes CD71+ and C25 + alloreactive T 
cells.  Normal donor PBMCs were co cultured alone or with allo-LCLs. On day 3, aliquots from each sample 
were stained for CD3 CD25 and CD3 CD71. A  CD25 or CD25/71 allodepletion was then done and FACS 
analysis was then performed. Data shown is of a representative example 
In the primary MLR, no residual proliferation to host was detectable after CD25/71 depletion 
in any donor-recipient pair tested (Figure 32a). To detect residual alloreactivity, allodepleted 
cells were rested for 2 days and then restimulated with original host/3rd party LCLs in IFN-γ 
ELISPOT and 2º MLR assays. Results are again expressed as a percentage of the response 
observed with thawed unmanipulated PBMC from the same donor. In secondary MLRs (Figs 
30 & 32b), the median residual proliferation in response to host LCL after combined CD25/71 
depletion was significantly lower (4.8% of response of unmanipulated PBMC from the same 
donor; range 0.98 – 61.3%) than with anti-CD25 beads alone (9.9%; range 5.5 – 76.5%). This 
difference was highly significant (p < 0.01). Responses to 3rd party LCL were equivalent to 
unmanipulated PBMC with both methods (median 92.8% response of unmanipulated PBMC 
for CD25/71 vs. 95.01 % for CD25 beads alone). Likewise, in the IFN-γ ELISPOT assay (Figs 
31 & Fig 32c), the median response of allodepleted cells to host LCL was over 3 x lower with 
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combined CD25/71 allodepletion (14.1% of response of unmanipulated PBMC; range 0 – 
51.1%) than with anti-CD25 beads alone (54.6 %; range 0.04 – 111.3%), (p < 0.05). Again, 
3rd party responses were maintained compared to unmanipulated PBMCs for both methods 
(median 3rd party response for CD25 beads 69%, CD25/71 beads 76% of response of 
unmanipulated PBMC). Thus in 2 assays measuring distinct phenotypes, combined CD25/71 
depletion led to significantly enhanced and more consistent allodepletion than CD25 alone 
 
 139
 
10
20
40
60
80
100
CD25
CD25/71
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 Donor 7 Donor 8
           Host
%
C
PM
 o
f U
nm
an
ip
ua
lte
d 
PB
M
C
s
10
50
100
150
200
CD25
CD25/71
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 Donor 7 Donor 8
3rd Party
%
 C
PM
 o
f U
nm
an
ip
ul
at
ed
 P
B
M
C
s
 
 
Figure 31: This Figure show the Primary data in the 2º MLR assay for the unmanipulated 
PBMCs, CD25 depleted and CD25/71 depleted cocultures to host and 3rd party LCLs for 
the 8 donor recipient pairs. Rested CD25 or CD25/71 allodepleted or unmanipulated PBMCs were 
restimulated with either host (above)  or 3rd party LCLs (below)  in a 2º MLR assay. Values are expressed as a % 
of the response of the unmanipulated PBMCs. i.e. unmanipulated response =100 %  
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Figure 32: This figure show the Primary data in the IFNγ ELISPOT assay for both the 
unmanipulated PBMCs, CD25 depleted, CD25/71 depleted to host and 3rd party LCLs 
for the 8 donor recipient pairs. Rested CD25 or CD25/71 allodepleted or unmanipulated PBMCs were 
restimulated with either host (above) or 3rd party (below) LCLs in a 2º IFNγ ELIPSOT assay.  Values are 
expressed as a % of the response of the unmanipulated PBMCs i.e. unmanipulated response =100 % 
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Figure 33 (a). Proliferative responses to host in Primary MLR are undetectable after both 
CD25 Beads and CD25/71 Immunomagnetic allodepletion. (n=5) Residual proliferation after 
allodepletion with anti-CD25 beads or CD25/71 beads following stimulation of donor PBMCs with LCLs (R/S 
40:1) Residual proliferation was calculated using the formula as described on page 142. The median residual 
proliferation for both CD25 beads and CD25/71 beads was 0 %.Line = median, box =25th-75th centile, error bars 
= min, max values 
 (b) Enhanced Depletion of Secondary Proliferative responses to host after CD25/71 
Allodepletion compared to CD25 depletion.  n=8. Rested allodepleted CD25 or CD25/71 PBMCs 
were restimulated with host or third party LCLs in a 2º proliferation assay. CD25/71 allodepletion led to 
significantly reduced residual proliferation to host compared to CD25 alone (p <0.01) without affecting third 
party responses  
(c) Residual Alloreactivity to host is lower after CD25/71 allodepletion than CD25 in 
IFN-Y  ELISPOT n=8 This figure shows the frequency of cells secreting IFN-  as determined by ELISPOT 
assays. Rested allodepleted CD25 or CD25/71 PBMCs were restimulated with host or third party LCLs in a 2º 
IFNγ ELISPOT assay. CD25/71 allodepletion led to significantly reduced residual response to host compared to 
CD25 beads alone (p<0.05) without affecting third party responses 
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Comparison of CD25/71 vs. CD25/45RA allodepletion 
 
Our data above identified CD71 and CD45RA as the optimal markers to target proliferating 
alloreactive T-cells that would be retained after CD25-based allodepletion. To determine if 
combined CD25/71 allodepletion was superior to the combination of CD25/45RA, we co-
cultured PBMC with HLA-mismatched LCL for 3 days, split co-cultures into 2 arms and then 
negatively selected either CD25+ and CD71+ cells or CD25+ and CD45RA+ cells using 
immunomagnetic beads. (n=5) Allodepleted fractions were then rested as above and 
restimulated with host or 3rd party LCLs in a secondary 2º MLR or IFNγ ELISPOT assays 
(Table 11). In secondary MLR, the median residual proliferation to host was lower in the 
CD25/71 arm than in the CD25/45RA fraction (0.02 % vs. 9.29 % p=0.08). Similarly, in the 
IFN-γ ELISPOT assay, the median response to host in the CD25/71 arm was also slightly 
lower than the CD25/45RA arm (17.5% of response of unmanipulated PBMC vs. 23.7% 
respectively p=NS). Thus combined CD25/71 allodepletion appears non-significantly superior 
to CD25/45RA allodepletion. Given that CD45RA is also expressed in a higher proportion of 
unstimulated T-cells than CD71 (so that CD45RA depletion would result in a greater loss of 
bystander T-cells than CD71), the CD25/71 combination was selected for further studies. 
  
Median Residual 
Response to Host 
2º MLR 2º IFNγ ELISPOT 
CD25/71 0.02 % (0-15.9 %) 17.5 % (0-56.1 %) 
CD25/45RA 9.29 % (0-30.6 %) 23.7 % (3.3 -63.9 %) 
 
Table 11: Enhanced Allodepletion with CD25/71 immunomagnetic Depletion compared to 
CD25/45RA. Normal donor PBMCs were co-cultured with HLA mismatched LCLs and on day 3 a combined 
CD25/71 or CD25/45RA immunomagnetic allodepletion was performed. Aliquots from rested fractions were then 
restimulated to the original host in a 2º MLR or IFNγ ELISPOT assay. Results are expressed as a percentage of 
the response observed with thawed unmanipulated PBMC from the same donor. (n=5)(Median and range) 
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Scale Up Studies 
Prior to scale up runs in the GMP facilities, we initially optimised conditions for a combined 
CD25/71-based allodepletion. 
Determining the Optimal APC 
 
In order to determine the optimum APC for enhancing allodepletion, in 4 donor recipient pairs, 
PBMCs were co-cultured with either HLA mismatched mature DCs, LCLs or cytokine pre-
treated PBMCs .The APCs were from the same donor for each experiment. The PBMCs were 
pre-treated with recombinant human TNFα and IFNγ at 1000 iu/106 PBMCs in order to up 
regulate HLA class I and II expression and hence optimize presentation of alloantigen. Normal 
donor PBMCs were thus co cultured with irradiated APCs [DC(R:S 10.1), LCLs(R:S 40.1) or 
cytokine treated PBMCs(R.S 1.1)  from the same recipient] .A combined immunomagnetic 
CD25/71 allodepletion was then performed on day 3. Due to a shortage of cell numbers, 
allodepleted donor T cells were rested in CTL media supplemented with IL-2 20u/ml, which 
would lead to an increase in residual alloreactivity. On day 5 rested allodepleted T cells were 
co cultured with either host or 3rd party LCLs in a 2º MLR. As can be seen in Fig 33 median 
residual reactivity to host was 44.5 % for PBMCs, 15.5 % for DCs, and 10.25 % for LCLs. 3rd 
party responses were maintained with the PBMC and LCL arms (73.3 % and 133.7 % 
respectively), but were reduced for the DC arm (39.87 %). Though the number of donor 
recipient pairs was small, this preliminary experiment would suggest that LCL or DCs, are the 
optimal APC for allodepletion. Given the possibility that allodepletion after PBMC/DC APCs 
might lead to spuriously higher residual alloreactivity compared to LCLs, due to preserved 
EBV specific responses restricted by shared HLA antigens, we plan to repeat this experiment 
using host/3rd party PBMCs as 2º stimulators in the MLR. 
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Figure 34: LCLs are the Optimum APC. Donor PBMCs were co cultured with 3 different APCs from the 
same individual (DC, LCLs, and cytokine stimulated PBMCs). On day 3 a combined CD25/71 immunomagnetic 
depletion was performed. Rested allodepleted PBMCs were then co cultured with either host LCLs or 3rd party 
LCLs in a 2º MLR. (n=4). Using LCLs as APC led to the lowest median reactivity to host and the best 3rd party 
activity. 
 
Evaluating the Potential for Transmitting infectious EBV with Irradiated 
LCLs 
 
Infusion of residual LCLs with the allodepleted PBMCs could potentially result in post 
transplant lymphoproliferative disease. This is unlikely because (a) LCLs are lethally 
irradiated (70Gy), and are pre-treated with acyclovir for 2 weeks prior to use and (b) we have 
previously shown that allodepleted T cells confer EBV specific immunity through T cells 
restricted by the non- shared haplotype86. However, in order to determine the transforming 
potential of LCLs, 4 LCLs lines were grown in RF10 containing 100µM acyclovir for 2 weeks. 
After this period the LCLs were spun down and the supernatant was sent for EBV PCR. This 
showed that all 4 LCL lines were strongly positive for EBV DNA. 
 
The 4 LCLs lines were then irradiated (70 Gy) and co-cultured with PBMCs (R.S 1.1) from 3 
donors in RF10 supplemented with 1µg/ml of ciclosporin. After 6 weeks, the number of viable 
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B cells was determined using FACS (7AA-D and CD19 staining). In none of the 12 donor 
recipient pairs were any viable B cells elicited. This demonstrates that while EBV DNA is 
detectable in LCLs supernatants, the risk of transmitting infectious EBV with irradiated 
acyclovir treated LCLs is very low. 
 
Comparison of co culture in Bags vs. Flasks 
 
We then wanted to determine the optimal conditions for co culturing our cultures (i.e. bags or 
T75 flasks). In 4 donor recipient pairs, PBMCs were co-cultured with HLA mismatched DCs 
(R: S 10.1). Co cultures were split from each donor recipient pair into either T75 flasks or cell 
expansion bags (Miteny Biotec 200-074-301). On day 4, aliquots from each were assessed for 
CD3+ CD25+ and CD3+ CD71+ by FACS expression. CD3+CD25 +expression was 1.4 xs 
higher in the co-cultures in the flasks, whilst CD3+CD71+ expression was 3.5 x times higher. 
(Fig 34)  The viability (assessed by trypan staining) was 63.8 % in the flasks, whilst 56.9 % in 
the bags after 4 days of co culture. This work was done by a post doctoral student Dr. 
Christoph Mancao.  A representative FACS plot in shown in Figure 35. 
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Figure 35: Co cultures in T75 flasks led to superior up regulation of CD25 and CD71 
expression and MFI compared to bags. n=4. Donor PBMCs were co cultured with HLA mismatched 
DCs and were then cultured in bags or flasks. On day 4, aliquots were then taken for FACS to determine 
CD3+CD25+ and CD3+CD71+ expression (shown below) and MFI (shown above).  
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Figure 36: Superior Upregulation of CD3CD25 and CD3CD71 in allogeneic MLRs in 
flasks compared to bags. Normal donor PBMCs were co-cultured with HLA-mismatched DCs either in cell 
culture bags or flasks and on day 4 aliquots were taken for FACS to determine expression of CD3+CD71+ and 
CD3+CD25+. A representative example is shown above. 
Comparison of anti CD25 Bead/Anti CD71 Biotin+ anti Biotin Beads vs. 
Anti CD25 Biotin/ Anti CD71 Biotin+ anti Biotin Bead Immunomagnetic 
Allodepletion 
 
In order to optimize our scale up studies, we first compared CD25 immunomagnetic beads as 
part of our CD25/71 immunomagnetic depletion with a biotinylated anti CD25. Data from 
Necker Hospital in Paris had suggested that the biotinylated CD25 may result in more effective 
depletion of alloreactivity than the CD25 immunomagnetic beads. Potentially, this could 
simplify combined CD25/71 allodepletion as both primary antibodies could be added in a 
single step. To confirm this, in our combined CD25/71 allodepletion, we obtained biotinylated 
anti CD25 from Dr. Marina Cavazzana-Calvo. Normal donor PBMCs were co-cultured with 
irradiated HLA mismatched LCLs. On day 3, we split the co-cultures and did a day 3 CD25/71 
immunomagnetic depletion using anti CD25 beads +biotinylated CD71 + anti biotin beads as 
we had previously done vs. biotinylated CD25 (biotinylated CD25+Biotinylated CD71+ 
antibiotin beads). The percentage of residual CD3+CD25+ and CD3+ CD71+ T cells was 
determined flow cytometrically. (See Table 12) 
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 Unmanipulated Co culture pre 
depletion 
CD25 Bead + 
Biotin CD71 
Biotin CD71+ 
Biotin CD25 
CD3 CD25 2.34 % 10.41 % 0.39 % 0.31 % 
CD3 CD71 1.23 % 5.67 % 0.1 % 0.09 % 
 
Table 12: Comparison of anti CD25 Bead + anti CD71 biotin/anti Biotin vs. anti CD25+ 
anti CD71 biotin/biotin bead immunomagnetic depletion.  Normal donor PBMCs were co cultured 
with HLA mismatched LCLs and on day 3 a CD25/71 immunomagnetic depletion was done using either CD25 
beads or a biotinylated anti CD25. The % of T cells expressing CD25 and CD71 was determined by flow 
cytometry (N=1) 
 
As shown in Table 12, in a single experiment, both methods of depletion gave effective 
depletion of CD25 and CD71. The allodepleted PBMCs were rested for 2 days and then 
restimulated with host/3rd party LCLs in a 2º IFNγ ELISPOT (Fig 36). We chose the 2º IFNγ 
ELISPOT assay rather than a 2º MLR, because our previous data had suggested that the former 
assay had higher levels of residual alloreactivity and thus might enhance differences between 
the forms of allodepletion. 
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Figure 37: Effective reduction of Residual Alloreactivity with both biotinylated anti CD25 and CD25 
microbeads. Normal Donor PBMCs were co cultured with HLA mismatched LCLs. A day 3 CD25/71 depletion 
was done using an anti biotinylated CD25 or CD25 microbeads. Rested allodepleted PBMCs were then co 
cultured to host/3rd party LCLs in a 2º IFN gamma ELISPOT (n=1). 
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As can be seen from our preliminary data, both anti CD25 beads and the biotinylated anti 
CD25/anti biotin beads gave undetectable residual responses to host, with preservation of 3rd 
party responses. However, further comparisons between the anti biotinylated anti CD25 and 
CD25 microbeads will need to be done. 
Yield 
 
For the 8 donor recipient pairs, yield following a day 3 CD25/71 allodepletion is shown below. 
(Table 13) 
Donor  Day 0 
Count 
(x106 
PBMCs) 
 % Day 0 
Viability 
Day 3 Pre 
depletion 
Count (x106 
PBMCs) 
% Day 3 Pre 
depletion 
Viability  
Day 3 
Post 
depletion 
Count 
(x106 
PBMCs) 
% Day 3 
Post 
depletion 
Viability  
 % of 
the 
Starting 
Count 
1 91.5 100 42 99 13.6 99 14.86
2 101 99 51.5 95 16.6 95 16.4
3 135 99 58 90.6 22.35 77 16.56
4 165 99 62 74 42 93 25.47
5 193.1 100 94 75 28 85 14.51
6 178 99 88 79 31.02 95 17.4
7 67 100 62 79 12.2 95 18.2
8 113 99 71 83 16.49 92 14.59
Mean 138.125 99.375 66.0625 84.325 29.8 91.375 17.2 
 
Table 13: Yield and Viability after a Day 3 CD25/71 allodepletion. Data demonstrating the total number of 
PBMCs (x 106 PBMCs) at start of co culture, pre CD25/71 depletion  on day 3 and after CD25/71 depletion on 
day 3. % Viability was assessed by trypan blue staining. (n=8) 
 
The mean % yield ± 1 SD from 8 donor recipient pairs is 17.2 % ± 3.58. We are routinely able 
to generate 8 x 107 allodepleted donor T-cells (ADTs) from a 450 ml blood donation, so that 
add back of 106/kg CD25/71 ADTs is straightforward. The mean viability post a day 3 
CD25/71 allodepletion was over 90 %.  
CD25/71 Allodepletion using The CliniMACS under GMP 
conditions 
 
To determine if we could reproduce our in vitro data on a larger scale, we performed scale up 
studies in our GMP facility, the Cell Therapy laboratories at Great Ormond Street Hospital 
using the CliniMACS system for depletions. Since we have not as yet obtained regulatory 
approval from The Medicine and Healthcare Regulatory Agency (MHRA) for use of EBV 
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transformed LCLs within this facility, DCs were used as stimulators in these experiments. 
Normal donor PBMCs from buffy coats were co-cultured with HLA mismatched irradiated 
dendritic cells (R.S.10.1) for 4 days (n=2). These experiments were performed before our 
comparison of bags vs. flasks and co-cultures were performed in cell culture bags, in order to 
maintain a closed system throughout the experiment. On day 4, co-cultures were harvested and 
a CD25/71 immunomagnetic labelling was done using biotinylated anti CD25/CD71 and anti 
biotin beads. 
 
For one of the donor recipient pairs, the depletion on the CLINIMACS was done using a TS 
tubing set (recommended by Miltenyi Biotec to perform our depletions). For the other donor 
recipient pair, the depletion was done using a CLINIMACS depletion tubing set. The TS 
tubing set is used for depletions for  up to 60x 109 total PBMCs and the CLINIMACS 
depletion tubing set for up to a total of 120x109 PBMCs. Samples were taken to determine the 
efficacy of depletion and for sterility. 
 
  
 TS Tubing CLINIMACS depletion 
Tubing set 
CD3 CD25 3.84 % 0.09 % 
CD3 CD71 2.14 % 0.04 % 
Table 14: CD25/71 depletions using TS Clinimacs set does not give adequate depletions. 
Normal donor PBMCs were co cultured with HLA mismatched DCs. (n=1). On day 4 a CD25/71 allodepletion 
was performed using a TS CLINIMACS set in 1 donor recipient pair, and a CLINIMACS depletion tubing set in 
the other pair. The allodepleted samples were then stained for residual CD3+ CD25+ and CD3+ CD71+ using 
flow cytometry. 
 
Following allodepletion the samples from the 2 different tubing sets were co stained for CD3 
CD25 and CD3 CD71 flow cytometrically. As can be seen in Table 14, depletions using the 
TS tubing did not lead to acceptable levels of allodepletion. In contrast, depletions performed 
with the CLINIMACS tubing set, did lead to comparable levels of depletion to that what we 
achieved using the MIDI MACS. Viability as assessed by 7AA-D staining was greater than 95 
% in both arms. The % cell yield as percentage of the starting PBMC count was 8.8% for the 
CLINIMACS depletion tubing set, and 10.4 % for the TS tubing set. These values are less than 
the 17 % we achieved using the MIDI MACS, and this may reflect increased cell loss in the 
bag system. Further comparison between the TS tubing set and the depletion tubing set using 
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the same donor recipient pairs are needed.   The CD25/71 allodepleted PBMCs from the 
depletion tubing set fraction were rested for 2 days and then restimulated to host/3rd party in a 
2ºIFNγ ELISPOT ( see Table 15a ) or 2ºMLR (Table 15b). Anti CMV responses were assessed 
by co-culturing unmanipulated PBMC or CD25/71 allodepleted PBMCs from the same donor 
with irradiated autologous PBMC pulsed with a CMV pp65 peptide mix in an IFN γ ELISPOT 
(n=1). (Table 15a) 
 
(a) 
 Host  3rd Party CMV pp65 
Unmanipulated 
PBMCs 
407 302 885 
CD25/71 allodepleted 0 20 395 
(b) 
 Host  3rd Party 
Unmanipulated 
PBMCs 
30553 21850 
CD25/71 allodepleted 0 13023 
 
Table 15: Loss of 3rd party responses after CD25/71 allodepletion using the CLINIMACS. 
(n=1) PBMCs were co cultured with HLA mismatched DCs and then on day 4 a CD25/71 allodepletion was 
performed using the CliniMACS system.  Rested allodepleted PBMCs were then restimulated to host/3rd party 
LCLs in a 2ºIFNγ ELISPOT (a) (No of spots/2x105 PBMCs) or 2ºMLR (CPM/2x105PBMCs) (b)                    
CMV responses were assessesed in an IFNγ ELISPOT by stimulating unmanipulated PBMC or allodepleted 
PBMCs with autologous PBMCs pulsed with CMV pp65 pepmix 
 
Our data show that while CD25/71 depletion completely abrogated IFN-γ responses to host, 
there was extensive loss of 3rd party responses in both assays (6.6 % on the IFNγ ELISPOT), 
(59.6 % on the 2º MLR). Responses to CMV in the IFNγ ELISPOT assay, showed relative 
preservation, though somewhat diminished compared to unmanipulated PBMCs were also 
decreased compared to unmanipulated PBMCs (44.6 %) (Table 15). These results are very 
preliminary, and the loss of 3rd party responses, may reflect the time taken to perform the 
depletion using the CLINIMACS due to the lack of familiarity with this system. Our Current 
Standard Operating Procedure (SOP) for generation of CD25/71 allodepleted donor T cells in 
shown in the Appendix . We plan to repeat the comparison between the tubing sets and 
subsequently to perform clinical scale CD25/71 depletions using this system to determine 
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yield, residual alloreactivity and preservation of antiviral responses in a further 5 donor-
recipient pairs.  
 
 
Conclusions 
 
To optimize our allodepletion strategy, we initially compared the effectiveness of CD25 
immunomagnetic depletion to that of CD25 IT. In 2 different assays we found no significant 
difference in residual alloreactivity to host between these methods. Clinical grade anti-CD25 
immunomagnetic beads (Miltenyi Biotec) are now available, overcoming the limited 
availability of IT. Whilst both methods gave extremely effective depletion of CD25+ T-cells 
(<1%) and residual proliferation to host in primary MLRs (undetectable with both methods), 
significant residual alloreactivity to host was observed in secondary MLRs and ELISPOT 
assays, when CD25 alone was targeted.  
 
We found that 70 % of the CFSE-dim CD25-ve population express CD71. Potentially, this 
enables us to target 2 independent phenotypes of alloreactive T-cells at the same time-point 
within a single co-culture. Flow cytometric analysis showed that immunomagnetic depletion 
deletes CD25+ and CD71+ cells to below background levels. In primary MLRs, residual 
responses to the stimulator were undetectable after CD25/71 depletion. In 2 separate functional 
secondary stimulation assays measuring distinct phenotypes, the combination of CD25/71 
allodepletion led to significantly enhanced and more consistent allodepletion compared to 
CD25 alone without compromising third party responses. Furthermore the combination of 
CD25/71 was superior to the CD25/45RA combination.  Our studies indicate that combined 
CD25/71 depletion results in a 20-fold reduction of proliferating alloreactive T-cells flow 
cytometrically and in secondary MLRs, with a 1-log depletion of response to host in IFN-γ 
ELISPOT assays. Hence, combined CD25/71 depletion may enable safe transfer of larger 
doses of allodepleted donor T-cells than hitherto possible.  
 
Additionally, we showed that LCLs are an excellent APC, for allodepletion strategies, eliciting 
allodepletion that is equal to mature DCs, and superior to that of cytokine treated PBMCs, with 
excellent preservation of 3rd party responses. We further showed that in 12 donor recipient 
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pairs, irradiated LCLs lines were unable to transform co-cultured donor PBMCs. This would 
suggest that the risk of transmitting infectious EBV by using acyclovir treated irradiated LCLs 
is extremely low. Finally, we have demonstrated that immunomagnetic CD25/71 allodepletion 
using The CLINIMACS system is feasible under GMP conditions. Though our results are very 
provisional, we showed acceptable levels of depletion of CD25+ and CD71+ T cells, 
undetectable anti host responses and relative preservation of anti CMV responses, using 
CliniMACS depletion tubing set. Further scale up experiments are planned. 
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CHAPTER 5 
 
 
Assessment of Antiviral Immunity after Combined 
CD25/71 Allodepletion 
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Aims 
1. To determine if T cell responses to CMV, EBV and adenoviral antigens are preserved 
after combined CD25/71 allodepletion compared to unmanipulated PBMCs 
 
Introduction 
 
 The rigorous T- cell depletion required to avoid graft versus host disease (GVHD) after haplo-
SCT results in delayed immune reconstitution, resulting in a high mortality/morbidity from 
viral (chiefly CMV, EBV and adenovirus) and fungal infections7. In particular, adenovirus 
appears to be the single most important cause of infectious death after haplo-SCT.7,168,169 
CD25 based allodepletion strategies preserve in vitro CMV and adenoviral immunity, 86 and 
when LCLs were used as APCs, partial immunity to EBV was preserved through the non 
shared haplotype. Clinically, patients who received adoptive immunotherapy with doses of 3 x 
106/kg of allodepleted donor T-cells generated using CD25 IT after haplo-SCT141 showed 
accelerated T-cell reconstitution and recovery of CMV and EBV-specific immunity. However, 
2 patients in this study died of adenovirus associated complications, and importantly, no 
patient had detectable T-cell responses to this virus before 9 months post-SCT. These data 
suggest that larger doses of allodepleted T-cells may be necessary to confer protective 
responses to pathogens which evoke low frequency T-cell responses in the donor.  
 
In the previous chapter we demonstrated that a combined immunomagnetic CD25/71 
allodepletion resulted in significantly lower residual alloreactivity to host compared to CD25 
based allodepletion. We next studied whether anti-viral responses are preserved following 
CD25/71 allodepletion. 
Antiviral Responses are Preserved after CD25/71 Allodepletion 
 
To determine the specificity of allodepletion with CD25/71 immunomagnetic negative 
selection, we studied whether anti-viral T-cell responses were retained following allodepletion. 
PBMCs from CMV or EBV–positive donors known to have significant populations of virus-
specific CD8+ cells detectable by MHC- peptide pentamers were co-cultured with HLA-
mismatched LCLs for 3 days and then negatively selected for CD25/71 using immunomagnetic 
beads as described in Chapter 4. As shown in Table 16 and the representative FACS plot in Fig 
37a, in 4 donors there was no significant difference in the frequency of CMV-pp65–specific 
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CD8+ T cells in allodepleted donor T-cell cultures compared to unmanipulated PBMCs from 
the same donors (median 2.5 % vs. 3.3 % respectively p=NS). Similarly (Table 17 and 
representative FACs plot in Figure 37b), the frequency of EBV-specific pentamer+ T-cells in 
CD25/71 allodepleted donor T-cells was equivalent to unmanipulated PBMCs (median of 0.34 
% vs. 0.37 % respectively p=NS). These results suggest that virus-specific CD8+T-cells are 
retained following allodepletion. 
Table 16: CD8+ T-cells response to CMV are preserved after CD25/71 allodepletion  
 
 Donor 1 B7 
TPR 
Donor 2 B7 TPR Donor 3 B7 TPR Donor 4 A2 
NLV 
Unmanipulated 3.01 % 14.23 % 2.05 % 0.46 % 
CD25/71 2.52 % 8.45 % 3.98 % 0.29 % 
 
FACS analysis of 4 CMV seropositive donors in unmanipulated PBMCs (top row) or after 
CD25/71 allodepletion (bottom row) following staining with HLA-A2 CMV pentamer. The 
percentage of pentamer positive cells in the CD3+/CD8+ lymphocyte gate was expressed as a 
proportion of the CD8+ cells. CMV- pp65-specific HLA-A*0201-NLVPMVATV (A2-NLV), 
and HLA-B*0702-TPRYTGGGAM (B7-TPR)  
 
 
 
Table 17: CD8+ T-cell responses to EBV are preserved after CD25/71 allodepletion  
 Donor 1 A2-
CLG 
Donor 2 A2-
CLG 
Donor 3 A2-CLG Donor 4 A2 
CLG 
Unmanipulated 0.19 % 0.11 % 0.49 % 0.55 % 
CD25/71 0.09 % 0.12 % 0.62 % 0.72 % 
 
FACS analysis of 4 EBV seropositive donors in unmanipulated PBMCs (top row) or after 
CD25/71 allodepletion (bottom row) following staining with HLA-A2 EBV pentamer. The 
percentage of pentamer positive cells in the CD3+/CD8+ lymphocyte gate was expressed as a 
proportion of the CD8+ cells. EBV- LMP-2 specific HLA-A*0201-CLGGLLTMV (A2-CLG).  
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Figure 39: (a) CMV-specific CD8+ T-cells are preserved after CD25/71 allodepletion The 
figure shows a representative FACS analysis from one of 4 donor-recipient pairs demonstrating staining of either 
unmanipulated PBMCs (left column) or CD25/71 allodepleted cells (right column) in a HLA-A2–positive, CMV-
seropositive donor with a HLA-A2–CMV pp65 pentamer (top right quadrants). The percentages of pentamer-
positive cells as a proportion of CD8+ cells with isotype subtracted are shown. 
(b) EBV-specific CD8+ T-cells are retained after CD25/71 allodepletion. The figure shows a 
representative FACS analysis from one of 4 donor-recipient pairs demonstrating staining of either unmanipulated 
PBMCs (left column) or CD25/71 allodepleted cells (right column) in a HLA-A2–positive, EBV-seropositive 
donor with a HLA-A2–CLG pentamer (top right quadrants). The percentages of pentamer-positive cells as a 
proportion of CD8+ cells with isotype subtracted are shown 
 
 
To study the functionality of anti-viral T-cells, we then performed IFN-γ ELISPOT analyses to 
determine the frequency of CMV, adenoviral and EBV-specific T-cells before and after 
allodepletion.  Donors were co-cultured with completely HLA antigen mismatched LCLs and 
CD25/71 allodepletion was performed at day 3 of co-culture. Unmanipulated PBMC or rested 
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CD25/71 allodepleted T-cells from the same seropositive donors were then restimulated with 
irradiated autologous PBMC pulsed with a peptide mix from the immunodominant CMV 
antigen pp65 or transduced with an adenoviral vector (AD5f35-GFP) or with autologous 
LCLs. As shown in Table 18 (showing the primary data for each donor recipient pair in the 
IFNγ ELISOT assay for CMV, EBV  and adenovirus in unmanipulated and CD25/71 
allodepleted co cultures) and  Figure 38a and 38b (showing the median and range for SFC to 
CMV, EBV and adenovirus in unmanipulated and CD25/71 allodepleted co cultures), there 
was no statistically significant difference (p=NS) in the frequency of cells secreting IFN-γ in 
response to CMV, EBV or adenoviral antigens in allo-depleted T-cell co-cultures and 
unmanipulated PBMC, implying that allo-depletion with combined CD25/71 immunomagnetic 
selection does not affect the function of virus-specific T-cells 
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 (a) Primary Data for Each donor Recipient Pair for CMV Responses in the IFNγ ELISPOT 
assay 
 
 Unmanipulated CD25/71  
Donor 1 55 109
Donor 2 100 93
Donor 3 332 257
Donor 4 206 92
Donor 5 63 64
Mean ± 
SD 
151.2±117.62 123±76.63876
 
(b) Primary Data for Each donor Recipient Pair for EBV Responses in the IFNγ ELISPOT 
assay 
 
 Unmanipulated CD25/71 
Donor 1 100 155
Donor 2 120 165
Donor 3 80 110
Donor 4 90 185
Donor 5 110 95
Mean ± SD 100±15.81 142±38.01316
 
 
(c) Primary Data for Each donor Recipient Pair for Adenovirus Responses in the IFNγ 
ELISPOT assay 
 
 Unmanipulated CD25/71  
Donor 1 135 205
Donor 2 155 150
Donor 3 425 615
Donor 4 115 145
Mean ± SD 207.5±145.91 278.75±225.80
 
Table 18: Primary data for each virus for every donor recipient pair in the IFNγ ELISPOT 
assay.  The frequency of cells secreting IFNγ  (SFC/105 PBMCs) in response to stimulation with irradiated 
autologous PBMC pulsed with a peptide mix from CMV pp65 (a) or autologous EBV LCL (b) was determined by 
ELISPOT assays. Unmanipulated PBMC or CD25/71 allodepleted T-cells from the same seropositive donors 
were compared (n=5) (c) The frequency of cells secreting IFN-  in response to stimulation with irradiated 
autologous PBMC transduced with an adenoviral vector (Ad5f35-GFP) was determined by ELISPOT assay 
(SFC/106 PBMCs). Unmanipulated or CD25/71 allodepleted T cells from the same seropositive donors were 
compared. (n=4) 
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Figure 41 (a) Functional T-cell responses to CMV and EBV are preserved after CD25/71 
allodepletion. (n=5) The frequency of cells secreting IFNγ in response to stimulation with irradiated 
autologous PBMC pulsed with a peptide mix from CMV pp65 or autologous EBV LCL was determined by 
ELISPOT assays. Unmanipulated PBMC or CD25/71 allodepleted T-cells from the same seropositive donors 
were compared. Line = median, box =25th-75th centile, error bars = min, max. 
(b) T cells responses to Adenovirus are preserved after CD25/71 allodepletion N=4 The 
frequency of cells secreting IFNγ in response to stimulation with irradiated autologous PBMC transduced with an 
adenoviral vector (Ad5f35-GFP) was determined by ELISPOT assay. Unmanipulated or CD25/71 allodepleted T 
cells from the same seropositive donors were compared. 
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Conclusion 
 
Infections remain a significant cause of morbidity and mortality after CD34 selected haplo-
SCT. Adoptive immunotherapy with EBV CTLs ,92and CMV-specific CTLs 94,  98 has been 
demonstrated to enhance anti-viral immunity after HLA-matched transplant but these 
approaches are untested in the haploidentical setting . Further, these approaches are limited to 
individual pathogens, and frequently require either prolonged periods of cell culture, thus 
limiting broader clinical applicability. In contrast, allodepleted T-cells confer immunity to a 
wide array of pathogens including all 3 viruses tested, and since the majority of alloreactive T-
cells have been deleted, the risk of GVHD is lower in the haploidentical setting. Moreover, the 
generation of allodepleted T-cells is substantially simpler than many existing protocols for 
CTL generation. 
 
We have demonstrated in 2 distinct assays that anti-CMV and EBV responses are maintained 
following combined CD25/71 allodepletion. Furthermore, IFNγ responses to adenoviral 
antigens are also preserved following CD25/71 allodepletion. We have not assessed whether 
protective responses to fungal pathogens such as Aspergillus are preserved in allodepleted T-
cells because the immunogenic antigens of these organisms are as yet poorly defined. While 
we would predict such responses would be preserved, as T-cells responding to them should not 
be activated, and therefore not depleted, this will need to be confirmed in future studies. Given 
that combined CD25/71 allodepletion is enhanced compared with CD25 depletion suggests 
that it may be possible to safely transfer larger doses of allodepleted donor T-cells than 
hitherto possible and our data suggest that, this may confer protective immunity not only to 
CMV and EBV but also to pathogens which evoke low frequency T-cell responses in the 
donor, such as adenovirus.  
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Chapter 6 
 
 
Enhancement of Anti leukaemic Activity of CD25/71 
Allodepleted Donor T cells 
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Aims 
1. To redirect the specificity of CD25/71 allodepleted donor T-cells with a single chain 
ScFv CD19 chimeric T cells receptor and demonstrate cytotoxicity and cytokine 
release to CD19+ targets 
 
Introduction 
 
Leukaemic relapse remains a major cause of mortality post T-cell deplete haploidentical 
transplantation.8 In clinical studies of adoptive immunotherapy with allodepleted donor T-cells 
generated using CD25 IT, the major cause of treatment failure was relapse.139,141 The 
persistence of anti-leukaemic responses after selective allodepletion is critical if the benefits of 
adoptive transfer are not to be offset by leukaemic relapse, as in our previous study 141. Our 
approach will deplete T-cell responses against the mismatched HLA alleles and ubiquitous 
minor histocompatibility antigens presented by the shared HLA alleles. Nonetheless, we and 
others 86,122,142have shown that anti-leukaemic activity may be retained after allodepletion. In 
particular, we have demonstrated that T-cell responses to potential myeloid tumour antigens 
are preserved by virtue of their lack of expression on the LCL used as stimulators. Such T-cell 
responses could be restricted either through HLA molecules shared by the recipient and donor 
or allorestricted. However, it is known that the precursor frequency of anti-leukaemic T cells is 
much lower than against viral antigens. Analogous to the situation with donor lymphocyte 
infusion, it is possible that infusing higher doses of allodepleted T-cells may confer anti-
leukaemic responses in myeloid malignancies. In order to augment the anti-leukaemic activity 
of allodepleted T-cells in lymphoid malignancies, we have investigated redirecting their 
specificity to target tumour specific antigens using chimeric T-cell receptors. (ChTCR). We 
have focused particularly on B lineage acute lymphoblastic leukaemias this is the commonest 
transplanted malignancy in childhood and relapse is the major cause of treatment failure after 
SCT in both children and adults. 
 
Existing approaches to enhancing graft versus leukaemia, are limited by the technically 
difficult nature of the process, the lack of expression of tumour specific antigens or down 
regulation of the MHC complex. One approach to target B cell malignancies, is based on the 
combining the effector functions of T-cells with the ability of monoclonal antibodies to 
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recognize cell surface molecules such as CD19. These chimeric T-cell receptors consist of an 
extracellular singe chain Fv consisting of the heavy and light chain variable regions of a 
monoclonal antibody which is attached to the cytoplasmic domain consisting of the CD3ζ 
chain. As outlined in the introduction, this approach overcomes the lack of immunogenic 
tumour antigens on ALL blasts, enable us to target tumour cells in a HLA independent fashion, 
bypasses tumour evasion strategies and should not cause GVHD as we will target CD19 which 
is highly expressed on B- lineage acute lymphoblastic leukaemias (ALLs), B cell lymphomas, 
and chronic lymphocytic leukaemias but is not expressed on non hematopoietic cells. The 
CD19 specific ScFv is derived from a murine IgG2a monoclonal antibody (clone FMC63) 
fused in frame to an IgG hinge a transmembrane domain and an intracellular CD3ζ. 
Transduction of PBMCs with retroviral vectors coding for CD19 ChTCRs have shown specific 
killing of CD19 targets in vitro and in mouse studies.150,153 
 
 However, the polyclonal  stimulation ( generally with OKT3/ anti CD28 and IL-2) required to 
promote T cells for retroviral transduction to occur, significantly alters the phenotype of the 
transduced cells, promoting differentiation of the transduced T-cells, leading to a reduction in 
anti-viral immunity.107,108 Gattinoni et al demonstrated that highly differentiated T-cells have 
potent in vitro cytotoxicity but weak in vivo activity whilst the converse is true for naïve T- 
cells. 155 In vivo studies with ChTCRs have shown poor efficacy despite strong in vitro 
activity. Potentially, this could be due to neoepitopes in the ChTCRs leading to immune 
clearance of the receptors, or to poor T-cell proliferation due to a lack of co-stimulatory 
domains in the TCR or the highly differentiated state of the transduced T-cells.153,155  
Therefore, a transduction regime of allodepleted T-cells which preserves their phenotype, as 
well as their anti-viral immunity is desirable. Lentiviral vectors have the advantage that they 
are less dependent than oncoretroiral vectors on cell division for stable transduction to occur so 
that less intensive stimulation can be used during transduction. Transduction of T-cells with 
lentiviral constructs stimulated using modest doses of  IL-2 or IL-7 only, has been shown to 
preserve the phenotype of transduced T-cells and preserve anti-viral immunity.107,170 
Moreover, lentiviral transduction is associated with a lower risk of insertional mutagenesis.161 
Thus we investigated if transduction of allodepleted donor T-cells with a lentiviral construct 
encoding for a CD19 chTCR with minimal stimulation was sufficient to redirect their 
specificity towards CD19+ leukaemic targets. 
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Construction of Chimeric TCR and Production of Lentiviral 
Supernatant 
 
The ScFv CD19ζ plasmid was supplied by Dr. Martin Pule. This consisted of the variable 
domains derived from the CD19 specific murine monoclonal antibody FMC-63 assembled as a 
single chain variable fragment (ScFv) molecule, in frame with a sequence encoding the human 
immunoglobulin IgG G1 hinge CH2-CH3, the CD28 transmembrane domain, and the 
cytoplasmic signalling domain of the human CD3ζ. The 1946 base pair fragment of the CD19 
chTCR was amplified by PCR.  Not 1 restriction restriction sites were added to the 5′ end of 
the reverse primer, and a Bgl II restriction site was added to the 5′ of the forward primer so 
that the fragment could be sub cloned into the Not 1 and Bam H1 sites of the pHR –SIN-SE 
lentiviral vector (gift of Dr. Martin Pule).  A schematic CD19R/ pHR –SIN-SE is shown in Fig 
39. This 2nd generation lentiviral vector has no HIV viral protein expression, but has essential 
viral cis elements for vector infection i.e. LTRs, RRE (rev response element which is required 
for viral mRNA export from the nucleus to the cytoplasm), and ψ-packaging signal. It is a SIN 
(self inactivated vector), which is believed to be safer, because of the deletion in the U3 region 
of the 3′LTR, which results in no viral enhancer and promoter transfer into target cells. There 
is a cPPT (central polypurine tract) which increases vector titre up to 10 fold, and a WPRE 
(woodchuck hepatitis post transcriptional element), which increases the stability of the mRNA. 
The CD19 chTCR is under the control of the SFFV promoter. The SFFV promoter (spleen 
focus forming virus LTR) has strong promoter activity in most human or mouse cells including 
primary macrophages, DCs, and lymphocytes. 
 
 
 
 
 
 
 
Figure 43: Schematic of the CD19R/ pHR –SIN-SE.  This consists of a self inactivated (SIN) lentiviral 
construct, with a HIV central polypurine tract (cPPT), Woodchuck hepatitis virus post transcriptional regulatory 
element (WPRE), and a spleen focus forming virus (SFFV) promoter. The CD19R transgene consists a human 
immunoglobulin leader sequence (S), the variable domains of the CD19 specific murine monoclonal antibody 
FMC-63 assembled as a single chain variable fragment (ScFv) (VL and VH), connected by a linker (L), in frame 
with a sequence encoding the human IgG1 hinge and CH2-CH3 domain (Spacer), the human CD28 
transmembrane domain (TM), and the cytoplasmic signalling domain of the human CD3ζ.  
 
5′LTR    cPPT      SFFV       S    VL    L   VH     Spacer    TM     CD3 Zeta   3′LTR∆U3 
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A vector map of CD19R/ pHR –SIN-SE is demonstrated in Fig 40a. To confirm that the 
modified lentiviral vector CD19R/ pHR –SIN-SE contained the CD19 chTCR transgene, the 
following restriction enzyme digests were performed: EcoR1/Not1, EcoR1/BamH1, and 
Not1/BamH1. Restriction enzyme digests with EcoR1/Not1, EcoR1/BamH1, Not1/BamH1 
produced the predicted size fragments (8.5/2.5 kbp; 9.7/1.3 kbp; 9.86/1.15kbp) respectively 
indicative of successful sub cloning of the CD19 chTCR transgene into the lentiviral construct. 
(Fig 40b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 168
(a) 
(b)
CD19R/ pHR -SIN-SE
11011 bp
CD19 chTCR
Ampicillin R
3' LTR
WPRE
cPPT
RRE
5'LTR
SFFV promoter
BamHI (4873)
EcoRI (3547)
NotI (6018)
XhoI (6813)
XbaI (6028)
XbaI (7140)
ClaI (3530)
ClaI (6071)
ClaI (6799)
 
 
10,000 bp
1000 bp
2500 bp
1       2       3       4       5
1500 bp
1. Vector Alone – 11.1 kbp
2. Vector+ EcoR1/Not1- 8.5 kbp +2.5 kbp
3. Vector +Not1/BamH1- 1.15kbp + 9.86kbp
4. Vector +EcoR1/BamH1 – 1.3 kbp+ 9.7 kbp
5. 1kb+ ladder
  
Figure 45: CD19R/ pHR –SIN-SE  vector map (b) Agarose gel demonstrating restriction 
enzyme digestion of CD19R/ pHR –SIN-SE with EcoR1/Not1, EcoR1/BamH1, and 
Not1/BamH1.  
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Production and Titration of Lentiviral Construct 
The modified lentiviral vector incorporating the CD19 chTCR transgene was prepared by 
transient co-transfection of three plasmids into 293 T cells: Lentiviral vector DNA (40µg) and 
packaging plasmids pMDG.2 (VSV-G) (10µg) and pCMV∆8.74(gag-pol) (30µg) as described 
in methods. Viral supernatant was harvested at 48 and 72 hours post transfection and 
concentrated by ultracentrifugation. In order to determine the number of transducing particles, 
the virus was titred on 293 T cells using serial dilutions of 1:5 and the cells were analysed for 
anti Fc expression 72 hours later.(Fig 41)  
0.24 % 87.4 % 63.11 %
20.54% 4.73 %
Untransduced 10 ul 2ul
0.4 ul 0.08 ul
Counts
Anti Fc Cy5  
Figure 47: Lentiviral construct (CD19R/ pHR –SIN-SE) was titrated on 293 T cells using 
serial dilution of viral supernatant. The equivalent volume of concentrated supernatant used per well of 
293 T cells is shown. Cells were analysed by flow cytometry 72 hours later for anti Fc expression and the number 
of transducing particles per ml was determined. Representative flow cytometry plots of anti Fc expression in 293 
T cells following exposure to CD19R/ pHR –SIN-SE  
 
The number of transducing particles per ml was determined as described in Chapter 2. Two 
batches were used for subsequent transductions, one of which gave the number of transducing 
particles as 2.04 x1010/ml and the other gave 1.7 x 1010/ml 
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Optimization of lentiviral transduction 
Transduction of T cells with lentiviral constructs using IL-2 or IL-7 only, has been shown to 
preserve the phenotype of transduced T cells and preserve anti-viral immunity.107,170 In order 
to determine the optimal cytokine conditions for transduction with our lentiviral vector, normal 
donor PBMCs were stimulated with IL-2 100 u/ml or IL-7 (5 or 10 ng/ml) for 96 hours and 
then transduced with concentrated lentiviral supernatant at a MOI of 20.  On day 8, the cells 
were harvested and the percentage of transduced T cells was determined by flow cytometry. 
(Fig 42).  As shown in Fig 42, the transduction efficiency with IL-2 prestimulation was more 
than double that achieved with IL-7 (40.8 % vs. 21.49 %). Thus, for future experiments, 
prestimulation with IL-2 100U/ml was used. 
Non Transduced IL-2  100 U/ml
Il-7 5ng/ml IL-7 10 ng/ml
1.85 %
97.24 %
40.86 %
58.08 %
15.6 %
83.46 %
21.49 %
77.45 %
Anti 
Fc
CD3   
 
Figure 49: IL-2 promotes superior transduction of T cells than IL-7. Normal donor PBMCs were 
co cultured in media supplemented with IL-2 (100u/ml) or IL-7 (5 or 10 ng/ml) for 96 hours. CD19R/ pHR –
SIN-SE Lentiviral supernatant was then added at a MOI of 20. On day 8 the expression of anti Fc in T cells was 
determined by flow cytometry. (n=1) The percentage of transduced T cells is shown in the top right hand 
quadrant. Data displayed is gated on the CD3 positive population. 
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Optimization of Multiplicity of Infection 
 
 
30.78 %
T 1 ml MOI 100
MOI 20
14.19%
CD3 Pe
Anti 
Fc 35.5%45.6 %
Untransduced MOI 100
MOI 150 MOI 150+ Polybrene
Viability 97.76 % Viability 92.16 % Viability 96.79 %
Viability 93.78 % Viability 72.17 %
 
 
 
 
Figure 51: MOI of 150 provides Optimum Transduction. Donor PBMCs were cultured in 1 ml 
media supplemented with IL-2 100 U/ml. On day 4 concentrated lentiviral supernatant (CD19R/ pHR –SIN-SE) 
was added at various MOIs. On day 8 the cells were stained for CD3 and anti Fc. Data displayed is gated on the 
CD3 positive population. The percentage of T cells staining for anti Fc is shown in the top right hand quadrant. 
NT- non transduced (n=1) 
 
 
A transduction regime using a MOI of 20 with IL-2 of 100 u/ml only has been shown to lead 
to transduction efficiencies of typically 20-25 %. Higher MOIs have not been reported to 
increase transduction efficiencies.107 In order to verify this and determine the optimum MOI to 
transduce allodepleted T cells, PBMCs were co-cultured in media supplemented with IL-2  
100 u/ml. On day 4 concentrated lentiviral supernatant was added at varying MOIs 
(20,100,150) and with /without polybrene (5µg/ml), a cationic polymer that increases 
transduction efficiency with retroviral vectors by enhancing receptor independent virus 
adsorption on target cells. Cells were harvested 4 days later and the percentage of transduced T 
cells was determined by flow cytometry and the viability was determined by trypan staining. 
As shown in Fig 43, the transduction efficiency of T-cells increased with increasing MOI and a 
MOI of 150 provided the best transduction (45.6 %), over 3 x times than that achieved with a 
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MOI of 20. Adding polybrene to the co-cultures did not increase transduction efficiencies, but 
decreased viability. Co-cultures to which lentiviral supernatant was added at a MOI of 150 had 
a viability of 94 % after 8 days. Thus, for future experiments a transduction without polybrene 
at a MOI of 150 was used. 
 
Detecting Cytotoxicity of CD19+ Targets by Transduced T cells 
 
We then studied whether transduction of PBMCs with our lentiviral CD19chTCR vector 
redirected their specificity so that they recognized and lysed CD19+ target cells. Normal donor 
PBMCs were resuspended in CTL media, and prestimulated with IL-2 100 u/ml. On day 4 
lentiviral supernatant at a MOI of 150 was added, and on day 8 the cells the cells were used as 
effectors in a 51Cr assay. A transduction efficiency of 31.2 % of T cells was achieved. Targets 
included K562 cells, K562 cells stably transduced with a CD19+GFP+ transgene, K562 cells 
transduced with GFP alone, autologous LCLs and HLA mismatched allogeneic LCLs. 
Effector: target ratios of 1:1, 5:1, and 30:1 were plated. In this assay, no specific lysis was 
detected to any of the CD19+ targets in the 51Cr assay (n=1). This may represent the 
predominantly naïve phenotype of the transduced population, 107 (though the CCR7/CD45RA 
expression of transduced cells was not determined) with the percentage of transduced CD8+ 
CTL being too small to elicit any detectable cytotoxicity.  
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Figure 53: OKT3 transduced ζCD19 PBMCs show significant cytotoxicity against CD19+ 
Targets. Normal donor PBMCs were stimulated with OKT3, CD28, IL-2 or IL-2 100u/ml only. (n=1) Mock 
transduced or PBMCs transduced with CD19R/PHR-SIN-SE were co cultured with K562 GPP+ CD19+/- cells. 
After a week, cells were stained with 7AA-D, and trucount beads. A fixed number of counting beads was 
acquired and the number of 7AA-D negative, GFP+ cells was determined. NT-non transduced  T-transduced 
 
To investigate this further, in our next experiments we included a positive control consisting of 
PBMCs transduced after polyclonal stimulation with OKT3/αCD28 and IL-2 which promotes 
with high efficiency transduction and differentiation of naïve T cells into effector CTLs. 
Additionally, we developed a more sensitive flow cytometric cytotoxicity assay based on 
assessment of cell viability. As we assessed cytotoxicity after a week of co-culture between 
effectors and targets, it enabled an assessment of cytotoxicity over a longer period, and thus 
was felt to be more sensitive than the 51Cr based cytotoxicity assay.  
 
Normal donor PBMCs were transduced/mock transduced in media supplemented with OKT3 
(1µg/ml) anti CD28 (1µg/ml) and IL-2 (100U/ml) to serve as s positive control, or IL-2  
100 u/ml only as described. Transduced/mock transduced PBMCs were co-cultured with an 
equal number of K562 GFP+CD19+ or K562GFP+CD19- cells. (Fig 44) After a week, the 
number of viable GFP+ cells was determined by staining with 7-AAD. A fixed number of 
trucount beads was acquired to ensure that comparison could be made between the different 
co- cultures. As shown in Fig 45,  PBMCs stimulated with OKT3/αCD28 demonstrated 82 % 
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cytotoxicity against K562-CD19+GFP+ cells but there was no significant cytotoxicity against 
CD19 negative K562-GFP+ targets. (cytotoxicity = 1-number of viable K562+CD19+/number 
of viable K562+CD19- x 100). PBMCs stimulated with IL-2 100 u/ml only demonstrated a 48 
% cytotoxicity at an E:T ratio of 1:1 against K562-CD19+GFP+ targets again with minimal 
cytolysis of CD19-ve K562+GFP+ cells.  Though this assay, demonstrated that our 
transduction regime can lead to detectable cytotoxicity of CD19+ targets, the level of 
cytotoxicity was disappointing. In order to maximize cytotoxicity in the transduced fractions, 
in future experiments we plan to flow cytometrically sort the CD3+/antiFc+ cells to enrich for 
transduced PBMCs and repeat the assay. 
 
An alternative assay to detect cytotoxicity is the granzyme B ELISPOT, which has been 
reported to be more sensitive than the 51Cr assay.171 Thus, CD19/pHR-SIN-SE transduced and 
mock transduced PBMCs were co cultured with CD19+/- targets and cytotoxicity was detected 
using the ELISPOT assay, as described in Methods. The transduction efficiency was 34.3 % 
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Figure 55: CD19ζ Transduced PBMCs secrete Granzyme B in Response to CD19+ Targets. 
Normal donor PBMCs were cultured in media supplemented with IL-2 100 u/ml and on day 4 concentrated 
CD19/pHR-SIN-SE lentiviral supernatant was added. On day 8, the transduced and mock transduced PBMCs 
were cultured with CD19+/- targets in a granzyme B ELISPOT. (n=1) 
 
As shown in Fig  45, transduced PBMCs demonstrated granzyme B release in response to 
K562 CD19+ (68 SFC/2 x 105 PBMCs) but only background levels in response to K562 
CD19- ve targets (3 SFC/2 x 105 PBMCs). Similarly, tranduced PBMCs showed enhanced 
granzyme B responses compared with mock transduced PBMCs to autologous LCL (130 vs. 4 
SFC respectively for transduced and mock transduced) and HLA mismatched allogeneic LCLs 
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(138 vs. 51 SFC for transduced and mock transduced respectively). The response of mock 
transduced PBMCs to HLA mismatched LCLs is likely to reflect an alloreactive T cell 
responses, which is augmented in transduced PBMCs through recognition of CD19. 
Transduced PBMCs also demonstrated enhanced granzyme B response to Ramos cells, an 
EBV- CD19+ Burkitt’s lymphoma cell line (138 vs. 8 SFC for transduced and mock 
transduced respectively). Thus, as the granzyme B ELISPOT was able to specifically and 
sensitively detect cytotoxicity elicited by transduced T cells, we then used this assay and the 
IFNγ ELISPOT assay to detect anti tumour responses elicited by transduced allodepleted 
PBMCs. 
 
Enhancement of Anti-leukaemic Activity of Allodepleted PBMCs 
 
In order to enhance the anti leukemic activity of allodepleted PBMCs against B-cell 
malignancies, CD25/71 allodepleted donor T cells from 6 HLA- mismatched normal donor-
recipient pairs were transduced with the CD19R/ pHR –SIN-SE lentivirus (MOI 150) using a 
method  (prestimulation with IL-2 100 u/ml ) which has been shown to preserve the phenotype 
and anti-viral immunity of transduced T-cells.107,170 The mean transduction efficiency was 19.6 
%± 6.4. A representative FACS plot of transduced and mock transduced allodepleted T-cells is 
shown in Fig 46. Unselected transduced CD25/71 allodepleted donor T-cells were then used as 
effectors in IFNγ and granzyme B ELISPOT assays. We observed that CD19/pHR-SIN-SE 
transduced allodepleted T-cells compared to mock transduced cells, secreted significantly 
more IFN-γ (Figure 47a) and granzyme B (Figure 47b) following stimulation with CD19+ 
tumor cell lines (K562-CD19 and Ramos, both p <0.05), autologous and allogeneic LCL (p 
<0.05) and 1o blasts from 4 patients with ALL (p<0.05). Transduced CD25/71 allodepleted 
donor T-cells showed no significant IFN-γ and granzyme B secretion to CD19-ve targets (K562 
or K562-GFP). These results indicate that allodepleted T cells can be redirected to recognise 
leukaemic targets through lentiviral chimeric TCR transfer. 
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Figure 57: Representative FACS plot demonstrating transduction of allodepleted T-cells 
with CD19R/ pHR –SIN-SE lentiviral construct 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 59 : Transduced Allodepleted PBMCs demonstrate CD19 specific cytotoxicity and 
cytokine release.(a) CD19R/ pHR –SIN-SE Transduced CD25/71 allodepleted PBMCs demonstrate 
significantly enhanced Granzyme B secretion to CD19+ targets(n=6)  CD19R transduced or mock transduced 
CD25/71 allodepleted PBMCs were cultured with CD19+/- targets in a granzyme B ELISPOT assay. Transduced 
allodepleted PBMCs showed significantly enhanced granzyme B secretion to autologous and allogeneic LCLs, 
K562 cells stably transduced with a GFP-CD19+ transgene, Ramos, and 1º ALL blasts (* p<0.05) compared to 
mock transduced (Mean ± SEM) (b) CD19R/ pHR –SIN-SE transduced CD25/71 allodepleted PBMCs 
demonstrate significantly enhanced IFNγ secretion to CD19+ targets. (n=6)  CD19R transduced or mock 
transduced CD25/71 allodepleted PBMCs were cultured with CD19+/- targets in an IFNγ ELISPOT assay. 
Transduced allodepleted PBMCs showed significantly enhanced IFNγ secretion to autologous and allogeneic 
LCLs, K562 cells stably transduced with a GFP-CD19+ transgene, Ramos, and 1º ALL blasts (* p<0.05) 
compared to mock transduced (Mean ± SEM) 
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Conclusion 
 
Leukaemic relapse is a major cause of mortality post haploidentical transplantation.8,141 While 
unmanipulated donor lymphocyte infusion (DLI), may have some role in preventing relapse in 
patients who become mixed chimeras post-SCT,172  this approach is ineffective in frank 
relapse.173 To enhance anti-leukaemic responses of DLI, some investigators have repeatedly 
stimulated donor PBMCs with host ALL blasts to generate tumour CTLs which have been 
infused post haploidentical transplantation. These CTLs however, still show significant host 
reactivity. 174 
 
The advantages of our approach are that over 90 % of alloreactive T-cells have been deleted, 
thus minimizing the risk of GVHD, and that a much higher proportion of transferred T-cells 
will recognize leukaemic targets following chimeric TCR transfer. We have demonstrated 
efficient transduction of allodepleted T-cells with a lentiviral CD19 chTCR construct using a 
regime incorporating IL-2 100 u/ml only. Furthermore, we then demonstrated that these 
transduced allodepleted T-cells have significantly enhanced granzyme B release and IFNγ 
release to CD19+ targets compared to mock transduced allodepleted donor T-cells. The degree 
of cytokine secretion to LCLs was considerably higher than to primary ALL blasts and Ramos 
cells. This may reflect the high expression of CD80 and CD86 on the LCLs, and the 
corresponding lack of co-stimulatory ligands on Ramos and primary ALL blasts. 175,176 The 
levels of cytotoxicity we observed after transduction of the CD25/71 allodepleted donor T- 
cells, is somewhat lower than that reported after retroviral transduction of normal donor T-
cells with CD19ζ constructs using OT3/CD28 stimulation.150,153 This may reflect that our 
transduction regime resulted in predominantly naïve T-cells being transduced, which lack 
cytolytic activity. However, lentiviral transduction may be associated with a lower risk of 
insertional mutagenesis,161 and  our transduction regimen has been shown to maintain the 
phenotype of T-cells, as well as preserve anti-viral immunity and third party activity.107,170 
Clearly, it will be important to confirm this is true of CD19 chTCR transduced allodepleted T- 
cells in future studies. 
 
Furthermore, though highly differentiated tumours CTLs demonstrate potent in vitro 
cytotoxicity, they have considerably less in vivo efficacy. 93,155  It is unclear how many 
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allodepleted donor T-cells would be required to confer clinically relevant anti-leukaemic 
responses in the haploidentical setting: because of the possibility of allorestricted responses, 
this may in fact be considerably lower than the numbers of DLI required to induce GVL after 
HLA-matched SCT. Because of the limitations of experimental models, it may be that this 
question can only be answered in a clinical study. 
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Chapter 7 
 
 
Discussion
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Discussion 
 
 
Interest in BMT from haploidentical donors arises from the immediate availability of a one 
haplotype-mismatched donor for virtually all patients, particularly those who urgently need 
transplantation. In the international registries the probability of finding a matched unrelated 
donor (MUD) ranges from 10% in poorly represented ethnic groups to 60% in Caucasians,1 so 
that the only feasible option in many cases is a haploidentical transplant. However, to avoid 
GVHD, grafts are T-cells depleted leading to a profound delay in T-cell reconstitution. This 
delay in T-cell reconstitution is exacerbated by thymic dysfunction induced by chemo 
radiotherapy and the occurrence of GVHD and its treatment. This predisposes to a high risk of 
mortality from relapse and infection especially from adenovirus. There have been numerous 
approaches to improving immune reconstitution after haplo-SCT such as allodepletion, RIC 
after CD3/19 depletion, transduction of donor T-cells with a suicide gene and ex vivo induction 
of anergy to alloantigens with CTLA-4 Ig. Allodepletion strategies selectively deplete 
alloreactive T-cells after ex vivo stimulation of donor lymphocytes in an allogeneic mixed 
lymphocyte reaction (MLR) and to adoptively transfer the residual allodepleted donor T-cells. 
Strategies for depletion of activated alloreactive donor T cells include negative selection of 
donor T cells expressing activation markers (e.g. CD25, CD69, CD134, CD137, CD147, HLA-
DR) 114-118 59,122,177, using immunotoxins or immunomagnetic selection, fluorescence activated 
cell sorting18,24,killing activated T-cells by photodynamic purging52,140,178chemotherapy agents,  
120 or inducing Fas mediated apoptosis.119  
 
Allodepletion has numerous advantages compared to other techniques used to enhance 
immune reconstitution after haplo-SCT.  Compared to transfer of antigen-specific CTL 
88,94,98,100, it augments cellular immunity to multiple pathogens and reduces the risk of GVHD 
in the HLA-mismatched setting. Adoptive transfer of donor T-cells transduced with a suicide 
gene in the haplo-SCT requires transduction with integrating viral vectors with the attendant 
complex regulatory requirements. Suicide genes may be ‘leaky’ with basal toxicity (e.g. 
icaspase 9110 , and truncated CD20179) and immunogenic (e.g. HSV-TK104,180). Most 
importantly, in vitro studies suggest that the transduction process affects desirable anti-viral 
reponses.27,107,132  
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Ex vivo induction of anergy may have negative regulatory effects on desirable T-cell 
responses; indeed, in the only clinical study of this approach to date91, no data was provided on 
recovery of immune responses to pathogens and a high rate of infection related mortality was 
observed. Further until very recently, clinical grade antibodies to induce co-stimulatory 
blockade were not available. Chen et al 10have observed more rapid immune reconstitution 
after reduced intensity conditioning and CD3/19 negative selection of the graft compared with 
conventional intensity CD34 positively-selected haplo-SCT. In this approach larger doses of 
residual T-cell doses (~105 CD3/kg) are infused with the graft as well as a multitude of 
accessory cells. However, this was associated with a 36% incidence of significant aGVHD. 
Further, while T-cell reconstitution appears improved compared to CD34-selected haplo-SCT, 
it remained slower than that observed with our previous study of adoptive transfer of 
allodepleted T-cells at 3 x 105/kg (median circulating T-cells at 3 months post-SCT 350/µL vs. 
616 /µL) and there was no assessment of anti-viral immunity. The increased T-cell 
reconstitution after RIC CD3/19 haplo-SCT may reflect increased proliferation of alloreactive 
T-cells in the patients who developed GVHD. No assessment of T-cell reconstitution in 
patients without GVHD was done. Thus, allodepletion offers a safer, more effective way of 
improving T-cell immunity after haplo-SCT. 
 
At present clinical trials of immunotherapy with allodepleted donor T-cells have focused on 
CD25-based approaches. We and others86,122 have demonstrated that allodepletion using a 
CD25 immunotoxin RFT5-SMPT-dgA (IT) specifically deletes host-reactive T-cell responses 
with preservation of anti-viral and anti-leukemic responses. Andre-Schmutz et al first showed 
that adoptive transfer of allodepleted donor T-cells generated using this IT after HLA-
mismatched SCT was safe and feasible138. Only 2/15 patients developed significant aGVHD 
and this correlated with the residual proliferative response to host in 1o MLR. Solomon et al. 
have adoptively transferred larger doses of allodepleted donor T-cells generated using a similar 
approach in 16 adults transplanted from HLA-matched sibling donors139. Despite 
allodepletion, grade II-IV GVHD was observed in 46 % of patients and was inversely 
associated with the efficacy of allodepletion. These patients showed good recovery of T-
regulatory cells140, so that GVHD is likely to reflect insufficient removal of alloreactive T 
cells, rather than deletion of T-regs.   
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With our collaborators, our group compared immune reconstitution after adoptive 
immunotherapy with 2 doses of allodepleted donor T-cells generated using CD25 IT in 16 
paediatric patients after haplo-SCT141. We demonstrated that transfer of allodepleted donor T- 
cells at a dose of 3 x 105/kg accelerated T-cell reconstitution and recovery of CMV and EBV-
specific immunity. However, the rate of leukemic relapse rate was high, resulting in an overall 
survival of only 5/16. This may be explained by the high-risk nature of this patient group and 
the low precursor frequency of leukaemia-reactive T-cells within the infused allodepleted 
donor T-cells. Additionally, 2 patients died of adenovirus associated complications, including 
1 who had persistent adenoviraemia despite 3 infusions of allodepleted donor T cells at 105/kg, 
which cleared after a single infusion at 2.5 x 106/kg. Importantly, no patient had detectable T-
cell responses to this virus before 9 months post-SCT. These data suggest that larger doses of 
allodepleted donor T-cells may be necessary to confer protective responses to pathogens such 
as adenovirus which evoke low frequency T-cell responses in the donor 102and for a graft-
versus-leukaemia (GVL) effect. While the incidence of significant acute and chronic GVHD 
was low in our clinical study, this was nonetheless observed in 2 cases, raising concerns about 
the safety of administering larger doses of allodepleted donor T cells in the haploidentical 
setting, particularly as our in vitro data indicates that significant residual alloreactivity persists 
after CD25 IT mediated allodepletion125. There is thus a pressing need to enhance the degree 
of depletion of alloreactive T-cells, to enable add back of sufficient T-cells for protective anti-
leukemic and anti-infective responses without causing GVHD.  
 
Activated T-cells express a variety of surface markers, including CD25, CD69, CD71, CD95, 
CD137, CD147, OX40, ICOS, HLA-DR, and secrete Th1 cytokines IL-2 and IFN-γ. As such, a 
plethora of potential targets and methods now exist for allodepletion strategies59,114-118 but 
there is no data on the relative expression of these targets on alloreactive T-cells to enable 
identification of the optimal targets for allodepletion. The data above imply that a significant 
minority of alloreactive T-cells are retained after CD25-based allodepletion, suggesting that 
CD25 may be expressed only in a subset of alloreactive T-cells and raising the possibility that 
targeting other molecules, perhaps in combination with CD25, could enhance allodepletion. In 
order to rationally design strategies for enhanced allodepletion, we systematically 
characterized the phenotype of alloreactive T-cells. While alloreactive T-cells have multiple 
phenotypes, proliferation in response to alloantigens is their most basic hallmark. We have 
identified proliferating alloreactive T-cells using carboxyfluorescein diacetate succinmidyl 
ester (CFSE) dye dilution. Godfrey et al24 have shown that flow cytometric depletion of 
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CFSE-dim T-cells almost completely abrogates in vitro alloreactivity in secondary MLRs and 
markedly reduces GVHD in an MHC Class II disparate murine model. While it is not practical 
to use this approach clinically, we used this method to systematically characterize the 
expression of cytokines, effector molecules and activation markers on proliferating 
alloreactive T cells. CFSE labelling is easier than alternative measurements of T-cell 
proliferation e.g. Ki67, BrDU which require cell fixation, and enables elucidation of the 
precursor frequency of dividing cells to be determined. 
 
 
Measurement of Alloreactivity 
 
Following depletion of alloreactive T-cells, there are currently a multitude of assays to 
determine residual alloreactivity. The lack of a standardised read out for measuring residual 
alloreactivity in this setting remains a significant problem, hindering comparisons between 
different methods of allodepletion. We have used a number of assays including flow cytometry 
to assess residual percentages of CD3+25/71+cells, primary MLRs, and delayed restimulation 
with host/3rd party antigen presenting cells in  IFNγ ELISPOT and bulk 2º MLR assays. 
 
Each of these assays has its own strengths and weaknesses. If allodepletion involves deleting 
cells expressing given surface markers(s), then while flow cytometry on the allodepleted 
fraction gives information as to the efficacy of depletion, it tells nothing about the persistence 
or otherwise of alloreactive T cells that do not express this marker(s). Thus, as such assays, 
examine only a single targeted phenotypic marker at a single time-point, as a general principle, 
it is preferable to assay an alternative phenotype to the method used for depletion. Further, the 
assay, used to estimate residual alloreactivity should detect as broad an array of alloreactive T-
cells as possible, rather than focussing on phenotypes expressed by only a minority of 
alloreactive-T-cells. Thus, we believe that multiple assays, are necessary and that, for instance, 
given that proliferation in response to alloantigen is almost a universal hallmark of 
alloreactivity, proliferation based assays are preferable to those assaying narrower alloreactive 
T-cells subsets, including LDA- based cytotoxicity114 and granzyme assays135,assays 
measuring the expression of individual markers or release of cytokines e.g. IFNγ59,125  in 
response to alloantigeneic stimuli, which may significantly underestimate residual 
alloreactivity.  
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2º IFNγ ELISPOTS are easy to perform, reproducible, but only examine a subset of the 
alloreactive response (CD4 TH1/ CD8 memory + effector). Our own data also showed that 
only a minority of proliferating alloreactive T-cells secrete IFNγ.  Using this assay, Amrolia et 
al demonstrated that allodepletion using CD25IT led to a median 17 fold reduction in residual 
alloreactivity125, whilst Wehler et al showed a 10 fold reduction after CD137 allodepletion 
compared to unmanipulated PBMCs59. The IFNγ ELISPOT is quantitative, and our data 
suggests that it correlates with the 2º MLR, though the levels of depletion are less. However, 
unmanipulated PBMCs show a poor response to allo PBMCs, thus they require allo LCLs as 
secondary stimulators. Furthermore, if PBMC/DCs are used as 1º stimulators, the allodepleted 
PBMCs will secrete IFNγ in response to the shared haplotype upon secondary restimulation 
leading to a spuriously elevated response. 
 
Proliferation remains the key hallmark of an alloreactive T-cell, and for alloreactive T-cell to 
cause clinical sequelae would probably require them to proliferate. MLRs examine both CD4 
and CD8 proliferative responses to host, but are highly variable. Residual proliferation greater 
than 1 % in the 1º MLR correlated with GVHD in the Paris allodepletion study138, but they are 
insensitive. The 2º MLR is more sensitive, but we have found results to be highly dependent 
on the timing of the 2º stimulation in relation to allodepletion with negligible responses if 
restimulation was done immediately after depletion. We found bulk 2º MLRs are more 
sensitive if the cells are rested after allodepletion and therefore used a delayed 2ºMLR to skew 
our assays in order to detect residual alloreactivity.. There have also been a variety of controls 
used in 2º MLRs: we believe thawed unmanipulated PBMCs to be the most appropriate control 
to compare allodepleted fractions with. In contrast, others have used  sensitized activated 
PBMCs.115,178 Clearly, however, the 2º MLR is not quantitative and there is no data correlating 
this assay following allodepletion with GVHD after transfer of allodepleted T-cells clinically. 
 
An alternative assay of residual alloreactivity is the limiting dilutional assay (LDA). This assay 
determines the frequency at limiting dilution of T-cell progenitors capable of generating an 
interleukin-2 (IL-2)–producing (T-helper) clone (HTLp assays), cytotoxic responses (CTLp) or 
colony formation in response to a given stimulator. LDAs are sensitive, but they are time 
consuming to perform, subjective to analyse, semi quantitative and are complicated by wide 
confidence intervals, which may obscure significant changes. Furthermore, cytotoxic 
responses (CD8 CTL)60 and IL-2 secretion (CD4 Helper)  (as evidenced by our own data Fig 
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17) are expressed only in a minority of alloreactive T cells. Cavazzana-Calvo et al 
demonstrated a 1-1.6 log reduction in CTLp114 frequencies and  Solomon et al139 demonstrated 
a median 5 fold reduction in HTLp frequencies after CD25IT based allodepletion. The HTLp 
assay showed poor correlation with the onset of GVHD in their clinical study in the matched 
sibling setting. Nevertheless, failure of CD25IT allodepletion as indicated by their HTLp assay 
led to severe visceral GVHD.  
 
 
Clearly, then we need standardised methodology to measure residual alloreactivity and hence 
facilitate comparison between allodepletion methods. None of the existing techniques has been 
proven to correlate clinically with GVHD. We chose to use a combination of primary MLRs 
(which whilst insensitive, were associated with GVHD in the study of Andre- Schmutz et al 
138) delayed bulk 2º proliferation assays, which probably capture most residual alloreactive T- 
cells, and IFNγ ELISPOTS assays, to assay a different phenotype of residual alloreactive T- 
cells, acknowledging this is only expressed on a subset of such cells. We accept that such in 
vitro assays have not been shown to correlate clinically with GVHD. However, it could be 
argued that the absolute level of allodepletion may not be important if techniques show 
enhanced level of allodepletion compared to existing strategies (e.g. CD25 based) , which have 
been shown to be safe clinically, is not clear.  
 
Due to the lack of time, we were unable to assess the efficacy of our allodepletion approach in 
an animal model. The relevance of mouse models in assessing the potential for GVHD in 
humans after allodepletion is not clear. Animal models have been used by several groups to 
determine the potential for GVHD after adoptive immunotherapy.52,112 Chen et al 
demonstrated that despite showing significant in vitro alloreactivity after PDP treatment, 
adoptive immunotherapy with T-cell depleted bone marrow and PDP treated T-cells into a 
mismatched mouse model, did not lead to GVHD and prolonged survival compared to bone 
marrow alone.52 Hartwig et al, used a parent P→F1 model to examine CD95 based 
allodepletion (H-2k→H-2kd ) 119.  Using this model, they demonstrated  that adoptive transfer of 
CD95 deleted T-cells did not induce lethal GVHD, in contrast to primed T-cells, whereas 
significant in vitro alloreactivity persisted when this method used in vitro using human 
PBMCs. 128 Furthermore, animal models of allodepletion do have limitations reflecting 
differences between mouse and human T-cells. This is exemplified by the finding in mice that 
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alloreactive T-cells causing GVHD predominantly reside in the naïve T-cell compartment.28 
Our data, demonstrating in vitro alloreactivity in both CD45RA+ ve and –ve fractions, 
indicates that such clear delineation in humans does not seem likely. This highlights the need 
to use multiple read outs of residual alloreactivity. We have found that proliferative and 
cytokine responses to 2o  stimulation with host antigen presenting cells were highly dependent 
on the timing of 2o stimulation in relation to immunodepletion, with negligible responses if 
restimulation was done immediately after depletion. 125 We also examined proliferation in a 1º 
MLR and assessed the residual % of CD3+CD25+CD71+ after allodepletion by flow 
cytometry. 
 
In future studies, one potential approach to assess the in vivo efficacy of our CD25/71 
allodepletion approach in an animal model would be to use a parent→F1 T- cell transfer in H2 
mismatched mice: BALB/cJ mice (H-2d) would be bred with another strain C3H/HeJ (H-2k) to 
create  H2 hybrid mice. The F1 recipient mice can thus not evoke a host versus graft effect 
against parental T-cells, whereas parental T-cells will cause lethal GVHD in F1 mice. Donor 
(parent) mouse PBMCs would initially be co-cultured with the hybrid F1 mouse DCs. Clearly, 
we would need to confirm that CD25 and CD71 are up regulated on alloreactive mouse T- 
cells, as what is seen with human T-cells. This being the case, an immunomagnetic CD25/71 
allodepletion could be performed. The hybrid mouse could be lethally irradiated and T-cell 
depleted donor bone marrow with or without residual allodepleted donor mouse PBMCs could 
then be infused into the hybrid recipient. This mouse model would then assess GVHD across a 
MHC haplotype mismatch. Weight and signs of acute GVHD (diarrhoea, fur ruffling, and 
hunchback) in the mice could be assessed in the recipient mice over a 30-100 day period and if 
GVHD occurred, this could be confirmed histologically. Additionally, if donor T-cells were 
generated from transgenic mice constitutively expressing firefly luciferase, this would allow 
tracking of donor T-cells in the recipient mouse. To assess the efficacy of antiviral immunity, 
the recipient mouse could be injected with lymphocytic choriomeningitis virus (LCMV) as a 
surrogate for CMV infection or mouse adenovirus strain 1, to assess adenoviral immunity.181 
This model is limited by the fact that activation marker up regulation in mice may differ to that 
of humans. More importantly, the monoclonal antibody clones used to delete CD25+ and 
CD71+  mouse T-cells will have different avidity to that used against human CD25+/CD71+ 
T-cells, thus making it difficult to extrapolate results from a mouse model to that of humans 
even if transfer of CD25/71 allodepleted T-cells does not cause GVHD in mice. Thus, in 
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summary there are a multitude of assays used to determine residual alloreactivity. We have 
chosen to use several assays so that we can assay the diverse phenotypes of alloreactive T cells 
i.e. 1º +2º MLRs, FACS of activation markers and the 2º IFNγ ELISPOT assays.  
 
 
Phenotypic Characterisation of Proliferating Alloreactive T cells 
 
In order to design rational strategies to refine allodepletion, we systematically characterized 
the activation and cytokine marker profile in proliferating alloreactive T-cells. While 
alloreactive T-cells can be identified by a number of phenotypes, we focused on proliferation 
in response to alloantigen as the most fundamental. Thus, we co-cultured CFSE labelled T- 
cells with HLA mismatched DCs, and then tracked the proliferating CFSE dim T-cells using 
flow cytometry. Our data showed that CD25 was expressed in over 80 % and CD71 in 65 % of 
proliferating alloreactive T-cells on day 3 of MLR. In contrast, CD69, CD45RA, ICOS, OX40, 
CD95, HLA-DR, IL-2, IFN-γ, and TNF α were all expressed only in a minority of 
proliferating alloreactive T-cells, indicating that these are poor targets for allodepletion. Thus 
this validates our previous strategy of using CD25 as an allodepletion targets and identifies 
CD71 as a novel target. 
 
Whilst our data provide strong support for targeting CD25 in allodepletion strategies, in order 
to optimize our allodepletion strategy, we initially compared the effectiveness of CD25 
immunomagnetic depletion to that of CD25 IT. In 2 different assays we found no significant 
difference in residual alloreactivity to host between these methods, confirming similar findings 
found by other investigators.124 Clinical grade anti-CD25 immunomagnetic beads (Miltenyi 
Biotec) are now available, overcoming the limited availability of IT. Whilst our methods gave 
extremely effective depletion of CD25+ (<1%) and residual proliferation to host in primary 
MLRs was undetectable, significant residual alloreactivity to host was observed in secondary 
MLRs and ELISPOT assays. These residual responses are comparable to those seen by some 
investigators 59,115,118,139 but somewhat higher than reported by others using CD25 based 
114,122,177 and other allodepletion strategies178. However, as highlighted above, comparing 
residual alloreactivity between such studies is very difficult because of methodological 
differences.  A number of these studies are complicated by reliance in primary MLR122, the 
wide confidence intervals for CTLp and HTLp assays122,177,178 and by comparison of 
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alloreactivity with donor PBMC previously sensitized to the recipient rather than 
unmanipulated donor PBMC18,115,178. As noted previously, we have found that proliferative 
and cytokine responses to secondary stimulation with host antigen presenting cells were highly 
dependent on the timing of secondary stimulation in relation to immunodepletion, with 
negligible responses if restimulation was done immediately after depletion 125. In order to skew 
our assays to optimise detection of residual anti-host responses, in our assays, cells were rested 
for 2 days after allodepletion before restimulation. By resting the allodepleted PBMCs, 
alloreactive PBMCs that were not removed by CD25 allodepletion continue to proliferate over 
the course of the 2 days, so that they constitute a greater percentage at the time of the 
secondary assays.  Nevertheless, down regulation of CD25 before allodepletion, up regulation 
of this marker after day 3, and the presence of CD25-ve alloreactive T cells may also explain 
why there was significant residual alloreactivity. 
 
Our studies identified CD71 as strongly expressed on proliferating alloreactive T cells. CD71 
is homodimeric receptor (180 kDa) which allows internalization of iron-bound transferrin in 
clathrin-coated pits. In endosomal vesicles, iron is then released by compartment acidification 
(pH 5–5.5), while apo-transferrin and CD71 are recycled into the blood or to the cell surface, 
respectively.  CD71 is expressed on marrow stromal cells from bone marrow, on activated T 
and B lymphocytes, macrophages, and all proliferating cells. It is upregulated on lymphocytes 
during proliferative responses to antigens or mitogens but is not expressed on resting 
lymphocytes. CD71 is present on reticulocytes and erythroid progenitors in fetal liver, cord 
blood, and peripheral blood, yet it is lost as these differentiate to mature erythrocytes. CD71 
expression is strictly regulated by intracellular iron level: CD71 mRNA is stabilized and 
abundant in iron-deficient cells to increase extracellular iron uptake. This post-transcriptional 
regulation is allowed by the presence of iron responsive elements (IRE) in the 3'-untranslated 
region of the CD71 transcript that is recognized by two iron regulatory proteins. Our data is 
consistent with that of Nguyen et al. who demonstrated69 that there was strong up regulation of 
CD71 and CD25 on human alloreactive T-cells in an allo MLR, peaking on days 7-9, and that 
CD71 expression correlated with alloreactive T-cell proliferation. 70 The low level of CD71 
expression on resting lymphocytes and its up regulation in a MLR identify CD71 as an 
excellent novel target for allodepletion. Consistent with this, administration of anti CD71 
antibodies have been shown in mismatched mouse model to significantly prolong pancreatic 
islet graft survival71. Administration of gallium (which binds to transferrin, depriving 
 190
proliferating cells of iron) potently inhibited MLRs and prolonged survival in a mouse model 
of GVHD.72Additionally, stimulation of CD71 also promotes phosphorylation of the TCRζ 
complex and thus may amplify TCR signalling .182  The internal cycling of CD71 may allow 
this receptor to be targeted with a CD71 immuntoxin, like CD25. However, for simplicity in 
our studies, the combination of anti- CD71 biotin and anti-biotin magnetic beads was used to 
delete CD71+T cells. Furthermore, the peak of CD71 expression and the mean fluorescent 
intensity coincided with that of CD25 (Day 3 of allo MLR) enabling us to target both markers 
at the same time. 
CD69 is a well-established T-cell activation marker but was poorly expressed in the CFSE-dim 
population. This may in part reflect down regulation of CD69 by the time appreciable CFSE 
dye dilution has occurred (day 3 of MLR). However, CD69 showed more variable expression 
compared to CD25 and CD71 and has been noted to be upregulated in bystander cells 116,183, 
limiting the usefulness of this marker as a target for allodepletion. Recent studies suggest that 
alloreactivity may reside predominantly in the CD45RA+ naïve T-cell compartment29,33, at 
least in mouse studies. The expression of this marker  in our studies, on a minority of 
alloreactive T-cells and on bystander T-cells, as well as the progressive maturation of 
alloreactive T-cells to a memory phenotype during MLR suggest that targeting this molecule 
as a sole strategy for allodepletion is unlikely to be successful. Our data also showed that a 
minority of alloreactive T-cells (<5 %) express OX40 and TNFα, which is comparable to that 
seen by some investigators135, but lower than others.18,53 However, both the latter groups 
performed their MLRs in media supplemented in serum and/or used thawed cryopreserved 
stimulators, and therefore up regulation of these markers may reflect responses to bovine 
peptides presented in the context of human HLA molecules. Activation induced cell death is 
an important part of controlling T-cells responses, and this pathway has been targeted as a 
means of enhancing allodepletion.128 CD95 expression progressively increased over time, but 
on a minority of proliferating alloreactive T cells (mean of 27 % at day 7), again suggesting 
that simply targeting CD95 is likely to result in ineffective allodepletion, even if performed at 
late time points in the MLR.  
  
Rationally Enhancing CD25 based Allodepletion 
 
While our data confirm CD25 as an excellent target for allodepletion strategies, a mean of 17 
% of proliferating alloreactive T-cells do not express CD25.  Therefore, we studied the 
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phenotype of proliferating CFSE-dim T-cells not expressing CD25. We have identified CD71 
as a novel target that is highly expressed on proliferating alloreactive T-cells, including those 
not expressing CD25. We found that 70 % of the CFSE-dim CD25-ve population express 
CD71. Potentially, this enables us to target 2 independent phenotypes of alloreactive T-cells at 
the same time-point within a single co-culture. Flow cytometric analysis showed that 
immunomagnetic depletion deletes CD25+ and CD71+ cells to below background levels. In 
primary MLRs, residual responses to the stimulator were undetectable after CD25/71 
depletion. In 2 separate functional secondary stimulation assays measuring distinct 
phenotypes, the combination of CD25/71 allodepletion led to significantly enhanced and more 
consistent allodepletion compared to CD25 alone without compromising third party or anti-
viral responses. Furthermore, the combination of CD25/71allodepletion was superior to the 
immunomagentic depletion of CD25/45RA+ T cells.  Our studies indicate that combined 
CD25/71 depletion results in a 20-fold reduction of proliferating alloreactive T-cells flow 
cytometrically and in secondary MLRs, with a 1-log depletion of response to host in IFN-γ 
ELISPOT assays. While extrapolation of these results to an in vivo setting requires an animal 
model 127,184, the fact that allodepletion appears enhanced compared with CD25 depletion 
suggests that it may be possible to safely transfer larger doses of allodepleted donor T-cells 
than hitherto possible using combined CD25/71 depletion 
 
Our approach led to a 1-1.5 log reduction in residual alloreactivity in our assays without 
compromising third party responses. Comparison with other clinically applicable allodepletion 
strategies is difficult because of different methods used. To assay residual alloreactivity after 
photodynamic purging, Meilke et al observed a 4 log reduction in residual alloreactivity 
compared to unmanipulated PBMCs, but a 1 log reduction compared to untreated sensitized 
control co cultures in 2º MLRs.131 This appears counterintuitive and contrasts with our own 
experience, where untreated sensitized co-cultures demonstrate considerably enhanced 
responses upon secondary restimulation to the original host. The authors postulate however, 
that prior sensitization to host induces regulatory T-cells, thus diminishing anti host responses. 
Despite this, in their HTLp assays, the reduction in alloreactivity was less impressive with a 
median 20 fold reduction in responses to host. In contrast,  Chen et al using a similar 
photodyamic purging method rested their allodepleted PBMCs, and observed over a  6 fold  
higher IFNγ secretion to host in 2º IFNγ ELISPOT assays compared to unmanipulated 
PBMCs.52 This discrepancy highlights the difficulty of comparing similar methods of 
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allodepletion with different read outs of alloreactivity. Further, the need for specialized 
equipment for photodynamic purging of alloreactive T-cells limits the applicability of this 
technique, and the optimal protocol in terms of concentration of the sensitizing agent and 
timing of light exposure to achieve selective allodepletion are not fully established.  Perhaps, 
most importantly, in vitro data suggests that photodynamic purging significantly reduces anti-
viral/antifungal activity of the allodepleted donor T-cells. 132 This was reflected  in a clinical 
study of adoptive immunotherapy of PDP treated donor T cells in the haplo-SCT setting in 
which 3/11 patients developed chronic GVHD and there was a high incidence of infectious 
related mortality133. The lack of systematic examination of anti-viral immunity after PDP 
treatment highlights a possible flaw in this process. 
 
 There have been numerous other approaches to targeting alloreactive T-cells e.g. CD137, 
CD69, CD95, naïve T-cells, and chemotherapeutic methods. Wehler et al generated CD8+ 
CTLs against leukaemia/tumour antigens in the haplo setting using CD137 mediated 
allodepletion.59 They generated CTL cultures, by stimulating CD8+lymphocytes with single 
HLA mismatched AML blasts or renal carcinoma cells. 59 On Day 21 of the culture, the 
lymphocytes were stimulated with HLA-negative K562 cells transfected with the disparate 
HLA-Class 1 cDNAs. After 24 hours, the CD137 positive alloreactive T-cells were depleted 
using an immunomagnetic approach.  This study was limited by only showing data on 1 donor 
recipient pair in the haplo-setting and the complexity and time required for cell culture.  
Furthermore, there was still significant anti host reactivity after allodepletion in single antigen 
mismatched donor-recipient pairs allodepletion (1 log reduction in IFNγ ELISPOT compared 
to sensitized non depleted co-cultures), thus suggesting that this could lead to GVHD in the 
haplo-SCT setting. Our data demonstrate that CD69 is expressed only in a minority of 
alloreactive T-cells and that up regulation is much more variable than CD25 or CD71, which 
could potentially lead to inconsistent allodepletion. Moreover, allodepletion targeting CD69-
positive T-cells has been associated with significant reductions in EBV + /WT1+ T cells, 
suggesting that this marker shows significant bystander up regulation and is thus not specific 
to alloreactive T cells. 116 CD95 allodepletion  was associated with 25-45 % residual 
alloreactivity compared to sensitized PBMCs  on 2◦ IFN gamma ELISPOTs thus suggesting 
that this method of allodepletion leads to very high levels of residual alloreactivity,128 
particularly given our data showing that sensitized PBMCs show considerably enhanced 
responses compared to host, compared to thawed unmanipulated PBMCs.  Furthermore, CD95 
agonistic antibodies have led to haemorrhagic hepatitis in animal models and a GMP grade 
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CD95 antibody does not exist 129. There are no published data targeting naïve T-cell markers 
such as CD45RA in human T-cells. However, our data show that CD45RA is expressed on a 
much higher proportion of inactivated T-cells than CD25/71, so that targeting naive T-cells 
may lead to significant depletion of desirable naïve T-cells. Further, CD25/71 allodepletion 
was non significantly superior to CD25/45RA allodepletion,  
 
 
 
A number of groups investigating the use of chemotherapy during ex vivo MLR to selectively 
delete alloreactive T-cells.55,120,121,134-136 However, such an approach requires careful dose 
titration to prevent deleterious effects to bystander T-cells. Indeed, in preliminary dose titration 
experiments we performed (shown in Appendix), with fludarabine and trimetrexate, we found 
that the optimum dose for deleting proliferating T cells whilst preserving non proliferating T 
cells for trimetrexate was, 1µm and for fludarabine was 50ng/ml (Fig 48). At doses above 
these concentrations, there was significant loss of non proliferating T cells. Due to the expense 
of bortezomib, we chose the dose for bortezomib for our co cultures based on previous 
published data.55 We then co-cultured CFSE labelled T-cells with HLA mismatched DCs, and 
added trimetrexate 1µm on day 0, fludarabine at day 2 (50 ng/ml) and bortezomib (500nM) on 
days 1-3 of the co-culture (Fig 49). Our controls included CFSE + T-cells alone and a co- 
culture set up at the same time but without chemotherapy drugs. The cells were harvested on 
day 3 and stained by flow cytometry for CD3 and CD25. The percentage reduction in CFSE 
Dim alloreactive population (including CD25 negative) was then calculated using Trucount 
beads. The addition of Trucount beads enabled comparison between the different co-cultures 
as a fixed number of beads were acquired. Our data showed that at this concentration of 
bortezomib, there was a complete loss of CFSE bright bystander cells as well as the CFSE 
Dim alloreactive T- cells, thus highlighting the non selectivity of this drug at this 
concentration. The fludarabine did not significantly reduce the CFSE Dim alloreactive T-cell 
population compared to control (8.25 % reduction in  the CFSE Dim population), thus 
highlighting the limited efficacy of this drug at this concentration. The trimetrexate produced 
over 84 % reduction in CFSE Dim population, a 61 % reduction in the CFSE Dim CD25 
negative population and a 26 % reduction in the CFSE bright bystander population. Further 
careful timing of administration of chemotherapeutic agents would be necessary as delayed 
administration of bortezmib (5 days after BMT)  has exacerbated GVHD in a murine model137.  
Likewise, bortezomib exposure in an ex vivo MLR, led to major decreases in third party 
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activity, thus suggesting that this reagent may not selectively delete alloreactive T-cells. 55. 
There are no published data on preservation of antiviral-T cell responses following 
allodepletion with chemotherapeutic agents. Our data using chemotherapeutic agents to target 
proliferating alloreactive T-cells is preliminary and will require further work. 
 
Thus, whilst a host of potential methods, for allodepletion now exist, many of these target only 
a minority of alloreactive T-cells are difficult to scale-up for clinical use or have not been 
shown to preserve desirable T-cell responses. In contrast, combined CD25/71 
immunomagnetic depletion fulfils all these criteria. Ideally, however, comparisons between 
different methods of allodepletion require assessment of residual alloreactivity and 
preservation of anti-viral responses in the same donor-recipient pairs. We plan to perform such 
a comparison between CD25/71 allodepletion with photodynamic purging in collaboration 
with The Necker group in future studies. 
Graft versus host disease represents a fine balance between alloreactive effectors and T 
regulatory cells. CD25 based allodepletion strategies target T regulatory cells, but this has not 
led to enhanced rates of GVHD.  This probably reflects concomitant effective depletion of 
alloreactive T-cells. CD69 and CD95 allodepletion do not affect FoxP3 levels, and thus 
targeting these markers may preserve T regulatory T-cells.116,128 CD45RA is expressed on 
human T regulatory cells 185and thus targeting CD45RA is likely to delete T regulatory cells 
and could thus potentially exacerbate GVHD if significant numbers of alloreactive effectors 
persist. Similarly, photodynamic purging also led to a reduction in FoxP3 + T-cells. 131 It is 
currently not known if CD71 is expressed on human T regulatory T-cells, and we will need to 
assess this in future studies.  
 
Antiviral Immunity after Allodepletion 
 
If adoptive immunotherapy with allodepleted donor T-cells is to be useful in restoring anti-
viral and anti-leukemic T-cell responses clinically, it is critical to demonstrate the specificity of 
depletion. A number of in vitro studies on allodepletion have not adequately addressed the 
issue of whether anti-viral responses are preserved following allodepletion. Often such studies 
have relied on demonstration of preserved proliferative or CTLp responses to third party 
stimulators as surrogate markers for anti-viral T-cell responses in allodepleted donor T- 
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cells.117,118 In other studies, where anti-viral responses have been examined, these assays have 
frequently not been systematic, e.g. responses to key pathogens have not been assessed such as 
adenovirus 122, or analyses have been non-quantitative without comparison to unmanipulated 
PBMCs, or limited to a small numbers of donor recipient pairs,131 or using a single 
technique.128.  There remain doubts over whether functionally useful anti-viral immunity is 
preserved after allodepletion using photodynamic purging or after transducing donor T-cells 
with suicide genes. Similarly, anti-viral immune reconstitution has not been assessed after RIC 
haplo-SCT. 27,107,132 The persistence of anti-viral responses after selective allodepletion is vital 
to confer enhanced immune reconstitution to viral pathogens post haplo-SCT. We have used 
IFNγ ELISPOT and pentamer assays to compare the frequency of T-cells recognising all 3 
major viral pathogens post-SCT (CMV,EBV, and adenovirus),  before and after allodepletion. 
These assays have the advantage that they enable direct quantification of the frequency of 
viral-specific T cells. In 2 distinct assays, we showed preservation of T-cell responses to 
CMV/EBV and adenoviral antigens after CD25/71 allodepletion in numerous donor-recipient 
pairs. The persistence of EBV immunity after CD25/71 allodepletion, despite using EBV 
derived  LCLs as APCs, was due to the use of donor-recipient pairs who were completely 
HLA mismatched, so that donor T-cells cannot recognise the preserved EBV epitopes. In the 
haploidentical setting, we have previously shown that T-cell responses to EBV epitopes 
presented through the non shared haplotype are preserved following CD25-based 
allodepletion86 and we anticipate this will also be so with our refined methods. 
 
We did not examine the cytotoxicity of allodepleted T-cells against virally infected cells, as 
this would either require repetitive stimulation to generate CTL lines or limiting dilutional 
CTLp assays which are complicated by wide confidence intervals. In our previous clinical 
study141, we showed that transfer of 3 x 105/kg allodepleted T-cell was sufficient to confer 
detectable T-cell responses to EBV and CMV after haplo-SCT, particularly in the context of 
viral reactivation. This is line with the dose of unmanipulated DLI required to confer cell-
mediated immunity to CMV and EBV after HLA-matched SCT.186,187 Our refined CD25/71 
may now allow us to adoptively transfer sufficient T-cells to confer protective immunity to 
pathogens which evoke low frequency T-cell responses in the donor, such as adenovirus, 
which is the single most important cause of infectious death after haplo-SCT 168,169. Based on 
the precursor frequency of adenovirus-specific CTL in normal donor PBMC 188and limited 
clinical data from DLI141,189, we anticipate that cell doses of between 1- 5 x 106/kg T-cells may 
be sufficient for such immunity. Since CD25/71 allodepleted T-cells show significantly lower 
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residual alloreactivity than after CD25 based allodepletion, it may well now be possible to 
transfer such doses of allodepleted T-cells without causing GVHD. However, because of the 
limitations of in vitro assays and murine models outlines above, this can only be really 
assessed in the context of a further clinical study.  
 
There are numerous other approaches to improving anti-viral reconstitution post haplo-SCT. 
IFNγ capture can be used to generate either CMV or adenovirus specific CTLs in vitro, but 
this approach still leaves significant alloreactivity to host (1/2 log reduction in residual 
alloreactivity following generation of adenovirus specific CTLs).99 Even though the number of 
virus-specific T-cells generated is very low (typically 106 T-cell from 500 mls of blood) the 
occurrence of GVHD in MSD/MUD patients who received CMV and adenovirus specific 
CTLs generated by IFNγ capture at doses of only 103-104/kg, suggests that this technique is 
not completely specific 190, and there remains the possibility of significant GVHD in the 
haploidentical setting. Where MHC Class I restricted immunodominant epitopes have been 
determined (e.g. for CMV), it has been possible to isolate and adoptively transfer CD8+ virus-
specific T-cells using MHC-peptide multimers.98 However, it is unclear how durable such 
responses are in the absence of CD4 help (as would be the case early after haplo-SCT). 
Further, it is only applicable if the donor has one of the common Caucasian HLA Class I 
alleles (e.g. A2 or B7) and is of limited value for pathogens such as EBV which have a broader 
array of immunodominant antigens than CMV. Other approaches e.g. generation of 
virus/Aspergillus-specific CTL lines and clones101 by repetitive antigenic stimulation remain 
too complex and time consuming to broadly applicable, even when multiple viruses are 
targeted 102. By contrast, our allodepletion approach is simple, applicable to all HLA 
backgrounds, preserves CD4 and CD8 T-cell responses and show preserved T cell responses to 
pathogens recognised by the donor.  
 
One limitation of our approach was the lack of assessment to fungal pathogens e.g. 
Aspergillus. The immune response to Aspergillus involves both the innate immune system and 
TH1 responses191  and Aspergillus remains a major pathogen post haplo-SCT.101 The T-cell 
response to Aspergillus and Candidal antigens has so far been poorly defined and the 
immunodominant antigens are unknown, so that existing techniques for assessing cell-
mediated immunity with LDAs 132 ELISAs and proliferation assays.135,191 have utilised poorly 
characterised crude lysates from the conidial/hyphal stages. This limits our ability to test 
quantitatively how completely T-cell responses to fungal pathogens are preserved after 
 197
CD25/71 allodepletion but nonetheless we plan to assess proliferative responses to fungal and 
control lysates in future experiments.  
Enhancing Anti-leukaemia Activity of Allodepleted Donor T cells 
 
The persistence of anti-leukaemic responses after selective allodepletion is critical if the 
benefits of adoptive transfer are not to be offset by leukaemic relapse, as in our previous study 
141and other studies using CD25 immunotoxin based allodepletion: in our study, 6 out of 11 
patients with haematological malignancies relapsed, 3/5 in The Necker study138, and 4/10 in 
The NIH study139. Similarly, relapse remains a significant problem after CD3/19 RIC haplo-
SCT (12/29 patients), despite the infusion of higher numbers of alloreactive NK cells 9. Our 
approach will deplete T-cell responses against the mismatched HLA alleles and ubiquitous 
minor histocompatibility antigens presented by the shared HLA alleles. Nonetheless, we and 
others 86,122,142have shown that anti-leukaemic activity may be retained after allodepletion. In 
particular, we have demonstrated that T-cell responses to potential myeloid tumour antigens 
are preserved by virtue of their lack of expression on the LCL used as stimulators. Potentially, 
such T-cell responses could be augmented after transfer of allodepleted donor T-cells into 
HLA-A2+ve patients with myeloid malignancies by vaccination with WT-1 or PR-1 peptides85 
Likewise, allorestricted responses against tumour- associated antigens presented through the 
non-shared haplotype143-146 should also be retained. It is unclear how many allodepleted donor 
T-cells would be required to confer clinically relevant anti-leukaemic responses in the 
haploidentical setting: because of the extreme lymphodepleted environment after haplo-SCT  
and the possibility of allorestricted responses, this may in fact be considerably lower than the 
numbers of DLI required to induce GVL after HLA-matched SCT, where T-cell doses of 107-
108/kg are required.78,192,193 Because of the limitations of experimental models, it may be that 
this question can only be answered in a clinical study. The close association of GVHD and 
GVL, nevertheless, suggests that these are intrinsically related, and by deleting the alloreactive 
T-cells that cause GVHD, we may abrogate responses to leukaemia. Further, it remains 
possible that even with the enhanced depletion of alloreactivity achieved with CD25/71 
allodepletion, it may still not possible to safely transfer enough T-cells for anti-leukaemic 
responses without causing GVHD. In order to overcome these limitations and to enable 
allodepleted T-cells to confer anti-leukaemic responses even in ALL, which is a frequent 
indication for haplo-SCT, we investigated whether it was possible to redirect the specificity of 
the allodepleted donor T-cells using a chimeric T-cell receptor transfer. We have shown that 
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the anti-leukaemic activity of allodepleted T-cells can be augmented, by transfer of a chimeric 
TCR recognising the surface molecule CD19. 
 
 The approach of chTCR transfer has a number of advantages in targeting residual leukaemic 
cells after SCT; 
1) It overcomes the lack of immunogenic tumour antigens on ALL blasts by redirecting T 
cells to surface molecules expressed by malignant cells. This has been the major 
obstacle to immunotherapy for ALL. 
2) It should not cause GVHD, as CD19 is highly expressed on B-ALLs, but is not 
expressed on non-haematopoietic cells. 
3) It enables targeting of tumour cells in a HLA-independent fashion, so that a single 
vector system can be used to treat all patients expressing this surface molecule 
4) It overcomes mechanisms by which leukaemic cells escape from T-cell recognition, 
including down regulation of HLA class I molecules or defects in antigen processing 
which may hinder alternative methods of enhancing anti-leukaemic activity of T cells 
e.g. TCR gene transfer. 
 
Redirected T-cells can also home to tumour sites, proliferate locally, and penetrate solid 
tumours.  
 
We investigated if lentiviral transfer of a chimeric TCR directed against CD19 could be used 
to redirect the specificity of allodepleted donor T-cells so that they recognize this malignancy. 
Previous studies have demonstrated that human T-cells expressing similar CD19 chimeric 
TCRs mediate regression of B-lineage malignancies in murine models 152,156. To preserve their 
phenotype and anti-viral specificity, we used a lentiviral vector and transduced allodepleted T- 
cells after stimulation with IL-2 alone rather than with mitogens. This regimen has been 
demonstrated to preserve the phenotype of naïve PBMCs, and not compromise anti-viral/third 
party activity.107,170 Due to a shortage of time we were unable to assess formally if anti-viral 
immunity is maintained with our CD19R/pHR-SIN-SE lentiviral vector. Potentially, this could 
be done using pentamer and IFNγ ELISPOT assays. As the transduced allodepleted donor T- 
cells recognize CD19 expressing B-cells, CMV (pp65) peptide mix-pulsed or adenovirally 
transduced autologous CD14+ monocytes rather than PBMCs could be used for such 
experiments. Further experiments to determine the phenotype of the transduced allodepleted 
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donor T cells (CD4/CD8, CD45RA, CD45RO, CD62L) after transduction will also be 
required. 
 
 
The levels of cytotoxicity we observed with CD19-redirected allodepleted donor T-cells, was 
lower than that reported with retrovirally transduced T-cells expressing the CD19ζ transgene. 
150,153 This may reflect the fact that our transduction regimen resulted in predominantly naïve 
T- cells being transduced, which lack cytolytic activity. However, as outlined above, our 
transduction may be associated with a lower risk of activation induced cell death ,161 and may 
preserve anti-viral responses of our transduced cells 107,170, whereas, transduction regimens 
using OKT3/CD28 promote differentiation and activation of naïve PBMCs into terminally 
differentiated CTLs.156,194 T-cells transduced after polyclonal stimulation, despite 
demonstrating potent in vitro activity, may have reduced in vivo activity because of cytokine 
dependence, activation induced cell death, and reduced capacity to home to tumour sites, 
proliferate and resist apoptosis. In contrast, naïve PBMCs have shown superior anti tumour 
activity than terminally differentiated CTLs in mouse models, partly due to higher co- 
expression of CD62L.155 Furthermore, transfer of low doses of antigen specific T-cells has led 
to their dramatic expansion post haplo-SCT in response to their cognate antigen.101,141 Thus, it 
is possible CD19-redirected allodepleted donor T- cells could rapidly expand in vivo when 
administered to lymphopenic patients not receiving immunosuppressive medication for GvHD 
prophylaxis. The addition of a CD28 co-stimulatory domain to the CD19ζ construct would 
increase IL-2 secretion, and enhance persistence, but there is no evidence to suggest that such 
a domain would enhance cytotoxicity.194 However, the addition of a CD28 co-stimulatory 
domain enhances the risk of autonomous proliferation and the addition of a suicide gene to 
such constructs may be required by the regulatory agencies as an additional safety measure.   
 
Potentially we could compare CD19ζ constructs with and without CD28 co-stimulatory 
domains by assessing IFNγ, granzyme B secretion and proliferation of CD19ζ transduced and 
CD19/CD28ζ transduced allodepleted T cells to CD19+ targets, to determine if using 
constructs which have CD28 co-stimulatory enhance proliferation and cytokine release. 
Further comparisons between different CD19 chTCRs would be also useful: e.g. comparison 
between a fully humanised anti CD19 chTCR195 and the existing FMC63 ScFv receptor. A 
fully humanised CD19chTCR (in contrast to FMC63 where the ScFv is murine), would have 
 200
the advantage of being less immunogenic and may therefore enhance the survival of 
transduced allodepleted T-cells in vivo.  
 
 
There are numerous potential approaches to measuring anti-leukaemic activity of allodepleted 
donor T cells. Although the  51Cr cytotoxicity remains the gold standard, various alternative 
assays have been developed, such as the granzyme B ELISPOT assay.171 In direct comparisons 
of the granzyme B ELISPOT, and the 51Cr cytotoxicity, the results have correlated well 
between the two.171 Furthermore, the granzyme B ELISPOT assay is non radioactive and 
granzyme B is a molecule that is released upon CTL mediated killing.196 While granzyme B 
activity may underestimate cytotoxicity, as it does not measure FasL mediated apoptosis, this 
is equally true of the 51Cr release assays. Furthermore, it is well established that only a small 
fraction of antigen-specific T-cells secrete cytokines in response to their cognate antigen at a 
given time point. This explains why despite 19 % of allodepleted T-cells being transduced 
with the CD19ζ transgene, only 0.2 % of transduced allodepleted cells secreted IFNγ in 
response to primary ALL blasts, and 0.4 % secreted IFNγ in response to autologous LCLs. On 
the other hand, CTLs may degranulate normally, but certain targets may be inherently resistant 
to their effects. Thus, to be certain that degranulation is inducing target cell death, cytotoxicity 
assays should be performed alongside the granzyme B ELISPOT.  
 
We plan to FACS sort our transduced allodepleted donor T-cells and assess cytotoxicity 
against CD19+ targets either in a conventional 51Cr release assay or with a FACS based 
cytotoxicity assay. In the latter approach, FACS cell sorted (CD3+, α Fc+) transduced and 
mock transduced allodepleted T-cells would be co-cultured with an equal number of CD19+/- 
targets such as Daudi, SUP-B15 and HSB-2 using a target: effector ratio of 1:1. After a week 
cells would be stained with 7 AA-D, CD19 and trucount counting beads added. A fixed 
number of beads would be acquired and the number of viable CD19+/- targets would then be 
determined in each co-culture. We anticipate that CD19ζ transduced allodepleted T-cells 
would lyse CD19+ ve but not –ve targets.  Irradiated donor LCLs could also be added to co- 
cultures to promote co-stimulation 
 
An alternative means of assessing anti-leukaemic activity is with MHC-peptide multimers to 
detect T-cells recognising leukaemia-associated antigens. Amrolia et al demonstrated that 
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proteinase 1 (PR1 +)  T cells were maintained after allodepletion with CD25 IT whilst using 
LCLs as APCs using tetramer studies 86 Likewise, it is possible to detect CD8+ ve T cells 
recognising the PR1 epitope of proteinase 3 in patients with myeloid malignancies.83,85 
Unfortunately, while we predict T-cell directed against myeloid leukaemia associated antigens 
should similarly be preserved following CD25/71 allodepletion by virtue of their lack of 
expression on LCL stimulators, we were unable to obtain patient samples with detectable 
WT1+ or PR1+ T-cells to determine if our refined allodepletion method affects the frequency 
of such T-cells. Potentially, we could co-culture PBMCs from HLA-A 0201+ve donors who 
have detectable CD8+ WT1+/PR1+ T cells, with HLA- A2+  mismatched LCLs and compare 
the frequency of CD8+ WT1+/PR1+ T cells in unmanipulated PBMCs and CD25/71 
allodepleted T-cells flow cytometrically with WT1/PR-1 specific multimers. 
 
 
Whilst tetramer studies, enable the size of a particular population to be determined and are 
restricted to defined antigens, they do not give functional data. A number of groups have used 
LDA based assays to assess functional responses to leukaemic blasts. For example, Mavroudis 
et al 142 demonstrated preserved HTLp responses to myeloid tumours after allodepletion using 
a CD25 immunotoxin, and Montagna et al 122 showed preserved CTLp responses to leukaemic 
blasts after a similar approach. As highlighted previously, these data are complicated by the 
indirect nature of the CTLp and HTLp assays, which involve in vitro restimulation, as well as 
by the wide confidence intervals for these assays, which may obscure significant changes. The 
rationale for using the HTLp assay (which depends on donor CD4+ T cells) to measure a GVL 
effect rests on accumulating evidence implicating CD4+ T cells in the alloresponse to CML.142  
In experimental studies, CD4+ cells inhibit leukaemia growth and are cytotoxic to myeloid 
leukaemia cells. Although HTLp assays may correlate with GVL reactivity, they do not 
directly measure a cytotoxic effector function against leukaemia. Similarly, our IFNγ 
ELISPOT assays with CD19ζ transduced allodepleted T-cells give us information primarily 
about CD4+ GVL responses, but not directly about cytotoxicity. Nevertheless, in vivo studies 
suggest that CD4+ T cells may play a critical role in tumor rejection via cross presentation of 
tumor antigens, and such T helper assistance may be of vital assistance in eradicating 
malignancies.197  
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The anti-leukaemic effects of CD19ζ transduced allodepleted donor T-cells needs to be tested 
in an animal model prior to scale up studies. One possibility is to test this approach using 
allodepleted mouse T-cells in a MHC mismatched mouse with a subcutaneous B-cell 
lymphoma, as has been done following administration of donor T cells and  T regs 112, 
administration of PDP treated T cells52 and fludarabine treated DLI120. However, the relevance 
of such models is unclear, as responses in such models are frequently more impressive than 
clinical responses e.g. to DLI. Further, such experiments would require the use of anti-mouse 
CD25/71 mouse antibodies which may well have different avidities to their anti-human 
counterparts, so that it is very difficult to extrapolate from such models. An alternative model 
is to use a xenogeneic approach in an immunodeficient mouse models e.g. NOD/SCID mouse 
which has been irradiated and then injected subcutaneously with a human 
lymphoma/leukaemia cell line. Such models have previously been used successfully to 
demonstrate the anti-leukaemic effect of T-cells retrovirally transduced with a chimeric TCR 
against CD19.152,176 Large doses of transduced donor T-cells expanded ex vivo in the presence 
of IL-15 were required to mediate regression of Raji cell tumors and data on long term 
persistence of transduced T-cells is lacking. Further, clearly such models do not mimic the 
localization of leukaemia to the bone marrow. Despite these limitations, this model remains 
the best available to evaluate anti tumor adoptive immunotherapy in vivo.  In future studies, we 
will evaluate the anti- leukaemic activity of CD19ζ transduced allodepleted donor T cells in a  
Rag I/II deficient, γ chain deficient, C5 deficient NOD/SCID mouse model. Mice would be 
irradiated and then be subcutaneously injected with a variety of human tumours e.g. primary 
human ALL blasts, Ramos cells, and LCLs.  Human CD19 ζ transduced and mock transduced 
allodepleted T cells could then be infused and survival and tumour growth could be 
documented. Tumour cells could also be labelled with luciferase using a retroviral vector and 
in vivo imaging performed following administration of ζCD19 transduced/mock transduced 
allodepleted donor T cells to determine if transduced allodepleted T-cells mediate tumour 
regression. 
 
CD19R/ pHR –SIN-SE transduced allodepleted donor T cells efficiently secreted IFN-γ and 
the cytolytic effector molecule granzyme B in response to CD19 tumor cell lines and primary 
ALL blasts. Our data suggest that potentially CD19-redirected allodepleted donor T-cells 
could be used to augment both anti-viral and anti-leukemic T-cell responses after haplo-SCT. 
Since CD19 is expressed only on the B- cell lineage, and the T-cells are allodepleted, such an 
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approach should not cause toxicity to extra-haematopoietic tissues. However, targeting of 
normal B-cells is likely to induce B-cell lymphopoenia, and impair humoral immunity 
necessitating, immunoglobulin replacement. At worst, the clinical consequences of this are 
likely to resemble X-linked (Bruton’s) agammaglobulinaemia, a genetic disorder of B-cell 
development. When receiving regular immunoglobulin replacements, such patients have a 
normal life expectancy. In patients at high risk of leukaemic relapse, this may be an acceptable 
price to pay for the potential benefit in reducing relapse risk. 
 
One of the concerns of retroviral transduction of human PBMCs is the risk of insertional 
mutagenesis. Acute leukaemia has developed in 4 of 9 children treated with gene therapy for 
X- linked SCID in France and 1 out of 10 in the UK. This adverse event was attributed to the 
integration of the retrovirus into the LMO2 locus in 3 patients, a key transcription factor in T- 
lymphoid progenitors, resulting in aberrant expression of this gene and uncontrolled 
proliferation of T lymphoid blasts. In above study, CD34 selected haematopoietic progenitors 
were transduced. However, there have been no reported cases of insertional mutagenesis in 
over 100 patients followed up over an extended period following treatment with retrovirally 
transduced mature T-cells. Likewise, there have also been no reported cases of insertional 
mutagenesis, in patients treated with T cells retrovirally transduced with a chimeric TCR to 
treat HIV or neuroblastoma. Thus, the risks of insertional mutagenesis following transduction 
of mature PBMCs is very low. Furthermore, our use of a self inactivating (SIN) lentiviral 
construct further reduces the risks of insertional mutagenesis 161, arising in transduced 
allodepleted T-cells. 
 
 
Scale Up 
 
Our studies suggest that for strategies targeting surface markers or cytokines secreted by 
alloreactive T-cells, CD25/71 is the optimal combination for effective depletion of alloreactive 
T-cells. Further studies comparing residual alloreactivity and preservation of anti-viral 
responses after CD25/71 depletion and other methodologies such as photodynamic 
purging52,140,178 using standardised assays will be required. However, these methodologies 
have not yet been tested clinically and their complexity/need for specialised equipment may 
limit their applicability. In contrast, combined CD25/71 depletion is simple and feasible 
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clinically. Keeping the period of co-culture short (3 days), and manipulations simple would be 
a major advantage in terms of clinical feasibility. The separation methodology used is already 
in widespread clinical use for CD34 selection in centres performing haplo-SCT and easily 
performed under Good Manufacturing Practice (GMP) conditions. Clinical grade anti-CD25 
and anti-biotin immunomagnetic beads are available and we are currently generating a GMP 
grade biotinylated anti-CD71. The mean yield of PBMCs using combined CD25/71 depletion 
was 17.1 % of the initial PBMC dose (range 14.5-25.4 %). We are routinely able to generate 8 
x 107 allodepleted T-cells from a 450 ml blood donation, so that add back of 106/kg CD25/71 
allodepleted donor T-cells would be feasible from a blood draw without the need for 
leucapheresis.  
 
The optimum APC for further clinical studies is a key issue, as optimizing antigen presentation 
is critical to allodepletion. PBMCs are easily accessible, but the phenotype is variable and they 
may not be available in aplastic patients. We have previously demonstrated that LCL 
stimulation resulted in a more consistent depletion of in vitro alloreactivity than stimulation 
with host PBMCs using anti CD25IT based allodepletion.86 Because of the difficulty in 
obtaining sufficient PBMCs, particularly in children, some groups have investigated using 
PBMCs from the non-donor parent as stimulators for allodepletion. However, we believe this 
approach is flawed, as it will not activate (and hence deplete) T-cell responses against minor 
histocompatibility antigens that differ between the donor and the recipient presented through 
the shared HLA molecules or against allorestricted minor histocompatibility antigens which 
differ between the recipient and the non-donor parent presented through the non-shared 
haplotype. Hence, we believe that the APC used for stimulation must be recipient derived.  
 
Our current studies suggest that allodepletion with anti CD25/71 beads following stimulation 
with host LCLs or DC, appears more consistently effective in depleting in vitro alloreactivity 
than after stimulation with cytokine stimulated host PBMCs  The levels of CD25 and CD71 
up regulation appear equivalent with DC and LCL, as do residual responses to host after 
CD25/71 allodepletion in 2º MLRs. PBMCs are easily accessible, though they have a variable 
phenotype, and are less effective as APCs compared to LCLs. In our comparison of DCs, 
cytokine stimulated PBMCs, and LCLs as APCs, the use of host/3rd party LCLs as secondary 
stimulators in the 2º MLR, may have led to higher responses in the DC/PBMC arm, due to 
preserved EBV responses through shared HLA antigens. We plan to repeat these experiments, 
but use host/3rd party PBMCs as secondary stimulators. LCLs are an excellent APC, as they 
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strongly express co-stimulatory molecules, have a standard phenotype, can be generated even 
in aplastics and do not express potential myeloid leukaemia antigens, and thus may retain a 
GVL response to myeloid leukaemias. However, they take 6 weeks to generate, significantly 
complicate generation of allodepleted cells under GMP conditions, and results in deletion of 
EBV-specific T-cells restricted through the shared haplotype. Though there were high levels of 
EBV PCR detected in aciclovir treated LCL co-cultures, co-culture of irradiated LCLs with 
donor PBMCs did not lead to their transformation and no EBV-associated lymphoproliferation 
was seen in our previous studies. On the other hand, DCs are excellent APCs, which can be 
generated much more rapidly (7 days), but will require much larger volumes of recipient 
blood. We estimate that while allodepleted T-cell doses of 106/kg could be generated from a 
blood draw, larger doses will require a leucapheresis. Because of the potential preservation of 
anti-leukaemic responses, use of LCL stimulators may be advantageous in clinical studies in 
myeloid malignancies such as AML. However, in view of the regulatory complexity of using 
LCLs under GMP conditions, for further studies in non-malignant patients we plan to use DCs 
as stimulators.  
 
Prior to a proposed clinical study, we will need to scale up our experiments in the cell/gene 
therapy laboratories at Great Ormond Street Hospital, to determine if we can reproduce our in 
vitro data on a large scale. One concern, from studies from The Necker Hospital group198, was 
the failure to reproduce their in small scale in vitro data using CD25 beads, when scaled up on 
the CliniMACS system. After co-culturing donor PBMCs with HLA-mismatched irradiated 
PBMCs, they performed 3 CD25 immunomagnetic depletion using a CliniMACs system. 
Initially, allodepleted cells were infused without prior assessment of residual alloreactivity and 
2 of 4 such patients developed severe GVHD. Subsequently, residual responses were tested in 
a HTLp-based LDA assay and CD25 bead allodepleted T-cells only met the release criteria of 
1.2 log depletion on host reactivity in half the cases. One limitation of their approach was the 
use of the PBMCs from the non-donor parent as APCs. As noted above, PBMCs may be sub-
optimal APCs for allodepletion, particularly when derived from the non-donor parent. Clearly, 
however, we need to demonstrate effective depletion of T-cell responses directed against the 
host in large scale experiments using our system. We hope that our use of host DCs as APCs, 
combined with targeting an additional marker expressed on CD25 negative alloreactive T-cells 
will enable us to achieve effective allodepletion even in the clinical setting.  Our initial scale-
up in 1 donor-recipient pair, suggested that this may well be possible although clearly this will 
need to be replicated in other donor-recipient pairs. 
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Our group is currently optimising conditions for CD25/71 immunomagnetic allodepletion 
under GMP conditions using the CliniMACS system. We have shown that use of upright T-
175 flasks rather than cell culture bags results in both better activation of donor T-cells and 
improved cell recovery. Our group is now testing whether the combination of αCD71 + anti-
CD25 beads/anti-biotin beads or αCD25 + αCD71 biotin and anti-biotin beads gives more 
effective depletion of alloreactivity. Additionally, we will perform further experiments to 
determine, whether as suggested from our previous large scale run, CLINIMACs depletion 
tubing sets (which are designed for depletion of larger number of cells) result in improved 
allodepletion compared to TS tubing sets. 
 
Once we have optimised our large-scale CD25/71 allodepletion under GMP conditions, we 
plan to collaborate with Prof. Cavazzana-Calvo’s group in Paris to systematically compare 
CD25/71 allodepletion with photodynamic purging using the Kiadis method131, in the same 
donor-recipient pairs, using standardised assays to assess residual alloreactivity. We plan to 
co-culture normal donor PBMC from buffy coats of 4 donors with HLA-mismatched DC (at a 
ratio of 10:1) under serum-free conditions in T-175 flasks for 3 days. Co-cultures will be split 
into 2 arms and allodepletion performed under GMP conditions using either immunomagnetic 
CD25/71 negative selection or photodynamic purging. Allodepleted T-cells from each arm will 
be plated out in a LDA proliferation assay, or rested in serum-free, cytokine-free media for 2 
days and then restimulated to host/3rd party PBMCs in a delayed 2ºMLRs.  The residual 
responses to host and 3rd party using both allodepletion methods will be compared to those of 
unmanipulated PBMCs from the same donor. The preservation of anti-viral responses after 
both methods will also be compared. These experiments will involve collaboration between 
several European groups and will determine the optimum method for selective allodepletion, 
as a prelude to a further collaborative study of allodepletion after non malignant haplo-SCTs.  
Proposed Clinical Trial 
 
While functional assays can provide useful comparisons of the efficiency of allodepletion, they 
cannot fully predict clinical outcome. We therefore now plan a further clinical study of 
immunotherapy with allodepleted donor T-cells to determine if CD25/71 allodepleted T-cells 
can safely augment anti-viral and anti-leukaemic responses after paediatric haplo-SCT. 
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If our scale-up experiments above our successful, we will assess the safety and biological 
effects of adoptive transfer of allodepleted donor T-cells generated using negative 
immunomagnetic selection for CD25/71 in a multi-centre, phaseI/II study children with non-
malignant disorders undergoing haploidentical or multiply HLA-mismatched unrelated donor 
SCT with a CD34-selected graft. We have chosen to focus, on patients with non-malignant 
diseases in this study in order to determine the impact of this intervention without the 
confounding factor of relapse of malignant disease. Eligibility criteria are shown below; 
 
Inclusion Criteria: 
Patients with the following non-malignant conditions who lack an HLA matched (10/10 or 
9/10 allelic) donor and are planned for SCT from a haploidentical or mismatched ( ≤ 8/10 
allelic) family/unrelated donor:  
           
Haemophagocytic lymphohistiocytosis 
Combined immunodeficiency state or SCID 
Severe aplastic anaemia unresponsive to immunosuppression 
Transfusion-dependent Fanconi’s anaemia 
Osteopetrosis 
Hurler’s syndrome 
Exclusion Criteria: 
1. Patients with a life expectancy (< 6 weeks) limited by diseases other than the primary 
indication for transplant 
2. Patients with pre-existing severe restrictive lung disease (FVC or FEV1< 50%       
predicted) 
3. Patients with severe hepatic disease (bilirubin greater than 50 uM or ALT>500IU/ml) 
4. Acute graft-versus-host disease ≥ grade 2 (Seattle criteria) at time of infusion of 
allodepleted cells 
5. Pulmonary disease requiring > 28% O2 supplementation or active pulmonary infiltrates 
on chest X-ray at time of infusion of allo-depleted cells 
6. Presence of severe intercurrent infection at time of infusion of allo-depleted T-cells (if 
present consult with principle investigator) 
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7. Patients in whom allodepleted donor T-cells do not meet release criteria will be 
excluded   
 
 
 
 
 
 
Four weeks prior to SCT, the patient will undergo an unstimulated leucapheresis for generation 
of recipient DCs. Prior to receiving G-CSF for CD34 mobilisation, 500 ml blood will be taken 
from the SCT donor for generation of allodepleted donor T-cells.  For parental donors who 
consent to entry on the study this should be straightforward and for mismatched unrelated 
donors in previous studies we have routinely obtained this volume of blood for adoptive 
immunotherapy from unrelated donor registries. Mononuclear cells from the stem cell donor 
will be co-cultured with recipient DCs and allo-depletion performed using anti-CD71 biotin + 
anti-CD25/anti-biotin immunomagnetic beads under GMP conditions at Great Ormond St 
Children’s Hospital according to established Standard Operating Procedures (see Appendix). 
Samples of the allodepleted donor T-cells will be tested to ensure the efficacy of allodepletion 
and sterility and the remainder cryopreserved in aliquots. Sufficient allo-depleted T cells will 
be prepared and safety tested at one time for a complete course for each patient. The efficacy 
of allo-depletion will be confirmed pre-infusion using immunophenotyping (< 1% CD3+71+ve 
cells), primary MLR (< 10% residual proliferation to host) and delayed secondary MLR assays 
(> 10-fold reduction in proliferative responses to host PBMCs compared to unmanipulated 
donor PBMC) studies. Allodepleted donor-T cells will be tested for bacterial/ fungal sterility 
(Bactec assay), Mycoplasma (by PCR) and endotoxin (LAL assay).  
 
Patients will then proceed with their transplant with the conditioning/GHVD prophylaxis and a 
CD34 selected graft. If patients have engrafted with no acute GVHD≥ 2, and allodepleted T-
cells meet the release criteria, they will receive intravenous infusions of allodepleted donor T-
cells at increasing doses (104/kg at day 30 post-SCT, 105/kg at day 60 and 106/kg at day 90) at 
monthly intervals post-SCT until either their circulating CD3 count > 1000/L or they develop 
acute GVHD ≥ Grade 2. Patients will be monitored for the outcome measures outlined below 
by clinical examination and laboratory assays on the for the first year post-SCT to assess for 
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toxicity and GVHD, incidence of virus-associated/invasive fungal disease, immune 
reconstitution and survival. 
 
 
Outcome measures 
 
Primary 
1. Toxicity attributable to  transfer of allodepleted donor T-cells: 
(a) Incidence of grade III or grade IV toxicity (graded by the NCI BMT Toxicity Criteria 
Version 2.0) attributable to transfer of allodepleted donor T-cells 
(b) Incidence of Grade II-IV and Grade III-IV acute GVHD before day 100 (graded by Seattle 
criteria) and limited/extensive chronic GVHD between days 100-365. 
 
2.   Time to recovery post-SCT of circulating T-cells to > 1000/µL and CD4 count to > 300/µL 
 
Secondary 
1. Incidence of virus-associated and invasive fungal disease in the first year post-SCT 
2. Time to recovery post-SCT of normal TCR diversity as assessed by Vβ spectratyping 
3. In vitro anti-viral responses of circulating PBMC after adoptive transfer of allodepleted 
donor T-cells using interferon-γ ELISPOT and HLA-peptide pentamer assays. 
4. Transplant-related mortality and overall survival at 1 and 2 years post-HSCT. 
 
 
This study will determine if immunotherapy with allodepleted donor T-cells generated using 
CD25/71 immunomagnetic depletion is safe and improves T-cell reconstitution after HLA-
mismatched SCT compared with historical control data. This will lay the foundation for larger, 
randomised studies to assess the effect of immunotherapy with allodepleted donor T-cells on 
transplant-related mortality and survival after HLA-mismatched SCT. 
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APPENDIX 
 
SOP for CD25/71 allodepletion 
 
Purpose and Principle of the Procedure 
 
Viral infections and relapse are the major causes of morbidity and mortality following a 
haploidentical (genetically mismatched parental) stem cell transplant. Infusion of donor 
lymphocytes can prevent or treat disease relapse and infections but there is a high incidence of 
GVHD using unmanipulated donor lymphocytes, due to the presence of alloreactive T-cells. 
The elimination of alloreactive T-cells may minimize the possibility of GVHD without 
eliminating T-cells responsible for the desirable anti-viral effects, so that infusion of such T- 
cells may improve T-cell reconstitution and decrease infections post –haploidentical 
transplantation.  Alloreactive T-cells express CD25 and CD71 and they can be removed by 
CD25 and CD71 beads in an allergenic MLR. The residual T-cells can then be infused to 
improve the immune reconstitution of the patient post transfer after bone marrow 
transplantation 
 
Material 
Clinical Grade AIM V     Invitrogen 
T75 vented flasks      Nunc (178891) 
Ficoll        GE Healthcare (17-1440-03) 
EBV–Lymphoblastoid cell lines (LCL) 
Biotinylated anti Human CD71 Antibody   BD Biosciences (555535)  
Biotinylated anti Human CD25 Antibody   Roche/Miltenyi (0.1ug/ml) 
CliniMACS®  plus Instrument     Miltenyi Biotec (151-01)  
CliniMACS®  CD25 reagent        Miltenyi Biotec (274-01)  
CliniMACS®  Flexible Labelling System (FLS)   Miltenyi Biotec (173-01) 
CliniMACS®   Tubing set     Miltenyi Biotec (161-01) 
Presystem –Filter      Miltenyi Biotec (181-01) 
CliniMACS®  Buffer      Miltenyi Biotec (700-25) 
Sample site coupler      Miltenyi Biotec (189-01) 
Transfer Set Coupler/Needle     Miltenyi Biotec (185-01) 
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Transfer Bag 600 mls      Miltenyi Biotec (190-01) 
Luer/Spike Interconnector     Miltenyi Biotec (187-01) 
Human Serum albumin  
Tubing Slide Clamps/ Scissor Clamps 
18 G needle 
Biological Safety Cabinet 
Refrigerator (4-8ºC) 
Centrifuge 
Incubator (37ºC/5% CO2) 
Haemacytometer and Trypan Blue 
Cryovials 
FACS tubes 
Cell strainer 70µm      BD Biosciences (352350) 
FACS Buffer ( PBS, 1% HSA) 
 
 
 
 
1. Day-42  Preparation of recipient LCL 
2. Day-10 Spin down 1 T-72 flask of recipient LCL and resuspend in 40 mls AIMV with 
100µM acyclovir. Transfer 20mls to each of 2 x T-75 flasks 
3. Day -7 Setting up co-culture and primary MLR. Obtain 300 mls of peripheral blood in 
preservative free heparin for co-culture and a further 10 mls for ID testing and tissue typing. 
Donor PBMCs need to be fresh. Prepare donor PBMCs over Ficoll gradient. Freeze 4 aliquots 
of 5x 106 PBMCs for follow up studies. 
4. Resuspend donor PBMCs at 2x 106/ml in AIMV. 
5. Harvest 40 mls of aciclovir treated recipient LCL in mid log phase into a 50 ml centrifuge 
tube. Centrifuge 400g X 5mins and resuspend in 3 mls AIMV. Count viable cells  using 
haemacytometer and adjust cell concentration to 2x106/ml 
6. Irradiate LCL to 70 Gy (DCs to 40 Gy) 
7. Add 1/40th volume of recipient irradiated LCLs to donor PBMC aliquot 
8. Incubate co-culture in 37ºC/5 % CO2 for 4 days 
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Day -4 CD25/71 depletion 
1. Take 2mls of co-culture using 5 ml Eppendorf Pippettman for FACS analysis 
2. Harvest co-culture into 50 ml centrifuge tube. Rinse the flask twice with 5 mls AIMV and 
pass the contents through a 70µm cell strainer these into a 50 ml centrifuge tube 
3. Centrifuge the tube at 400g X 5minutes 
4. Remove the supernatant and resuspend in 10 ml CliniMACS® buffer/0.5% HSA (“buffer”) 
to break any clumps. Bring up the volume to 50 mls buffer, count and centrifuge 400g X 
5minutes again. 
5. Remove the supernatant and resuspend to adjust concentration to 800µl buffer/108 PBMCs 
in buffer in 50 ml centrifuge tube. 
6. Clean the bung of one vial biotinylated anti human CD71 antibody with an alcohol wipe 
and allow to air dry. 
7. Draw up using a 18 G needle and syringe. Add 200 µl of biotin CD71 antibody and 2µg of 
biotin CD25 antibody/108 PBMCs.  Add the contents to the co-culture and incubate for 15 
mins at 4 degrees. (Biotinylated CD71 – clone MA712). Mix well 
8. Wash with buffer by filling up the tube (50 mls buffer/108 PBMCs) and resuspend cells in 
1ml/108 PBMCs buffer. 
9. Clean the bung with an alcohol wipe of one vial FLS reagent and allow to air dry.  
10. Using 18 G needle and syringe add 100 ul FLS reagent each per 108 PBMCs. Mix well 
and incubate at room temperature for 30 minutes on a roller. 
11. Wash again with  buffer and then resuspend at 1x 108  PBMC per ml buffer, in a minimum 
volume of 40ml 
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Allodepletion with Chemotherapy Agents 
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Figure 61:Dose viability Experiments for Trimetrexate (a) and fludarabine (b). Varying 
concentrations of trimetrexate and fludarabine were added to resting T cells or PHA stimulated T cells. The 
trimetrexate was added on day 0 and the fludarabine on day 2. The number of viable T cells was then determined 
by trypan staining and divided by the number of cells on day 0 to determine % viability. The optimum dose for 
trimetrexate was 1µm and for fludarabine was 50 ng/ml (n=5) 
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Figure 63:Trimetrexate Selectively deletes Proliferating Alloreactive T cells. (n=5). 
Fludarabine, Trimetrexate and bortezomib were added to allo MLRs. (consisting of CFSE labelled T cells co 
cultured with HLA- mismatched DCs). Controls consisted of CFSE labelled T cells alone or co cultures without 
chemotherapy drugs. On day 3, the % of CFSE Dim proliferating alloreactive T cells (including CD25-ve) and 
bystander CFSE bright was determined using Trucout beads. Bortezomib led to deletion of all cells, whilst 
fludarabine had little effect on proliferating alloreactive T-cells. Trimetrexate led to over 80 % reduction in CFSE 
Dim population, a 60 % reduction in CFSE Dim CD25 negative and a 20 % reduction in bystander cells. 
  
0
20
40
60
80
100
120
 Fludarabine
50 ng/ml
 Trimetrexate
1µm
Bortezomib
500 nM
%
 C
ha
ng
e 
in
 C
D
3 
C
ou
nt
s
% Reduction in CFSE Dim
% Reduction in CFSE Dim
CD25 Neg
% Reduction in CFSE
Bright
 215
Acknowledgements 
SS was a recipient of a training fellowship from the Medical Research Council of the UK. CD25 IT was a kind 
gift of Professor Ellen Vitetta (Cancer Immunobiology Center, Southwestern Medical Center, Dallas, Texas, 
USA). Dr. Martin Pule kindly supplied the Ramos/K562 cell lines, the lentiviral constructs, and the anti CD19 
chTCR. The ALL blasts were kindly supplied by Dr. Amrolia. The data on comparison of flasks and bags for 
allodepletion was supplied by Dr. Christoph Mancao. Dr. Martin Pule, Professors Bobby Gaspar and Christine 
Kinnon provided advice, encouragement and help at various stages. Dr. Helen Karlsson and Jen Brewin were also 
of tremendous help throughout the three years. 
 
I particularly want to thank my family, especially my wife Omalee and also my supervisor Dr. Persis Amrolia, 
both of whom showed endless patience and support throughout my time in research 
 
  
 216
References 
 
1. Aversa F. Haploidentical haematopoietic stem cell transplantation for acute leukaemia 
in adults: experience in Europe and the United States. Bone Marrow Transplant. 2008. 
2. Veys P, Amrolia P, Rao K. The role of haploidentical stem cell transplantation in the 
management of children with haematological disorders. Br J Haematol. 2003;123:193-206. 
3. Dey BR, Spitzer TR. Current status of haploidentical stem cell transplantation. Br J 
Haematol. 2006;135:423-437. 
4. Lang P, Greil J, Bader P, et al. Long-term outcome after haploidentical stem cell 
transplantation in children. Blood Cells Mol Dis. 2004;33:281-287. 
5. Eyrich M, Lang P, Lal S, et al. A prospective analysis of the pattern of immune 
reconstitution in a paediatric cohort following transplantation of positively selected human 
leucocyte antigen-disparate haematopoietic stem cells from parental donors. Br J Haematol. 
2001;114:422-432. 
6. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-
cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N 
Engl J Med. 1998;339:1186-1193. 
7. Feuchtinger T, Richard C, Pfeiffer M, et al. Adenoviral infections after transplantation 
of positive selected stem cells from haploidentical donors in children: an update. Klin Padiatr. 
2005;217:339-344. 
8. Aversa F, Martelli MF. Transplantation of haploidentically mismatched stem cells for 
the treatment of malignant diseases. Springer Semin Immunopathol. 2004;26:155-168. 
9. Bethge WA, Faul C, Bornhauser M, et al. Haploidentical allogeneic hematopoietic cell 
transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: An 
update. Blood Cells Mol Dis. 2008;40:13-19. 
10. Chen X, Hale GA, Barfield R, et al. Rapid immune reconstitution after a reduced-
intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric 
refractory haematological malignancies. Br J Haematol. 2006;135:524-532. 
11. Bader P, Soerensen J, Koehl U, et al. 66: Excellent Engraftment and Rapid Immune 
Recovery in Haploidentical Stem Cell Transplantation Using CD3/CD19 Depleted Peripheral 
Stem Cell Grafts After Reduced Intensity Conditioning. Biology of Blood and Marrow 
Transplantation. 2008;14:27. 
12. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol. 
2006;43:3-10. 
13. Kernan NA, Collins NH, Juliano L, Cartagena T, Dupont B, O'Reilly RJ. Clonable T 
lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-
v-host disease. Blood. 1986;68:770-773. 
14. Barber LD, Madrigal JA. Exploiting beneficial alloreactive T cells. Vox Sang. 
2006;91:20-27. 
15. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7:340-352. 
16. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813-
1826. 
17. Nikolich-Zugich J. High specificity, not degeneracy, allows T cell alloresponses. Nat 
Immunol. 2007;8:335-337. 
18. Martins SL, St John LS, Champlin RE, et al. Functional assessment and specific 
depletion of alloreactive human T cells using flow cytometry. Blood. 2004;104:3429-3436. 
 217
19. Jameson BA, McDonnell JM, Marini JC, Korngold R. A rationally designed CD4 
analogue inhibits experimental allergic encephalomyelitis. Nature. 1994;368:744-746. 
20. Goulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens 
between HLA-identical donors and recipients and the development of graft-versus-host disease 
after bone marrow transplantation. N Engl J Med. 1996;334:281-285. 
21. Socie G, Loiseau P, Tamouza R, et al. Both genetic and clinical factors predict the 
development of graft-versus-host disease after allogeneic hematopoietic stem cell 
transplantation. Transplantation. 2001;72:699-706. 
22. Chakraverty R, Sykes M. The role of antigen-presenting cells in triggering graft-
versus-host disease and graft-versus-leukemia. Blood. 2007;110:9-17. 
23. Morris ES, Hill GR. Advances in the understanding of acute graft-versus-host disease. 
Br J Haematol. 2007;137:3-19. 
24. Godfrey WR, Krampf MR, Taylor PA, Blazar BR. Ex vivo depletion of alloreactive 
cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. 
Blood. 2004;103:1158-1165. 
25. Ichiki Y, Bowlus CL, Shimoda S, Ishibashi H, Vierling JM, Gershwin ME. T cell 
immunity and graft-versus-host disease (GVHD). Autoimmun Rev. 2006;5:1-9. 
26. Debes GF, Arnold CN, Young AJ, et al. Chemokine receptor CCR7 required for T 
lymphocyte exit from peripheral tissues. Nat Immunol. 2005;6:889-894. 
27. Bondanza A, Valtolina V, Magnani Z, et al. Suicide gene therapy of graft-versus-host 
disease induced by central memory human T lymphocytes. Blood. 2006;107:1828-1836. 
28. Chen BJ, Cui X, Sempowski GD, Liu C, Chao NJ. Transfer of allogeneic CD62L- 
memory T cells without graft-versus-host disease. Blood. 2004;103:1534-1541. 
29. Bleakley M, Mollerup A, Chaney C, Brown M, Riddell SR. Human Minor 
Histocompatibility Antigen-Specific CD8+ T Cells Are Found Predominantly in the 
CD45RA+ CD62L+ Naive T Cell Subset. ASH Annual Meeting Abstracts. 2005;106:578-. 
30. Fowler DH. Shared biology of GVHD and GVT effects: potential methods of 
separation. Crit Rev Oncol Hematol. 2006;57:225-244. 
31. Yakoub-Agha I, Saule P, Depil S, et al. A high proportion of donor CD4+ T cells 
expressing the lymph node-homing chemokine receptor CCR7 increases incidence and 
severity of acute graft-versus-host disease in patients undergoing allogeneic stem cell 
transplantation for hematological malignancy. Leukemia. 2006;20:1557-1565. 
32. Chen BJ, Deoliveira D, Cui X, et al. Inability of memory T cells to induce graft-versus-
host disease is a result of an abortive alloresponse. Blood. 2007;109:3115-3123. 
33. Le NT, Chen BJ, Chao NJ. Selective elimination of alloreactivity from 
immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting. 
Cytotherapy. 2005;7:126-133. 
34. Sun Y, Tawara I, Toubai T, Reddy P. Pathophysiology of acute graft-versus-host 
disease: recent advances. Transl Res. 2007;150:197-214. 
35. Barrett J. Improving outcome of allogeneic stem cell transplantation by 
immunomodulation of the early post-transplant environment. Curr Opin Immunol. 
2006;18:592-598. 
36. Visentainer JE, Lieber SR, Persoli LB, et al. Serum cytokine levels and acute graft-
versus-host disease after HLA-identical hematopoietic stem cell transplantation. Exp Hematol. 
2003;31:1044-1050. 
37. Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-
2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 
2000;95:83-89. 
 218
38. Welniak LA, Blazar BR, Anver MR, Wiltrout RH, Murphy WJ. Opposing roles of 
interferon-gamma on CD4+ T cell-mediated graft-versus-host disease: effects of conditioning. 
Biol Blood Marrow Transplant. 2000;6:604-612. 
39. Burman AC, Banovic T, Kuns RD, et al. IFNgamma differentially controls the 
development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. 
Blood. 2007;110:1064-1072. 
40. Elmaagacli AH, Koldehoff M, Hindahl H, et al. Mutations in innate immune system 
NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-
versus-host disease in patients who underwent an allogeneic transplantation. Transplantation. 
2006;81:247-254. 
41. Borsotti C, Franklin AR, Lu SX, et al. Absence of donor T cell derived soluble TNF 
decreases graft-versus-host-disease without impairing graft-versus-tumor activity. Blood. 
2007. 
42. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor 
alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011-
1016. 
43. Srinivasan R, Chakrabarti S, Walsh T, et al. Improved survival in steroid-refractory 
acute graft versus host disease after non-myeloablative allogeneic transplantation using a 
daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol. 
2004;124:777-786. 
44. Blaser BW, Schwind NR, Karol S, et al. Trans-presentation of donor-derived 
interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for 
graft-versus-tumor activity. Blood. 2006;108:2463-2469. 
45. Kappel LW, Goldberg GL, Ivanov II, et al. 27: IL-17 is Required for CD4-Mediated 
GVHD. Biology of Blood and Marrow Transplantation. 2008;14:12-13. 
46. Lohr J, Knoechel B, Wang JJ, Villarino AV, Abbas AK. Role of IL-17 and regulatory 
T lymphocytes in a systemic autoimmune disease. J Exp Med. 2006;203:2785-2791. 
47. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity 
in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp 
Med. 1996;183:2645-2656. 
48. Maeda Y, Levy RB, Reddy P, et al. Both perforin and Fas ligand are required for the 
regulation of alloreactive CD8+ T cells during acute graft-versus-host disease. Blood. 
2005;105:2023-2027. 
49. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of 
CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, 
revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541-547. 
50. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of 
peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 1997;6:411-417. 
51. Peggs KS, Allison JP. Co-stimulatory pathways in lymphocyte regulation: the 
immunoglobulin superfamily. Br J Haematol. 2005;130:809-824. 
52. Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while 
preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by 
photodynamic cell purging process. Blood. 2002;99:3083-3088. 
53. Ukyo N, Hori T, Yanagita S, Ishikawa T, Uchiyama T. Costimulation through OX40 is 
crucial for induction of an alloreactive human T-cell response. Immunology. 2003;109:226-
231. 
54. Blazar BR, Sharpe AH, Chen AI, et al. Ligation of OX40 (CD134) regulates graft-
versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant 
recipients. Blood. 2003;101:3741-3748. 
 219
55. Blanco B, Perez-Simon JA, Sanchez-Abarca LI, et al. Bortezomib induces selective 
depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood. 
2006;107:3575-3583. 
56. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, Colombo MP. 
Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a 
novel regulatory role for OX40 and its comparison with GITR. Blood. 2005;105:2845-2851. 
57. Ohata J, Sakurai J, Saito K, Tani K, Asano S, Azuma M. Differential graft-versus-
leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease 
prophylaxis. Clin Exp Immunol. 2002;129:61-68. 
58. Blazar BR, Taylor PA, Noelle RJ, Vallera DA. CD4(+) T cells tolerized ex vivo to host 
alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease 
lethality capacity but retain nominal antigen responses. J Clin Invest. 1998;102:473-482. 
59. Wehler TC, Nonn M, Brandt B, et al. Targeting the activation-induced antigen CD137 
can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. 
Blood. 2007;109:365-373. 
60. Popma SH, Griswold DE, Li L. Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-
Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell 
proliferation induced by anti-CD3 antibodies correlates with impaired expansion of 
alloreactive T cells. Int Immunopharmacol. 2005;5:155-162. 
61. Shiow LR, Rosen DB, Brdickova N, et al. CD69 acts downstream of interferon-
alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature. 
2006;440:540-544. 
62. Craston R, Koh M, Mc Dermott A, Ray N, Prentice HG, Lowdell MW. Temporal 
dynamics of CD69 expression on lymphoid cells. J Immunol Methods. 1997;209:37-45. 
63. Holzelova E, Vonarbourg C, Stolzenberg MC, et al. Autoimmune lymphoproliferative 
syndrome with somatic Fas mutations. N Engl J Med. 2004;351:1409-1418. 
64. Shustov A, Nguyen P, Finkelman F, Elkon KB, Via CS. Differential expression of Fas 
and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas 
ligand requires CD8+ T cell activation and IFN-gamma production. J Immunol. 
1998;161:2848-2855. 
65. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched 
related donors extends access to allogeneic marrow transplant. Blood. 1997;89:3864-3872. 
66. O'Flaherty E, Wong WK, Pettit SJ, Seymour K, Ali S, Kirby JA. Regulation of T-cell 
apoptosis: a mixed lymphocyte reaction model. Immunology. 2000;100:289-299. 
67. Zhang HG, Su X, Liu D, et al. Induction of specific T cell tolerance by Fas ligand-
expressing antigen-presenting cells. J Immunol. 1999;162:1423-1430. 
68. Artac H, Coskun M, Karadogan I, Yegin O, Yesilipek A. Transferrin receptor in 
proliferation of T lymphocytes in infants with iron deficiency. Int J Lab Hematol. 
2007;29:310-315. 
69. Nguyen XD, Eichler H, Dugrillon A, Piechaczek C, Braun M, Kluter H. Flow 
cytometric analysis of T cell proliferation in a mixed lymphocyte reaction with dendritic cells. 
J Immunol Methods. 2003;275:57-68. 
70. Macedo MF, de Sousa M, Ned RM, Mascarenhas C, Andrews NC, Correia-Neves M. 
Transferrin is required for early T-cell differentiation. Immunology. 2004;112:543-549. 
71. Li X, Cicalese L, DeMasi M, Benedetti E, Rastellini C. Mechanisms underlying the 
immunosuppressive activity of antitransferrin receptor monoclonal antibody. Transplant Proc. 
2001;33:136. 
72. Drobyski WR, Ul-Haq R, Majewski D, Chitambar CR. Modulation of in vitro and in 
vivo T-cell responses by transferrin-gallium and gallium nitrate. Blood. 1996;88:3056-3064. 
 220
73. Pachnio A, Dietrich S, Klapper W, et al. Proliferation-based T-cell selection for 
immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow 
transplantation. Bone Marrow Transplant. 2006;38:157-167. 
74. Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for 
leukemia. Ann Intern Med. 1994;120:646-652. 
75. Schetelig J, Kiani A, Schmitz M, Ehninger G, Bornhauser M. T cell-mediated graft-
versus-leukemia reactions after allogeneic stem cell transplantation. Cancer Immunol 
Immunother. 2005;54:1043-1058. 
76. Kennedy-Nasser AA, Bollard CM, Rooney CM. Adoptive immunotherapy for 
Hodgkin's lymphoma. Int J Hematol. 2006;83:385-390. 
77. Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single-dose and escalating-dose 
regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid 
leukemia. Blood. 2000;95:67-71. 
78. Simula MP, Marktel S, Fozza C, et al. Response to donor lymphocyte infusions for 
chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to 
maximize therapeutic efficacy. Leukemia. 2007;21:943-948. 
79. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy 
evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after 
bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-
host disease. Blood. 1995;86:1261-1268. 
80. Barrett AJ. Mechanisms of the graft-versus-leukemia reaction. Stem Cells. 
1997;15:248-258. 
81. Di Terlizzi S, Zino E, Mazzi B, et al. Therapeutic and diagnostic applications of minor 
histocompatibility antigen HA-1 and HA-2 disparities in allogeneic hematopoietic stem cell 
transplantation: a survey of different populations. Biol Blood Marrow Transplant. 2006;12:95-
101. 
82. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte 
antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from 
healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 
1999;59:2675-2681. 
83. Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-
specific memory CD8+ T cells exist in healthy individuals and in patients with chronic 
myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102:2892-2900. 
84. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 
2001;411:385-389. 
85. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell 
responses following combined PR1 and WT1 peptide vaccination in patients with myeloid 
malignancies. Blood. 2008;111:236-242. 
86. Amrolia PJ, Muccioli-Casadei G, Yvon E, et al. Selective depletion of donor 
alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003;102:2292-
2299. 
87. Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for allogeneic 
haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: 
impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J 
Haematol. 2007;139:70-80. 
88. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention 
and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. 
Blood. 1998;92:1549-1555. 
89. Leen AM, Heslop HE. Cytotoxic T lymphocytes as immune-therapy in haematological 
practice. Br J Haematol. 2008. 
 221
90. Zakrzewski JL, Kochman AA, Lu SX, et al. Adoptive transfer of T-cell precursors 
enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat 
Med. 2006;12:1039-1047. 
91. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic 
histoincompatible bone marrow allografts. N Engl J Med. 1999;340:1704-1714. 
92. Roskrow MA, Suzuki N, Gan Y, et al. Epstein-Barr virus (EBV)-specific cytotoxic T 
lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. 
Blood. 1998;91:2925-2934. 
93. Cooper LJ. Adoptive cellular immunotherapy for childhood malignancies. Bone 
Marrow Transplant. 2007. 
94. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early 
cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell 
lines. Lancet. 2003;362:1375-1377. 
95. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T 
cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 
2002;99:3916-3922. 
96. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity 
against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones 
from the donor. N Engl J Med. 1995;333:1038-1044. 
97. Rauser G, Einsele H, Sinzger C, et al. Rapid generation of combined CMV-specific 
CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell 
transplants. Blood. 2004;103:3565-3572. 
98. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-
specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp 
Med. 2005;202:379-386. 
99. Chatziandreou I, Gilmour KC, McNicol AM, et al. Capture and generation of 
adenovirus specific T cells for adoptive immunotherapy. Br J Haematol. 2007;136:117-126. 
100. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-
specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic 
stem cell transplantation. Br J Haematol. 2006;134:64-76. 
101. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to 
pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106:4397-4406. 
102. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for 
multiple viruses expand and produce clinically relevant effects in immunocompromised 
individuals. Nat Med. 2006;12:1160-1166. 
103. Ciceri F, Bonini C, Marktel S, et al. Antitumor effects of HSV-TK-engineered donor 
lymphocytes after allogeneic stem-cell transplantation. Blood. 2007;109:4698-4707. 
104. Traversari C, Marktel S, Magnani Z, et al. The potential immunogenicity of the TK 
suicide gene does not prevent full clinical benefit associated with the use of TK-transduced 
donor lymphocytes in HSCT for hematologic malignancies. Blood. 2007;109:4708-4715. 
105. Stanghellini MTL, Bonini C, Provasi E, et al. Infusions of HSV-TK Engineered Donor 
Lymphocytes Effectively Protect Patients Undergoing Haploidentical Stem Cells 
Trasplantation (HSCT) from Infectious Mortality. ASH Annual Meeting Abstracts. 
2007;110:1056-. 
106. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific 
immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-
modified donor T cells after allogeneic hematopoietic cell transplantation. Blood. 
2006;107:2294-2302. 
 222
107. Qasim W, Mackey T, Sinclair J, et al. Lentiviral vectors for T-cell suicide gene 
therapy: preservation of T-cell effector function after cytokine-mediated transduction. Mol 
Ther. 2007;15:355-360. 
108. Sauce D, Bodinier M, Garin M, et al. Retrovirus-mediated gene transfer in primary T 
lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent 
and selection process-dependent mechanisms. Blood. 2002;99:1165-1173. 
109. Robinet E, Fehse B, Ebeling S, Sauce D, Ferrand C, Tiberghien P. Improving the ex 
vivo retroviral-mediated suicide-gene transfer process in T lymphocytes to preserve immune 
function. Cytotherapy. 2005;7:150-157. 
110. Straathof KC, Pule MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-
cell therapy. Blood. 2005;105:4247-4254. 
111. Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-
cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic 
SCT. Blood. 2006;108:1291-1297. 
112. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve 
graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow 
transplantation. Nat Med. 2003;9:1144-1150. 
113. Cohen JL, Salomon BL. Therapeutic potential of CD4+ CD25+ regulatory T cells in 
allogeneic transplantation. Cytotherapy. 2005;7:166-170. 
114. Cavazzana-Calvo M, Fromont C, Le Deist F, et al. Specific elimination of alloreactive 
T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation. 
1990;50:1-7. 
115. Fehse B, Frerk O, Goldmann M, Bulduk M, Zander AR. Efficient depletion of 
alloreactive donor T lymphocytes based on expression of two activation-induced antigens 
(CD25 and CD69). Br J Haematol. 2000;109:644-651. 
116. Hartwig UF, Nonn M, Khan S, Meyer RG, Huber C, Herr W. Depletion of alloreactive 
T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T 
lymphocytes. Bone Marrow Transplant. 2006;37:297-305. 
117. Koh MB, Prentice HG, Lowdell MW. Selective removal of alloreactive cells from 
haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow 
Transplant. 1999;23:1071-1079. 
118. van Dijk AMC, Kessler FL, Stadhouders-Keet SAE, Verdonck LF, de Gast GC, Otten 
HG. Selective depletion of major and minor histocompatibility antigen reactive T cells: 
towards prevention of acute graft-versus-host disease. British Journal of Haematology. 
1999;107:169-175. 
119. Hartwig UF, Robbers M, Wickenhauser C, Huber C. Murine acute graft-versus-host 
disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced 
cell death. Blood. 2002;99:3041-3049. 
120. Giver CR, Montes RO, Mittelstaedt S, et al. Ex vivo fludarabine exposure inhibits 
graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects. 
Biol Blood Marrow Transplant. 2003;9:616-632. 
121. Sun K, Welniak LA, Panoskaltsis-Mortari A, et al. Inhibition of acute graft-versus-host 
disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. 
Proc Natl Acad Sci U S A. 2004;101:8120-8125. 
122. Montagna D, Yvon E, Calcaterra V, et al. Depletion of alloreactive T cells by a specific 
anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and 
antiviral activity. Blood. 1999;93:3550-3557. 
123. Andre-Schmutz I, Dal Cortivo L, Fischer A, Cavazzana-Calvo M. Improving immune 
reconstitution while preventing GvHD in allogeneic stem cell transplantation. Cytotherapy. 
2005;7:102-108. 
 223
124. Vaclavkova P, Cao Y, Wu LK, Michalek J, Vitetta ES. A comparison of an anti-CD25 
immunotoxin, Ontak and anti-CD25 microbeads for their ability to deplete alloreactive T cells 
in vitro. Bone Marrow Transplant. 2006;37:559-567. 
125. Amrolia PJ, Mucioli-Casadei G, Huls H, et al. Add-back of allodepleted donor T cells 
to improve immune reconstitution after haplo-identical stem cell transplantation. Cytotherapy. 
2005;7:116-125. 
126. Davies JK, Koh MB, Lowdell MW. Antiviral immunity and T-regulatory cell function 
are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-
mismatched settings. Biol Blood Marrow Transplant. 2004;10:259-268. 
127. Koh MB, Prentice HG, Corbo M, Morgan M, Cotter FE, Lowdell MW. Alloantigen-
specific T-cell depletion in a major histocompatibility complex fully mismatched murine 
model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid 
engraftment. Br J Haematol. 2002;118:108-116. 
128. Hartwig UF, Nonn M, Khan S, Link I, Huber C, Herr W. Depletion of alloreactive 
donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, 
antiviral, and immunoregulatory T cell immunity. Biol Blood Marrow Transplant. 2008;14:99-
109. 
129. Jodo S, Kung JT, Xiao S, et al. Anti-CD95-induced lethality requires radioresistant 
Fcgamma RII+ cells. A novel mechanism for fulminant hepatic failure. J Biol Chem. 
2003;278:7553-7557. 
130. Boumedine RS, Roy DC. Elimination of alloreactive T cells using photodynamic 
therapy. Cytotherapy. 2005;7:134-143. 
131. Mielke S, Nunes R, Rezvani K, et al. A clinical scale selective allodepletion approach 
for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T 
lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. 
Blood. 2007. 
132. Perruccio K, Topini F, Tosti A, et al. Photodynamic purging of alloreactive T cells for 
adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cells Mol Dis. 
2008;40:76-83. 
133. Roy D-C, Cohen S, Busque L, et al. Phase I Clinical Trial of Haplotype Mismatched 
Myeloablative Stem Cell Transplantation: Higher Doses of Donor Lymphocyte Infusions 
Depleted of Alloreactive Cells Using ATIR May Improve Outcome without Causing GVHD. 
ASH Annual Meeting Abstracts. 2007;110:2976-. 
134. Li JM, Giver CR, Waller EK. Graft engineering using ex vivo methods to limit GVHD: 
fludarabine treatment generates superior GVL effects in allogeneic BMT. Exp Hematol. 
2006;34:895-904. 
135. Szabolcs P, Park KD, Marti L, et al. Superior depletion of alloreactive T cells from 
peripheral blood stem cell and umbilical cord blood grafts by the combined use of trimetrexate 
and interleukin-2 immunotoxin. Biol Blood Marrow Transplant. 2004;10:772-783. 
136. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR. NF-kappaB as 
a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib 
and PS-1145. Blood. 2006;107:827-834. 
137. Sun K, Wilkins DE, Anver MR, et al. Differential effects of proteasome inhibition by 
bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of 
bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood. 
2005;106:3293-3299. 
138. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, et al. Immune reconstitution 
without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 
study. Lancet. 2002;360:130-137. 
 224
139. Solomon SR, Mielke S, Savani BN, et al. Selective depletion of alloreactive donor 
lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older 
patients undergoing matched sibling donor stem cell transplantation. Blood. 2005;106:1123-
1129. 
140. Mielke S, Rezvani K, Savani BN, et al. Reconstitution of foxp3+ regulatory T cells 
(Tregs) after CD25-depleted allotransplantion in elderly patients and association with acute 
graft-versus-host disease (GvHD). Blood. 2007. 
141. Amrolia PJ, Muccioli-Casadei G, Huls H, et al. Adoptive immunotherapy with 
allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell 
transplantation. Blood. 2006;108:1797-1808. 
142. Mavroudis DA, Dermime S, Molldrem J, et al. Specific depletion of alloreactive T 
cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-
leukaemia reactions. Br J Haematol. 1998;101:565-570. 
143. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34(+) 
progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198-2203. 
144. Amrolia PJ, Reid SD, Gao L, et al. Allorestricted cytotoxic T cells specific for human 
CD45 show potent antileukemic activity. Blood. 2003;101:1007-1014. 
145. Schuster IG, Busch DH, Eppinger E, et al. Allorestricted T cells with specificity for the 
FMNL1-derived peptide PP2 have potent antitumor activity against hematological and other 
malignancies. Blood. 2007. 
146. Heemskerk MH, Hoogeboom M, de Paus RA, et al. Redirection of antileukemic 
reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen 
HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood. 
2003;102:3530-3540. 
147. Biagi E, Marin V, Giordano Attianese GM, Dander E, D'Amico G, Biondi A. Chimeric 
T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies. 
Haematologica. 2007;92:381-388. 
148. Pule M, Finney H, Lawson A. Artificial T-cell receptors. Cytotherapy. 2003;5:211-226. 
149. Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T 
cell antigen receptor that augments cytokine release and supports clonal expansion of primary 
human T cells. Mol Ther. 2005;12:933-941. 
150. Cooper LJ, Al-Kadhimi Z, DiGiusto D, et al. Development and application of CD19-
specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis. 
2004;33:83-89. 
151. Rossig C, Bar A, Pscherer S, et al. Target antigen expression on a professional antigen-
presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell 
receptors. J Immunother (1997). 2006;29:21-31. 
152. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by 
genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat 
Med. 2003;9:279-286. 
153. Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive 
immunotherapy. Mol Ther. 2004;10:5-18. 
154. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined 
with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 
patients. J Clin Invest. 2008;118:3143-3150. 
155. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in 
vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T 
cells. J Clin Invest. 2005;115:1616-1626. 
 225
156. Cooper LJ, Al-Kadhimi Z, Serrano LM, et al. Enhanced antilymphoma efficacy of 
CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present 
influenza MP1. Blood. 2005;105:1622-1631. 
157. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral 
vector achieves efficient gene delivery in vivo. Nat Biotechnol. 1997;15:871-875. 
158. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a 
conditional packaging system. J Virol. 1998;72:8463-8471. 
159. Vigna E, Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer 
and promising candidates for gene therapy. J Gene Med. 2000;2:308-316. 
160. Cullen BR. HIV-1 auxiliary proteins: making connections in a dying cell. Cell. 
1998;93:685-692. 
161. Cattoglio C, Facchini G, Sartori D, et al. Hot spots of retroviral integration in human 
CD34+ hematopoietic cells. Blood. 2007;110:1770-1778. 
162. Bobisse S, Zanovello P, Rosato A. T-cell receptor gene transfer by lentiviral vectors in 
adoptive cell therapy. Expert Opin Biol Ther. 2007;7:893-906. 
163. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally 
replicating lentiviral vector. Proc Natl Acad Sci U S A. 2006;103:17372-17377. 
164. Demaison C, Parsley K, Brouns G, et al. High-level transduction and gene expression 
in hematopoietic repopulating cells using a human immunodeficiency [correction of 
imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus 
forming virus promoter. Hum Gene Ther. 2002;13:803-813. 
165. Karlsson H, Brewin J, Kinnon C, Veys P, Amrolia PJ. Generation of Trispecific 
Cytotoxic T Cells Recognizing Cytomegalovirus, Adenovirus, and Epstein-Barr Virus: An 
Approach for Adoptive Immunotherapy of Multiple Pathogens. J Immunother (1997). 
2007;30:544-556. 
166. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven proliferation and 
differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp 
Med. 2001;194:1711-1719. 
167. Valmori D, Merlo A, Souleimanian NE, Hesdorffer CS, Ayyoub M. A peripheral 
circulating compartment of natural naive CD4 Tregs. J Clin Invest. 2005;115:1953-1962. 
168. Lion T, Baumgartinger R, Watzinger F, et al. Molecular monitoring of adenovirus in 
peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of 
disseminated disease. Blood. 2003;102:1114-1120. 
169. Kampmann B, Cubitt D, Walls T, et al. Improved outcome for children with 
disseminated adenoviral infection following allogeneic stem cell transplantation. Br J 
Haematol. 2005;130:595-603. 
170. Cavalieri S, Cazzaniga S, Geuna M, et al. Human T lymphocytes transduced by 
lentiviral vectors in the absence of TCR activation maintain an intact immune competence. 
Blood. 2003;102:497-505. 
171. Shafer-Weaver K, Sayers T, Strobl S, et al. The Granzyme B ELISPOT assay: an 
alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med. 
2003;1:14. 
172. Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed chimerism is an important 
prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after 
allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin 
Oncol. 2004;22:1696-1705. 
173. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in 
allogeneic chimeras. Blood. 2004;103:767-776. 
174. Jurickova I, Waller EK, Yeager AM, Boyer MW. Generation of alloreactive anti-
leukemic cytotoxic T lymphocytes with attenuated GVHD properties from haploidentical 
 226
parents in childhood acute lymphoblastic leukemia. Bone Marrow Transplant. 2002;30:687-
697. 
175. Roucard C, Thomas C, Pasquier MA, et al. In vivo and in vitro modulation of HLA-
DM and HLA-DO is induced by B lymphocyte activation. J Immunol. 2001;167:6849-6858. 
176. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate 
systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13:5426-5435. 
177. Mavroudis DA, Jiang YZ, Hensel N, et al. Specific depletion of alloreactivity against 
haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to 
graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone 
Marrow Transplant. 1996;17:793-799. 
178. Guimond M, Balassy A, Barrette M, Brochu S, Perreault C, Roy DC. P-glycoprotein 
targeting: a unique strategy to selectively eliminate immunoreactive T cells. Blood. 
2002;100:375-382. 
179. van Meerten T, Claessen MJ, Hagenbeek A, Ebeling SB. The CD20/alphaCD20 
'suicide' system: novel vectors with improved safety and expression profiles and efficient 
elimination of CD20-transgenic T cells. Gene Ther. 2006;13:789-797. 
180. Bonini C, Bondanza A, Perna SK, et al. The Suicide Gene Therapy Challenge: How to 
Improve a Successful Gene Therapy Approach. Mol Ther. 2007. 
181. Lenaerts L, Verbeken E, De Clercq E, Naesens L. Mouse adenovirus type 1 infection in 
SCID mice: an experimental model for antiviral therapy of systemic adenovirus infections. 
Antimicrob Agents Chemother. 2005;49:4689-4699. 
182. Salmeron A, Borroto A, Fresno M, Crumpton MJ, Ley SC, Alarcon B. Transferrin 
receptor induces tyrosine phosphorylation in T cells and is physically associated with the TCR 
zeta-chain. J Immunol. 1995;154:1675-1683. 
183. Villa I, Kvale E, Lund-Johansen F, Olweus J. Assay for monitoring in vitro selective 
depletion strategies in allogeneic stem cell transplantation. Cytotherapy. 2007;9:600-610. 
184. Cavazzana-Calvo M, Stephan JL, Sarnacki S, et al. Attenuation of graft-versus-host 
disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-
2 haplotype disparate mouse combination. Blood. 1994;83:288-298. 
185. Hoffmann P, Eder R, Boeld TJ, et al. Only the CD45RA+ subpopulation of 
CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro 
expansion. Blood. 2006;108:4260-4267. 
186. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat 
Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow 
transplantation. N Engl J Med. 1994;330:1185-1191. 
187. Small TN, Papadopoulos EB, Boulad F, et al. Comparison of immune reconstitution 
after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age 
and donor leukocyte infusions. Blood. 1999;93:467-480. 
188. Leen AM, Sili U, Vanin EF, et al. Conserved CTL epitopes on the adenovirus hexon 
protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood. 
2004;104:2432-2440. 
189. Hromas R, Cornetta K, Srour E, Blanke C, Broun ER. Donor leukocyte infusion as 
therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow 
transplantation. Blood. 1994;84:1689-1690. 
190. Mackinnon S, Thomson K, Verfuerth S, Peggs K, Lowdell M. Adoptive cellular 
therapy for cytomegalovirus infection following allogeneic stem cell transplantation using 
virus-specific T cells. Blood Cells Mol Dis. 2008;40:63-67. 
191. Hebart H, Bollinger C, Fisch P, et al. Analysis of T-cell responses to Aspergillus 
fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood. 
2002;100:4521-4528. 
 227
192. Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions 
following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 
2004;103:1548-1556. 
193. Guglielmi C, Arcese W, Dazzi F, et al. Donor lymphocyte infusion for relapsed chronic 
myelogenous leukemia: prognostic relevance of the initial cell dose. Blood. 2002;100:397-405. 
194. Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK. Addition of the 
CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T 
regulatory cells. Leukemia. 2006;20:1819-1828. 
195. Manuri PR, Olivares S, Dara N, et al. 30: A Fully-Human Chimeric Antigen Receptor 
for Redirecting Specificity of T Cells to B-Lineage Tumors. Biology of Blood and Marrow 
Transplantation. 2008;14:13-14. 
196. Waterhouse NJ, Sedelies KA, Clarke CJ. Granzyme B; the chalk-mark of a cytotoxic 
lymphocyte. J Transl Med. 2004;2:36. 
197. Perez-Diez A, Joncker NT, Choi K, et al. CD4 cells can be more efficient at tumor 
rejection than CD8 cells. Blood. 2007;109:5346-5354. 
198. Dal Cortivo L, Mahlaoui N, Picard C, et al. Adoptive Immunotherapy with Donor 
Allodepleted T Cells. ASH Annual Meeting Abstracts. 2005;106:479-. 
 
 
